<SEC-DOCUMENT>0001144204-17-040922.txt : 20170807
<SEC-HEADER>0001144204-17-040922.hdr.sgml : 20170807
<ACCEPTANCE-DATETIME>20170807173024
ACCESSION NUMBER:		0001144204-17-040922
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20170630
FILED AS OF DATE:		20170807
DATE AS OF CHANGE:		20170807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TAPIMMUNE INC.
		CENTRAL INDEX KEY:			0001094038
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880277072
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37939
		FILM NUMBER:		171012707

	BUSINESS ADDRESS:	
		STREET 1:		5 WEST FORSYTH STREET
		STREET 2:		SUITE 200
		CITY:			JACKSONVILLE
		STATE:			FL
		ZIP:			32202
		BUSINESS PHONE:		(904) 516-5436

	MAIL ADDRESS:	
		STREET 1:		5 WEST FORSYTH STREET
		STREET 2:		SUITE 200
		CITY:			JACKSONVILLE
		STATE:			FL
		ZIP:			32202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAPIMMUNE INC
		DATE OF NAME CHANGE:	20070628

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENEMAX CORP
		DATE OF NAME CHANGE:	20020718

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EDUVERSE COM
		DATE OF NAME CHANGE:	19990827
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v471682_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE
COMMISSION</B><BR>
<B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B><U>FORM
10-Q</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2"><B><FONT STYLE="font-family: Wingdings">&#120;</FONT></B></FONT></TD><TD STYLE="text-align: justify">Quarterly Report Under Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the quarterly period ended</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>June 30, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify">Transition Report Under Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the transition period from _____ to _____.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <B><U>001-37939</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 60pt; width: 123pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.75pt solid"><FONT STYLE="text-transform: uppercase"><B><U>TAPIMMUNE
INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of registrant in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>NEVADA</B></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>45-4497941</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(State or other jurisdiction of incorporation or organization)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5 West Forsyth Street, Suite
        200</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Jacksonville, FL</B></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>32202</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Zip Code)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>904-516-5436</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Issuer's telephone number)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>50 N. Laura Street, Suite 2500</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Jacksonville, FL 32202</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">(Former Address if Changed Since Last Report)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes <FONT STYLE="font-family: Wingdings"><B>&#120;</B></FONT> No <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files). Yes <FONT STYLE="font-family: Wingdings">&#120;
</FONT>No <FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, non-accelerated filer, a smaller reporting company, or an emerging growth company.
See definition of &ldquo;accelerated filer&rdquo;, &ldquo;large accelerated filer&rdquo;, &ldquo;smaller reporting company&rdquo;,
and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act (check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>&nbsp;&nbsp;Large accelerated filer</TD>
    <TD STYLE="width: 33%; padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 33%; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>&nbsp;&nbsp;Accelerated filer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>&nbsp;&nbsp;Non-accelerated filer (Do not check</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Wingdings 2"><B><FONT STYLE="font-family: Wingdings">&#120;</FONT></B></FONT>&nbsp;Smaller reporting company</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if smaller reporting company)</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;Emerging growth company</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yes <FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT> No
<FONT STYLE="font-family: Wingdings 2"><B><FONT STYLE="font-family: Wingdings">&#120;</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 2, 2017, the Company had 10,158,993
shares of common stock issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">__________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; padding: 0 0 1pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 80%; padding: 0 0 1pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-top: 0; padding-right: 0; border-bottom: Black 1pt solid; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART I &ndash; FINANCIAL INFORMATION</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;1.</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements (Unaudited)</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Balance Sheets as of June 30, 2017 and December 31, 2016</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2017 and 2016</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statement of Stockholders' Equity for the six months ended June 30, 2017</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2017 and 2016</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Condensed Consolidated Financial Statements </FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;2.</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;3.</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk.</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;4.</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures.</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART II &ndash; OTHER INFORMATION </B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;1.</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings.</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;1A.</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors.</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;2.</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds.</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;3.</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults Upon Senior Securities.</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;4.</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures.</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;5.</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information.</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;6.</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0; text-indent: 0"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</FONT></A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTE REGARDING REVERSE STOCK SPLIT</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 13, 2016, we filed a Certificate
        of Change pursuant to NRS 78.209 with the Secretary of State of the State of Nevada to effect a reverse split of our common stock
        at a ratio of one for twelve, effective on September 16, 2016. All historical share and per share amounts reflected in this report
        have been adjusted to reflect the reverse stock split.</P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: -0.8in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: -0.8in"><B>PART&nbsp;I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: -0.8in"><B><A NAME="a_001"></A>Item 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: -0.8in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal; text-transform: uppercase">TAPIMMUNE
INC.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><FONT STYLE="font-style: normal; text-transform: uppercase">CONDENSED
CONSOLIDATED BALANCE SHEETS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June 30,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2017</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December 31,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2016</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">ASSETS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in">Cash</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">9,962,615</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">7,851,243</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Prepaid expenses and deposits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">179,181</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">70,149</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,141,796</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,921,392</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,141,796</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,921,392</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Accounts payable and accrued liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,561,075</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,224,940</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Research agreement obligations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">492,365</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Warrant liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Promissory note</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,576,075</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,736,805</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,576,075</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,736,805</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">COMMITMENTS AND CONTINGENCIES</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders' equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Preferred stock - $0.001 par value, 5,000,000 shares authorized at June 30, 2017 and December 31, 2016, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in">Series A, $0.001 par value, 1,250,000 shares designated, 0 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in">Series B, $0.001 par value, 1,500,000 shares designated, 0 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in">Common stock, $0.001 par value, 41,666,667 shares authorized, 10,158,993 and 8,421,185 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,159</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,421</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">159,306,674</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">151,991,974</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(150,751,112</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(145,815,808</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total stockholders' equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,565,721</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,184,587</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders' equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,141,796</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,921,392</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>See accompanying notes to these unaudited
condensed consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal">TAPIMMUNE
INC.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal"><A NAME="a_003"></A>CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 36%; font-size: 10pt; text-align: left; padding-left: 0.125in">Research and development</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,202,725</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,248,165</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">2,191,817</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">2,233,916</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,190,517</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,177,408</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,618,310</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,945,396</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,393,242</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,425,573</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,810,127</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,179,312</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Loss from operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,393,242</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,425,573</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,810,127</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,179,312</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Other income (expense):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Change in fair value of warrant liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,237,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,241,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Debt extinguishment gain</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">492,365</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">492,365</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Grant income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">231,200</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">231,200</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Shares issued in debt settlement agreements</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(70,315</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(70,315</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Other income</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,828</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,828</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net (loss) income</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(1,893,377</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">5,974,140</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(4,313,262</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">1,224,401</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Basic net (loss) income per share</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.22</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.01</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.51</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.21</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Diluted net (loss) income per share</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.22</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.35</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.51</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.19</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Weighted average number of common shares outstanding, basic</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,576,634</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,935,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,503,521</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,908,917</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Weighted average number of common shares outstanding, diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,576,634</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,524,750</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,503,521</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,652,417</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>See accompanying notes to these unaudited
condensed consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TAPIMMUNE INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS&rsquo;
EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Additional</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Paid-in </B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">Accumulated</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Total</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Stockholders'</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Par value</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Equity</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; font: bold 10pt Times New Roman, Times, Serif">Balance, January 1, 2017</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">8,421,185</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">8,421</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">151,991,974</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(145,815,808</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">6,184,587</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Common stock and warrants issued in private placement</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,503,567</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,504</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,188,499</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,190,003</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Fees and legal costs relating to private placement</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(781,660</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(781,660</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in">Exercise of warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">167,926</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">168</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">666,498</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">666,666</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Legal costs relating to exercise of warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(28,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(28,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in">Fair value of repriced warrants as inducement</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">622,042</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(622,042</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Stock-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">66,315</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">66</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">647,321</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">647,387</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,313,262</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,313,262</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, June 30, 2017</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">10,158,993</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">10,159</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">159,306,674</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(150,751,112</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">8,565,721</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>See accompanying notes to these unaudited
condensed consolidated financial statements.&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal">TAPIMMUNE
INC.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal"><A NAME="a_005"></A>CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash Flows from Operating Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in">Net (loss) income</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(4,313,262</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,224,401</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in">Reconciliation of net (loss) income to net cash used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Changes in fair value of warrant liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,500</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,241,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Shares issued in debt settlement agreements</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">70,315</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Stock-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">647,387</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">544,934</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Debt extinguishment gain</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(492,365</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.25in">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Prepaid expenses and deposits</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(109,032</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">47,409</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Accounts payable and accrued expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">336,135</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">570,033</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Net cash used in operating activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,935,637</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,783,908</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash Flows from Financing Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Repayment of promissory note</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(25,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Proceeds from issuance of common stock and warrants in private placement, net of offering costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,408,343</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Proceeds from exercise of stock warrants, net of offering costs</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">638,666</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Net cash provided by (used in) financing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,047,009</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(25,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0in">Net increase (decrease)&nbsp;in cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,111,372</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,808,908</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Cash at beginning of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,851,243</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,576,564</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Cash at end of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">9,962,615</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,767,656</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>See accompanying notes to these unaudited
condensed consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal">TAPIMMUNE
INC.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal">CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Supplemental schedule of non-cash financing activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilson&rsquo;s compensation</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">191,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Fair value of repriced warrants as inducement</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">622,042</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>See accompanying notes to these unaudited
condensed consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal">TAPIMMUNE
INC.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><FONT STYLE="font-style: normal">NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal">June
30, 2017</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Note 1: Nature
of Operations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TapImmune Inc. (the &ldquo;Company&rdquo;
or &ldquo;we&rdquo;), a Nevada corporation incorporated in 1992, is a biotechnology company focusing on immunotherapy specializing
in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious
disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly
stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation
in tumor cells allowing their recognition and killing by the immune system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">NOTE 2: Basis of
Presentation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of
America (&ldquo;U.S. GAAP&rdquo;) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8
of Regulation S-X of the Securities and Exchange Commission (&ldquo;SEC&rdquo;) and on the same basis as the Company prepares its
annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation
of such interim results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results for the condensed consolidated
statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2017 or for any
future interim period. The condensed consolidated balance sheet at June 30, 2017 has been derived from unaudited financial statements;
however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying
condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year
ended December 31, 2016, and notes thereto included in the Company&rsquo;s annual report on Form 10-K filed on March 14, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">NOTE 3: LIQUIDITY
AND FINANCIAL CONDITION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s activities since inception
have consisted principally of acquiring product and technology rights, raising capital, and performing research and development.
Successful completion of the Company&rsquo;s development programs and, ultimately, the attainment of profitable operations are
dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a
customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception,
the Company has been funded by a combination of equity and debt financings and warrant exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to continue to incur
substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will
need to complete certain research and development activities and clinical studies. Further, the Company&rsquo;s product candidates
will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures
to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The
Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term,
revenue from product sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2017, the Company had cash
of $9,963,000. The Company had net losses and negative cash flows from operations. Management intends to continue its research
efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt
and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can
be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters
raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Note 4: SIGNIFICANT
ACCOUNTING POLICIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no material changes in
the Company&rsquo;s significant accounting policies to those previously disclosed in the Company&rsquo;s annual report on Form
10-K, which was filed with the SEC on March 14, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>New Accounting Pronouncement</I>s</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, new accounting pronouncements
are issued by the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) or other standard setting bodies that we adopt as of
the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are
not yet effective will have a material impact on our financial position or results of operations upon adoption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Accounting for Certain Financial Instruments with Down
Round Features</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 13, 2017, the FASB has issued a two-part Accounting
Standards Update (&ldquo;ASU&rdquo;), No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features and
(ii) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and
Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ASU is effective for public business entities for fiscal
years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company
will be evaluating the impact of adopting this standard on the consolidated financial statements and disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Compensation-Stock Compensation</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2017, the FASB issued ASU 2017-09,
Compensation&mdash;Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change
to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is
required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as
a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and
interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting
this standard on the consolidated financial statements and disclosures, but does not expect it to have a significant impact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Note 5: NET (LOSS)
InCOME PER SHARE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic (loss) income per common share is
computed by dividing net (loss) income by the weighted average number of common shares outstanding during the reporting period.
Diluted income per common share is computed similar to basic income per common share except that it reflects the potential dilution
that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income (loss) per-share amounts for all
prior periods have been retroactively adjusted to reflect the Company&rsquo;s 1-for-12 reverse stock split, which was effective
September 16, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the computation
of net loss per share:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Numerator:</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 36%; font-size: 10pt; text-align: left">Net (loss) income</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(1,893,377</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">5,974,140</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(4,313,262</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,224,401</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">Less: non-cash income from change in fair value of common stock warrants</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,697,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,492,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net (loss) income - diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,893,377</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,277,140</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,313,262</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,267,599</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">Denominator:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Weighted average common shares outstanding - basic</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,576,634</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,935,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,503,521</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,908,917</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Dilutive effect of warrants, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">565,417</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">743,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Dilutive effect of stock options, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">24,333</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Weighted average common shares outstanding - diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,576,634</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,524,750</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,503,521</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,652,417</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Net (loss) income per share data:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Basic</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.22</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.01</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.51</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.21</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.22</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.35</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.51</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.19</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following securities, rounded to the thousand, were not
included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; font-size: 10pt; text-align: left">Common stock options</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">455,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">251,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">455,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">297,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Common stock warrants - equity treatment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,540,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">213,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,540,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">213,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Common stock warrants - liability treatment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,500</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,283,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,500</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,068,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Potentially dilutive securities</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,998,500</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,747,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,998,500</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,578,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>Note
6: Research Agreement OBLIGATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Crucell Holland B. V. (&ldquo;Crucell&rdquo;) &ndash; Research
License and Option Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2003 and further amended in 2008, the
Company acquired a research license and option agreement from Crucell Holland B.V. for use of an adenovirus technology. The Company
has not made use of the technology in its current work and has not asked for nor received any work product from Crucell. Crucell
was acquired by Johnson and Johnson in 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2016, the Company had
accrued $492,365 under the amended agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon further legal review and analysis
of the agreement undertaken during the quarter, the Company concluded that the statute of limitations has run out on the obligation,
and a legal opinion received by the Company confirms the amounts are not currently owed. As such, as of June 30, 2017, the Company
was no longer obligated to make the payments under the agreement and therefore, the Company recorded a debt extinguishment gain
of $492,365 and reduced the liability amount owed to $0.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Note 7: WARRANT
LIABILITY AND FAIR VALUE MEASUREMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of quantitative information with
respect to valuation methodology and significant unobservable inputs used for the Company&rsquo;s common stock purchase warrants
that are categorized within Level 3 of the fair value hierarchy for the six months ended June 30, 2017 and 2016 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-size: 10pt">Stock price</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: right">3.88</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: right">6.12</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Exercise price</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.20 - $300.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Contractual term (years)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.03</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.28 - 4.20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Volatility (annual)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">78</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">68% - 151</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Risk-free rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.00</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.00</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Dividend yield (per share)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing assumptions are reviewed
quarterly and are subject to change based primarily on management&rsquo;s assessment of the probability of the events described
occurring. Accordingly, changes to these assessments could materially affect the valuations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Financial Liabilities Measured at Fair Value on a Recurring
Basis</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial liabilities measured at fair
value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair value measured at June 30, 2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Quoted prices in active</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Significant other</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Significant</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">markets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">observable inputs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">unobservable inputs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Fair value at</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">(Level 1)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">(Level 2)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">(Level 3)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">June 30, 2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; font-size: 10pt; text-align: justify">Warrant liability</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">10,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">10,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair value measured at December 31, 2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Quoted prices in active</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Significant other</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Significant</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">markets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">observable inputs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">unobservable inputs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Fair value at</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">(Level 1)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">(Level 2)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">(Level 3)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31, 2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; font-size: 10pt; text-align: justify">Warrant liability</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">14,500</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">14,500</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value accounting standards define
fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an
asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either
directly or indirectly; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 3 inputs: Unobservable inputs for which there is little or no market data, which require
the reporting entity to develop its own assumptions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no transfers between Level 1,
2 or 3 during the six months ended June 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents changes in
Level 3 liabilities measured at fair value for the six months ended June 30, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Warrant</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Liability</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-size: 10pt">Balance - December 31, 2016</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: right">14,500</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Change in fair value of warrant liability</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,500</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Balance &ndash; June 30, 2017</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">10,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Note 8: Promissory
note</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2017 and December 31, 2016,
the Company had an outstanding promissory note in the amount of $5,000. The promissory note outstanding and due at June 30, 2017
bears 10% annual interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Note 9: STOCKHOLDERS&rsquo;
EQUITY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reverse Stock Split</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 16, 2016, the Company effected
a one for twelve reverse stock-split of our issued and outstanding common stock and has retroactively adjusted our common shares
outstanding, options and warrants amounts outstanding. The Company has presented its share data for and as of all periods presented
on this basis. The par value was not adjusted as a result of the one for twelve reverse stock split. All prior period share transactions
included in the Company&rsquo;s stock transactions and balances have been retroactively restated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2017 Common Stock Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>June 2017 Private Placement Transaction</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 26, 2017, the Company completed
private placement of units with certain accredited investors. In the private placement transaction, the Company sold 1,503,567
shares of common stock for $3.97 per share and five-year warrants to purchase an equal number of shares of common stock, at an
exercise price of $3.97 per share, for $0.125 per warrant, with one common share and one warrant being sold together as a unit
for a total of $4.095 per unit. The Company issued and sold an aggregate of 1,503,567 million units for aggregate gross proceeds
of $6.2 million. The Company incurred $0.8 million in agency fees and legal costs. In connection with the offering, the Company
reduced the exercise price for the warrants to purchase an aggregate of 653,187 shares of common stock issued to investors in the
private placement that closed in August 2016 from $6.00 per share to $3.97 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company issued five-year
warrants to the placement agent in the offering providing for the purchase of up to 150,357 shares of Company common stock for
$3.97 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to a Registration Rights Agreement
to be entered into at the closing of the private placement offering, promptly, but no later than 90 calendar days after the closing
of the offering, the Company is required to file a registration statement with the Securities and Exchange Commission registering
for resale (a) the common stock issued in the offering; (b) the shares of common stock issuable upon the exercise of the private
placement warrants; and (c) the shares of common stock issuable upon the exercise of the warrants issued to Katalyst Securities
LLC, which acted as placement agent for the offering. The Company is required to use its commercially reasonable efforts to ensure
that the Registration Statement is declared effective within 90 calendar days after filing with the Securities and Exchange Commission,
on or before December 23, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the registration rights
agreements, should the Company fail to meet the above criteria, the Company is subject to pay the investors liquidated damages.
The liquidated damages shall be a cash sum payment calculated at a rate of ten percent (10%) per annum of the aggregate purchase
price for the registrable securities or aggregate amount upon exercise of the placement agent warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with U.S. GAAP, a contingent
obligation to make future payments must be recorded if the transfer of consideration under a registration payment arrangement is
probable and can be reasonably estimated. The Company has determined that should it be required to pay liquidated damages to the
investors of the private placements, the aggregate contingent liability it would be required to record would be approximately $57,000
per month for each month it fails or is estimated to fail to meet the above criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the June 26, 2017 private placement
closing, and on June 30, 2017, the Company concluded that it is not probable that it will be required to remit any payments to
the investors for failing to obtain an effective registration statement or failing to maintain its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>June 2017 Exercise and Repricing
of Warrants Held by Existing Institutional Investors</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 23, 2017, certain existing institutional
shareholders of the Company who hold various outstanding warrants (i.e. C, D, E and F) to purchase Company common stock, entered
into warrant repricing and exercise agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Series E repriced and exercised warrants
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximately 168,000 of Series E warrants
were repriced from $15.00 per share to $3.97 per share and exercised immediately for gross proceeds of approximately $0.7 million.
Series E warrants to purchase approximately 187,000 shares of Company common stock being reduced from $15.00 per share to $4.50
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Series C, D &amp; F repriced warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the exercise prices for certain
investors of Series C, Series D and Series F warrants were reduced as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Series</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Warrant Shares Repriced</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Pre-reduced&nbsp;&nbsp;Price</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Post-reduced Price</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; font-size: 10pt; text-align: left">Series C</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: right">313,750</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: right">6.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: right">4.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Series D</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">312,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">9.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Series F</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">292,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">7.20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value relating to the modification
of exercise prices on all of the repriced warrants was treated as deemed dividend on the statement of stockholders&rsquo; equity
of $622,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A weighted average summary of quantitative
information with respect to valuation methodology and significant unobservable inputs used for the Company&rsquo;s common stock
purchase warrants that are included in the modification is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average Inputs</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Before Modification</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">After Modification</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 62%; font-size: 10pt">Exercise price</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">8.32</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">4.04</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Contractual term (years)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.34</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.34</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Volatility (annual)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">200</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">200</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Risk-free rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.50</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.50</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Dividend yield (per share)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.00</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.00</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>2017 Management Compensation</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 9, 2017, the Company issued 12,761
shares of stock in relation to the discretionary 2016 bonus awarded to Dr. Glynn Wilson. The fair value of the common stock of
$55,000 was recognized as stock-based compensation in general and administrative expenses. The issuance was based on the closing
price or our common stock of $4.31 per share, on the day immediately preceding the date the 2016 bonus award was approved by the
Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 9, 2017, the Company issued 5,220
shares of stock in relation to the discretionary 2016 bonus awarded to our former Chief Operating Officer. The fair value of the
common stock of $22,500 was recognized as stock-based compensation in general and administrative expenses. The issuance was based
on the closing price or our common stock of $4.31 per share, on the day immediately preceding the date the 2016 bonus award was
approved by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Consulting Arrangements</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2017,
the Company issued 48,334 shares of common stock as part of consulting agreements. The fair value of the common stock of $205,000
was recognized as stock-based compensation in general and administrative expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Note 10: STOCK-BASED
COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded $271,000 and $331,000
of stock-based compensation expense for the three months ended June 30, 2017 and 2016, respectively. The Company recorded $647,000
and $545,000 of stock-based compensation expense for the six months ended June 30, 2017 and 2016, respectively. Stock-based compensation
expense is included in general and administrative expense on the condensed consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2017, the total stock-based
compensation cost related to unvested awards not yet recognized was $680,000. The expected weighted average period compensation
costs to be recognized was 0.68 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future option grants will impact the compensation
expense recognized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Note 11: SUBSEQUENT
EVENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2017, the Board of Directors
of the Company approved the 2017 bonus program for Dr. Glynn Wilson, our Chief Executive Officer and President, and Mr. Michael
J. Loiacono, our Chief Financial Officer, Treasurer and Secretary, as recommended by the Compensation Committee of the Board of
Directors. Under such bonus program, Dr. Wilson and Mr. Loiacono are eligible for bonuses of up to $140,000 and $60,000, respectively,
equaling up to 50% and 30%, of their respective base salaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The bonus amount of up to $140,000 to Dr.
Wilson is to be allocated upon the achievement of the following objectives:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">up to 40% of the bonus amount for meeting scientific,
technical and clinical objectives;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">up to 20% of the bonus amount for financial performance
and corporate objectives related to our raising capital; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">up to 40% of the bonus amount designated to be discretionary
as determined by the Board.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order for Dr. Wilson to achieve his
eligible bonus of $140,000, he would need 100% attainment in each of the above objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The bonus amount of up to $60,000 to Mr.
Loiacono is to be allocated upon the achievement of the following objectives:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">up to 33.3% of the bonus amount for meeting corporate
and operational objectives;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">up to 33.3% of the bonus amount for financial performance
objectives including related to our raising capital; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">up to 33.3% of the bonus amount designated to be discretionary
as determined by the Board.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order for Mr. Loiacono to achieve his
eligible bonus of $60,000, he would need 100% attainment in each of the above objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The bonuses will be paid in a combination of cash and common
stock at the discretion of the Compensation Committee.<BR CLEAR="ALL"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 0.5pt solid"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_007"></A>Item 2.</TD><TD>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This quarterly report on Form 10-Q contains
forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, that involve
risks and uncertainties. All statements other than statements relating to historical matters including statements to the effect
that we &ldquo;believe&rdquo;, &ldquo;expect&rdquo;, &ldquo;anticipate&rdquo;, &ldquo;plan&rdquo;, &ldquo;target&rdquo;, &ldquo;intend&rdquo;
and similar expressions should be considered forward-looking statements. Our actual results could differ materially from those
discussed in the forward-looking statements as a result of a number of important factors, including factors discussed in this section
and elsewhere in this quarterly report on Form 10-Q, and the risks discussed in our other filings with the Securities and Exchange
Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management&rsquo;s
analysis, judgment, belief or expectation only as the date hereof. We assume no obligation to update these forward-looking statements
to reflect events or circumstance that arise after the date hereof.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>As used in this quarterly report: (i)
the terms &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;, &ldquo;TapImmune&rdquo; and the &ldquo;Company&rdquo; mean TapImmune
Inc. and its wholly owned subsidiary, GeneMax Pharmaceuticals Inc. which wholly owns GeneMax Pharmaceuticals Canada Inc., unless
the context otherwise requires; (ii) &ldquo;SEC&rdquo; refers to the Securities and Exchange Commission; (iii) &ldquo;Securities
Act&rdquo; refers to the Securities Act of 1933, as amended; (iv) &ldquo;Exchange Act&rdquo; refers to the Securities Exchange
Act of 1934, as amended; and (v) all dollar amounts refer to United States dollars unless otherwise indicated.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following should be read in conjunction
with our unaudited condensed consolidated interim financial statements and related notes for the three and six months ended June
30, 2017 included in this quarterly report, as well as our Annual Report on Form 10-K for the year ended December 31, 2016 filed
on March 14, 2017.</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a clinical-stage immuno-oncology
company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment
of cancer and metastatic disease. We are also developing a proprietary technology to improve the ability of the cellular immune
system to recognize and destroy diseased cells. This DNA expression technology named PolyStart&trade; is in pre-clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuno-oncology has become the most rapidly
growing sector in the pharmaceutical and biotech industry. The approval and success of checkpoint inhibitors, including Yervoy
and Opdivo (Bristol Myers Squibb) and Keytruda (Merck &amp; Co.), together with the development of CAR T-cell therapies (Juno Therapeutics,
Kite Pharma), has provided much momentum in this sector. In addition, new evidence points to the increasing use of combination
immunotherapies for the treatment of cancer. This has provided greater opportunities for the successful development of T-cell vaccines
in combination with other approaches.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 23, 2017 the U.S. Food and Drug
Administration (&ldquo;FDA&rdquo;) approved expanded use of Keytruda for immunotherapy. The FDA granted accelerated approval to
a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the FDA has approved
a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To enhance shareholder value and taking
into account development timelines, we plan to advance our clinical programs by expanding our Folate Receptor Alpha program (TPIV200)
for breast and ovarian cancers and our HER2/neu peptide antigen program (TPIV110) in Phase II clinical trials. In parallel, we
plan to complete the pre-clinical development of our PolyStart&trade; technology as an integral component of a prime-boost vaccine
methodology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the strength of our science
and development approaches is becoming more widely appreciated, particularly as our clinical program has now generated positive
Phase I data in both clinical programs in breast and ovarian cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to focus primarily on our Phase
II triple-negative breast cancer trials using TPIV200 (which has achieved Fast Track and Orphan Drug Status) as well as planning
for Phase II HER2/neu breast cancer trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to continue to prosecute our
PolyStart&trade; patent filings and develop new PolyStart&trade; constructs to facilitate collaborative efforts in our current
clinical indications. We will also evaluate those indications where others have already indicated interest in combination therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that these fundamental programs
and corporate activities have positioned our company to capitalize on the acceptance of immunotherapy as a leading therapeutic
strategy in cancer and infectious disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are continuously working on improving
our product formulation and supply. TPIV200 and TPIV110 are both off-the-shelf, lyophilized products that only require reconstitution
at the clinical site before injection. We believe our off-the-shelf product may provide a significant competitive advantage over
autologous products that require preparation for each patient. We also believe the investments we have made in the formulation
work for both very stable products will result in commercially viable products consistent with typically high pharmaceutical profit
margins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the Phase I data produced for
both TPIV200 and TPIV100 in collaboration with the Mayo Clinic are the driving force behind the high-value collaborations we have
established and maintained with organizations such as Mayo Clinic, AstraZeneca, Memorial Sloan Kettering, and the U.S. Department
of Defense. As we move forward into advanced Phase II studies, some of which incorporate collaborations with prestigious third-party
organizations, we believe this represents further independent validation of the potential of our technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Intellectual Property Strategies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">A key component
to success is having a comprehensive patent strategy that continually updates and extends patent coverage for key products. It
is highly unlikely that early patents will extend through ultimate product marketing, so extending patent life is an important
strategy for ensuring product protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have three
active patent families that we are supporting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">1. Filed patents
on the PolyStart&trade; expression vector (owned by TapImmune and filed in 2014: this IP covers the use with TAP). We announced
the allowance of this patent in February 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">2. Filed patents
on HER2/neu Class II and Class I antigens: exclusive license from Mayo Foundation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">3. Filed patents
on Folate Receptor Alpha antigens: exclusive license from Mayo Foundation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">While the pathway
to successful product development takes time, we believe we have put in place significant for success. The strength of our product
pipeline and access to leading scientists and institutions gives us a unique opportunity to make a major contribution to global
health care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">With respect to
the broader market, a major driver and positive influence on our activities has been the emergence and general acceptance of the
potential of a new generation of immunotherapies that promise to change the standard of care for cancer. The immunotherapy sector
has been greatly stimulated by the approval of Provenge&reg; for prostate cancer and Yervoy&trade; for metastatic melanoma, progression
of the areas of checkpoint inhibitors and adoptive T-cell therapy, as well as multiple other approaches reaching Phase II and Phase
III status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that through our combination
of technologies, we are well positioned to be a leading player in this emerging market. It is important to note that many of the
late-stage immunotherapies currently in development do not represent competition to our programs, but instead offer synergistic
opportunities to partner our antigen-based immunotherapeutics, and PolyStart&trade; expression system. Thus, the use of naturally
processed T-cell antigens discovered using samples derived from cancer patients plus our PolyStart&trade; expression technology
to improve antigen presentation to T-cells could not only produce an effective cancer vaccine in its own right but also to enhance
the efficacy of other immunotherapy approaches such as CAR-T and PD1 inhibitors for example.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Products and Technology in Development-Clinical</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>TPIV200 </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Phase I Human Clinical Trials &ndash;
</I>Folate Alpha Breast and Ovarian Cancers &ndash; Mayo Clinic</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Folate Receptor Alpha is expressed in over
80% of triple-negative breast cancers and in over 90% of ovarian cancers, for which the only treatment options are surgery, radiation
therapy, and chemotherapy, leaving a very important and urgent clinical need for a new therapeutic. Time to recurrence is relatively
short for these types of cancer and survival prognosis is extremely poor after recurrence. In the United States alone, there are
approximately 30,000 ovarian cancer patients and 40,000 triple-negative breast cancer patients newly diagnosed every year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A 24-patient Phase I clinical trial using
TPIV200 was completed in 2015. The vaccine is well tolerated and safe and 20 out of 21 evaluable patients showed positive immune
responses, which provided a strong rationale for progressing to Phase II trials. Good Manufacturing Practice (&ldquo;GMP&rdquo;)
for Phase II trials resulted in a commercially viable formulation. On July 27, 2015, we exercised our option agreement with Mayo
Clinic with the signing of a worldwide exclusive license agreement to commercialize the proprietary Folate Receptor Alpha Vaccine
technology for all cancer indications. As part of this Agreement, the investigational new drug application (&ldquo;IND&rdquo;)
for Folate Receptor Alpha (&ldquo;TPIV200&rdquo;) was transferred from Mayo Clinic to us for amendment to support our Phase II
Clinical trials on our lead product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 15, 2015, we announced that
our collaborators at the Mayo Clinic had been awarded a grant of $13.3 million from the U.S. Department of Defense (&ldquo;DOD&rdquo;).
This grant, commencing September 15, 2015, covers the costs for a 280-patient Phase II clinical trial of Folate Receptor Alpha
vaccine in patients with triple-negative breast cancer. We are working closely with Mayo Clinic on this clinical trial by providing
clinical and manufacturing expertise as well as providing GMP vaccines to supply the study. The vaccine formulation is suitable
for multiple Phase II clinical programs in triple-negative breast and ovarian cancers in combination with other immunotherapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9, 2015, we announced that
we received Orphan Drug Designation from the U.S. Food &amp; Drug Administration&rsquo;s Office of Orphan Products Development
(&ldquo;OOPD&rdquo;) for our cancer vaccine TPIV200 in the treatment of ovarian cancer. The TPIV200 ovarian cancer clinical program
will now receive benefits including tax credits on clinical research and seven-year market exclusivity upon receiving marketing
approval. TPIV200 is a multi-epitope peptide vaccine that targets Folate Receptor Alpha, which is overexpressed in multiple cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 3, 2016, we announced that
the U.S. Food &amp; Drug Administration (&ldquo;FDA&rdquo;) has designated the investigation of TPIV200 with GM-CSF adjuvant for
maintenance therapy in subjects with platinum-sensitive advanced ovarian cancer who achieved stable disease or partial response
following completion of standard of care chemotherapy, as a Fast Track Development Program. A Phase II study in this indication
was initiated at the end of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently enrolling a Company-sponsored
triple-negative breast cancer study at twelve clinical sites nation-wide. The study will enroll a total of 80 patients. It is open-label
and designed to look at dosing regimens, immune responses, and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An ovarian cancer study sponsored by Memorial
Sloan Kettering Cancer Center in New York City in collaboration with AstraZeneca Pharmaceuticals was initiated in 2016. This study
is currently enrolling platinum-resistant ovarian cancer patients and is designed to look at the effects of combination therapy
with AstraZeneca&rsquo;s checkpoint inhibitor durvalumab, which was recently licensed as IMFINZI&trade; for bladder cancer. The
study will enroll up to 40 patients and is open label. We have no business relationship with AstraZeneca and we are paying for
half of the clinical study, plus providing TPIV200 for the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>TPIV 100/110 </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Phase I Human Clinical Trials &ndash;
HER2/neu+ Breast Cancer &ndash; Mayo Clinic</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Phase I study using TPIV100 (the four-peptide
product) was completed in 2015. Final safety analysis on all the patients treated is complete and the product was shown to be safe.
In addition, 19 out of 20 evaluable patients showed robust T-cell immune responses to the antigens in the vaccine composition,
providing a solid case for advancement to Phase II in 2017. An additional secondary endpoint incorporated into this Phase I Trial
was a two-year follow on recording time to disease recurrence in the participating breast cancer patients. This data is being submitted
for publication in a peer-reviewed journal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For Phase I(b)/II studies, we plan to add
a Class I peptide, licensed from the Mayo Clinic (April 16, 2012), to the four Class II peptides, producing TPIV110 (the five-peptide
product). Management believes that the combination of Class I and Class II HER2/neu antigens, gives us the leading HER2/neu vaccine
platform. We plan to amend the IND to incorporate the fifth peptide in the Phase I(b)/II study. Discussions with the FDA have resulted
in a pre-clinical development project that should allow us to file the amended IND in 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Products and Technology-Pre-clinical
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PolyStart&trade;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 7, 2017, we announced that
we received a Notice of Allowance from the U.S. Patent and Trademark Office of our patent application titled, &ldquo;Chimeric nucleic
acid molecules with non-AUG initiation sequences and uses thereof,&rdquo; which represents our first patent on our PolyStart&trade;
program. We anticipate additional patent filings in connection with our research and development in this area. We plan to develop
PolyStart&trade; primarily as a &lsquo;boost strategy&rsquo; to be used synergistically with our peptide-based vaccines for breast
and ovarian cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>TapImmune&rsquo;s
Clinical Program Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 321.75pt; width: 503.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>(Refer to the
&ldquo;Clinical Program Pipeline Status Updates&rdquo; section below for latest updates on above clinical pipeline chart).</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition to
the exciting clinical developments, our peptide vaccine technology may be coupled with our recently developed in-house PolyStart&trade;
nucleic acid-based technology, which is designed to make vaccines significantly more effective by producing four times the required
peptides for the immune systems to recognize and act on.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Developments and Updates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Completed GMP Manufacturing Scale
Up and Second Clinical Lot of TPIV200; to Supply Additional Phase II Clinical Trials</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We successfully completed a multi-gram
production scale-up as well as GMP manufacturing of a second clinical lot of TPIV200. The vaccine supply will be used in the company&rsquo;s
ongoing Phase II study in platinum-sensitive ovarian cancer, as well as the planned 280-patient Phase II study sponsored by the
Mayo Clinic and funded by the U.S. Department of Defense for treating triple-negative breast cancer. We also made various improvements
to the vaccine manufacturing process, resulting in, what we believe to be, a superior formulation of the vaccine that is more amenable
to large-scale manufacturing and commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Clinical Program Pipeline Status
Updates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Enrolling Patients: Phase II TPIV200
Trial in Triple-Negative Breast Cancer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have opened eleven clinical sites and
have enrolled over 50% of the patients in a Phase II trial of our Folate Receptor Alpha cancer vaccine, TPIV200, in the treatment
of triple-negative breast cancer, one of the most difficult cancers to treat, representing a clear unmet medical need. The open-label,
80-patient clinical trial is designed to evaluate dosing regimens, adjuvants, efficacy, and immune responses in women with triple-negative
breast cancer. Key data from the trial is expected to be included in a future Biologics License Application submission to the FDA
for marketing clearance. This trial is sponsored and conducted by TapImmune.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An independent Data Safety Monitoring Board
(DSMB) reviews the safety every quarter in this ongoing Phase 2 study enrolling women with stage I-III triple-negative breast cancer
who have completed initial surgery and chemo/radiation therapy. The randomized four-arm study is evaluating two doses of TPIV200
(a high dose and a low dose), each of which will be tested both with and without immune priming with cyclophosphamide prior to
vaccination. The first planned safety review was performed when enrollment reached the 25% benchmark (20 out of 80 total patients),
and showed no safety issues; the study has continued to enroll patients at multiple clinical sites. The study is expected to complete
enrollment by year end 2017, with top-line data expected in early 2018. Details regarding this trial can be found at www.clinicaltrials.gov
under identifier numbers NCT02593227 and FRV-002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Enrolling Patients: Phase II Trial
at Memorial Sloan Kettering of TPIV200 in Platinum-Resistant Ovarian Cancer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Phase II study of TPIV200 in ovarian
cancer patients who are not responsive to platinum, a commonly used chemotherapy for ovarian cancer, sponsored by Memorial Sloan
Kettering Cancer Center (&ldquo;MSKCC&rdquo;), and in collaboration with AstraZeneca and TapImmune, has begun enrollment for a
40-patient study. The open-label study is designed to evaluate a combination therapy which includes our TPIV200 T-cell vaccine
and AstraZeneca&rsquo;s checkpoint inhibitor, durvalumab. Because they are unresponsive to platinum, these patients have no real
remaining options. If the combination therapy proves effective, we believe it would address a critical unmet need. TPIV200 has
received Orphan Drug designation for use in the treatment of ovarian cancer. We successfully completed enrollment of the first
safety cohort. This may enable MSKCC to increase the number of patients that can be enrolled and will subsequently increase the
study&rsquo;s enrollment rate. Currently more than 50% of patients have been enrolled. An interim analysis is planned in the fourth
quarter of 2017. Details regarding this trial can be found at www.clinicaltrials.gov under identifier numbers NCT02764333 and 16-011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Enrolling Patients: Phase II TPIV200
Trial in Platinum-Sensitive Ovarian Cancer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have opened four clinical sites (with
at least another 10 sites anticipated to open during 2017) in a Phase II trial of TPIV200 for a 120-patient study on ovarian cancer
patients who are responsive to platinum. We have received the FDA&rsquo;s Fast Track designation to develop TPIV200 as a maintenance
therapy in combination with platinum, in platinum-responsive ovarian cancer patients. This multi-center, double-blind efficacy
study is sponsored and conducted by TapImmune. We expect to complete enrollment mid-2019. An interim analysis is planned based
upon 50% patient enrollment, which we anticipate completing in the second half of 2018. Details regarding this trial can be found
at www.clinicaltrials.gov under identifier numbers NCT02978222 and FRV-004.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patient Enrollment to Commence in
2017: Phase II Mayo Clinic-U.S. DOD Trial of TPIV200 in Triple-Negative Breast Cancer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We anticipate this Phase II study of TPIV200
in the treatment of triple-negative breast cancer, conducted by the Mayo Clinic and sponsored by the U.S. DOD, will begin to enroll
patients in 2017. The anticipated 280-patient study will be led by Dr. Keith Knutson of the Mayo Clinic in Jacksonville, Florida.
Dr. Knutson is the inventor of the technology and a member of the Scientific Advisory Board at TapImmune. While TapImmune is supplying
doses of TPIV200 for the trial, and being reimbursed for the costs associated with manufacturing, the remaining costs associated
with conducting this study will be funded by a $13.3 million grant made by the DOD to the Mayo Clinic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Open IND with FDA for TPIV110 in
2017: Phase II Protocol Now in Preparation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have enhanced the formulation of our
second cancer vaccine product, TPIV110 (five peptide product), following very strong safety and immune responses from a Phase I
Mayo Clinic study using TPIV100 (four peptide product). TPIV110 targets HER2/neu, which makes it applicable to breast, ovarian,
and colorectal cancers. The enhanced TPIV product adds a fifth antigen which should produce an even more robust immune response
activating both CD4+ and CD8+ T-cells. We have participated in a pre-Investigational New Drug (&ldquo;pre-IND&rdquo;) meeting with
the FDA and are now in discussions with the FDA as to requirements for filing the amended IND containing the fifth peptide, which
we expect to file later this year. The protocol for a Phase II trial of TPIV110 in the treatment of HER2/neu positive breast cancer
patients is currently under review by our Clinical Advisory Board and collaborators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Mayo Clinic to Vaccinate Women With
Ductal Carcinoma In Situ (DCIS) Using TapImmune TPIV100 HER2-targeted T-Cell Vaccine</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 14, 2017, we announced that our
partners at the Mayo Clinic received a grant from the U.S. Department of Defense to conduct a Phase II study of our HER2-targeted
vaccine candidate in an early form of breast cancer called DCIS. This is the second TapImmune vaccine to be tested in a fully funded
Phase II study sponsored by the Mayo Clinic. If successful, TapImmune&rsquo;s vaccine may eventually augment or even replace standard
surgery and chemotherapy, and potentially could become part of a routine immunization schedule for preventing breast cancer in
healthy women. The study is expected to enroll 40-45 women with DCIS and commence in 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In this discussion
of the Company&rsquo;s results of operations and financial condition, amounts, other than per-share amounts, have been rounded
to the nearest thousand dollars.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Three Months Ended June 30, 2017 Compared to Three Months
Ended June 30, 2016</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recorded a net loss of $1,893,000 or
($0.22) basic and diluted per share during the three months ended June 30, 2017 compared to net income of $5,974,000 or $1.01 basic
and $0.35 diluted per share during the three months ended June 30, 2016. The change period over period was due to the following
changes in operating expenses and other income (expense):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Operating Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating expenses incurred during the
three months ended June 30, 2017 were $2,393,000 compared to $2,426,000 in the prior period. Significant changes in operating expenses
are outlined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Research and development expenses during the three months ended June 30, 2017 were
                                                                                                               $1,203,000
                                                                                                               compared to $1,248,000 during the prior year period. The three months ended June 30, 2017 had increased expenses from prior
                                                                                                               period relating to our clinical trials. However, during the three months ended June 30, 2016, we incurred research expenses
                                                                                                               related                                                                                                                to
                                                                                                               the                                                                                                                Mayo
                                                                                                               Foundation license fee agreements which resulted in a decrease in total research and development expenses from prior year
                                                                                                               period.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">General and administrative expenses increased to $1,191,000 during the three months ended June
30, 2017 from $1,177,000 during the prior year period. Increased expenses period over period were found in the following areas:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">stock-based compensation for employees and outside consultants,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">compensation expenses resulting from increased headcount,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">investor relations expenses, and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">NASDAQ and other public-related expenses.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the three months ended
June 30, 2016, we incurred higher expenses in the areas of legal, audit and other professional fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Income (Expense)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Change in fair value of warrant liabilities</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The change in fair value of warrant liabilities
for the three months ended June 30, 2017 was $7,500 as compared to $8,237,000 for the three months ended June 30, 2016. On August
10, 2016, we amended the Series A and A-1, Series C and C-1, Series D and D-1 and Series E and E-1 warrants agreements issued by
us in January and March 2015 to remove the clause that caused the warrants to be classified as warrant liabilities, and the variance
period over period is due to that reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the warrant liabilities decreased by $7,500 for the three months ended June 30, 2017 and is reflected by a corresponding
gain in the condensed consolidated statement of operations. This compares to a decrease in the fair value of derivative liabilities
for the three months ended June 30, 2016 of $8,237,000. We revalue the derivative liabilities at each balance sheet date to fair
value. The fair value is determined using Black-Scholes valuation model using various assumptions. The two most significant changes
in the assumptions were the difference in the strike price and the number of warrants with derivative liabilities. The change in
fair value for the three months ended June 30, 2016 was primarily due to the difference in strike price at March 31, 2016 and June
30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Debt extinguishment gain</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2003 and further amended in 2008, we
acquired a research license and option agreement from Crucell Holland B.V. for use of an adenovirus technology. We have not made
use of the technology in our current work and have not asked for nor received any work product from Crucell. Crucell was acquired
by Johnson and Johnson in 2010. As of December 31, 2016, we had accrued $493,000 as amounts owed under the amended agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon further legal review and analysis
of the agreement undertaken during the quarter, we concluded that the statute of limitations has run out on the obligation, and
a legal opinion received by us confirms the amounts are not currently owed. As such, as of June 30, 2017, we were no longer obligated
to make the payments under the agreement. Therefore, we recorded a debt extinguishment gain of $493,000 during the three months
ended June 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Grant income</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30,
2016, we received $231,000 of a grant awarded to Mayo Foundation from the US Department of Defense for the Phase II Clinical Trial
of TPIV200. The grant compensated us for clinical supplies manufactured by us and provided for the clinical study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Shares issued in debt settlement
agreements</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three-month period ended June
30, 2016, we incurred $70,000 loss in connection with shares issued to satisfy an outstanding debt agreement from previous years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Six Months Ended June 30, 2017 Compared to Six Months
Ended June 30, 2016</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recorded a net loss of $4,313,000 or
($0.51) basic and diluted per share during the six months ended June 30, 2017 compared to net income of $1,224,000 or $0.21 basic
and ($0.19) diluted per share during the six months ended June 30, 2016. The change period over period was due to the following
changes in operating expenses and other expense:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Operating Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating expenses incurred during the
six months ended June 30, 2017 were $4,810,000 compared to $4,179,000 in the prior period. Significant changes in operating expenses
are outlined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Research and development expenses during the six months ended June 30, 2017 were $2,192,000
                                                                                                               compared to $2,234,000 during the prior year period. The six months ended June 30, 2017 had increases from prior period for
                                                                                                               planned expenses relating to our clinical trials. However, during the six months ended June 30, 2016, we incurred research
                                                                                                               expenses related to the Mayo Foundation license fee agreements which resulted in a decrease in total research and development
                                                                                                               expenses from prior year period.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">General and administrative expenses increased to $2,618,000 during the six months ended June 30,
2017 from $1,945,000 during the prior year period. This was due to increased expenses relating to:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">stock-based compensation for employees and outside consultants,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">compensation expenses resulting from increased headcount,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">investor relations expenses,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">NASDAQ and other public-related expenses, and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">increased legal, audit and other professional fees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Income (Expense)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Change in fair value of warrant liabilities</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The change in fair value of warrant liabilities
for the six months ended June 30, 2017 was $4,500 as compared to $5,241,000 for the six months ended June 30, 2016. On August 10,
2016, we amended the Series A and A-1, Series C and C-1, Series D and D-1 and Series E and E-1 warrants agreements issued by us
in January and March 2015 to remove the clause that caused the warrants to be classified as warrant liabilities, and the variance
period over period is due to that reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the warrant liabilities decreased by $4,500 for the six months ended June 30, 2017 and is reflected by a corresponding
loss in the condensed consolidated statement of operations. This compares to a decrease in the fair value of derivative liabilities
for the six months ended June 30, 2016 of $5,241,000. We revalue the derivative liabilities at each balance sheet date to fair
value. The fair value is determined using Black-Scholes valuation model using various assumptions. The two most significant changes
in the assumptions were the difference in the strike price and the number of warrants with derivative liabilities. The change in
fair value for the six months ended June 30, 2016 was primarily due to the difference in strike price at December 31, 2015 and
June 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Debt extinguishment gain</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2003 and further amended in 2008, we
acquired a research license and option agreement from Crucell Holland B.V. for use of an adenovirus technology. We have not made
use of the technology in our current work and have not asked for nor received any work product from Crucell. Crucell was acquired
by Johnson and Johnson in 2010. As of December 31, 2016, we had accrued $493,000 as amounts owed under the amended agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon further legal review and analysis
of the agreement undertaken during the quarter ended June 30, 2017, we concluded that the statute of limitations has run out on
the obligation, and a legal opinion received by us confirms the amounts are not currently owed. As such, as of June 30, 2017, we
were no longer obligated to make the payments under the agreement. Therefore, we recorded a debt extinguishment gain of $493,000
during the six months ended June 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Grant income</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2016,
we received $231,000 of a grant awarded to Mayo Foundation from the US Department of Defense for the Phase II Clinical Trial of
TPIV200. The grant compensated us for clinical supplies manufactured by us and provided for the clinical study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Shares issued in debt settlement
agreements</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six-month period ended June
30, 2016 we incurred $70,000 loss in connection with shares issued to satisfy an outstanding debt agreement from previous years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Liquidity and Capital Resources</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not generated any revenues since
inception. We have financed our operations primarily through public and private offerings of our stock and debt including warrants
and the exercises thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth our cash
and working capital as of June 30, 2017 and December 31, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June
30, 2017</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December
31, 2016 </B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 62%; font-size: 10pt">Cash</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">9,963,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">7,851,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Working capital</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">8,566,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">6,185,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash Flows </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes our cash flows for the six months
ended June 30, 2017 and 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Net cash provided by (used in):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 62%; font-size: 10pt; text-align: left; padding-left: 0.125in">Operating activities</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">(3,936,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">(2,784,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Financing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,047,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(25,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Net increase (decrease) in cash</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,111,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,809,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>June 2017 Private Placement Transaction</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 26, 2017, we completed private
placements of units with certain accredited investors. In the private placement transaction, we sold 1,503,567 shares of common
stock for $3.97 per share and five-year warrants to purchase an equal number of shares of common stock, at an exercise price of
$3.97 per share, for $0.125 per warrant, with one common share and one warrant being sold together as a unit for a total of $4.095
per unit. We issued and sold an aggregate of 1,503,567 million units for aggregate gross proceeds of $6.2 million. We incurred
$0.8 million in agency fees and legal costs. In connection with the offering, we reduced the exercise price for the warrants to
purchase an aggregate of 653,187 shares of common stock issued to investors in the private placement that closed in August 2016
from $6.00 per share to $3.97 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we issued five-year warrants
to the placement agent in the offering providing for the purchase of up to 150,357 shares of our common stock for $3.97 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to a Registration Rights Agreement
to be entered into at the closing of the private placement offering, promptly, but no later than 90 calendar days after the closing
of the offering, we are required to file a registration statement with the Securities and Exchange Commission registering for resale
(a) the common stock issued in the offering; (b) the shares of common stock issuable upon the exercise of the private placement
warrants; and (c) the shares of common stock issuable upon the exercise of the warrants issued to Katalyst Securities LLC, which
acted as placement agent for the offering. We are required to use its commercially reasonable efforts to ensure that the Registration
Statement is declared effective within 90 calendar days after filing with the Securities and Exchange Commission, on or before
December 23, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the registration rights
agreements, should we fail to meet the above criteria, we are subject to pay the investors liquidated damages. The liquidated damages
shall be a cash sum payment calculated at a rate of ten percent (10%) per annum of the aggregate purchase price for the registrable
securities or aggregate amount upon exercise of the placement agent warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with U.S. GAAP, a contingent
obligation to make future payments must be recorded if the transfer of consideration under a registration payment arrangement is
probable and can be reasonably estimated. We have determined that should it be required to pay liquidated damages to the investors
of the private placements, the aggregate contingent liability it would be required to record would be approximately $57,000 per
month for each month it fails or is estimated to fail to meet the above criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the June 26, 2017 private placement
closing, and on June 30, 2017, we concluded that it is not probable that it will be required to remit any payments to the investors
for failing to obtain an effective registration statement or failing to maintain its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>June 2017 Exercise and Repricing
of Warrants Held by Existing Institutional Investors</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 23, 2017, certain existing institutional
shareholders of the Company who hold various outstanding warrants (i.e. C, D, E and F) to purchase Company common stock, entered
into warrant repricing and exercise agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Series E repriced and exercised warrants
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximately 168,000 of Series E warrants
were repriced from $15.00 per share to $3.97 per share and exercised immediately for gross proceeds of approximately $0.7 million.
Series E warrants to purchase approximately 187,000 shares of Company common stock being reduced from $15.00 per share to $4.50
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Series C, D &amp; F repriced warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the exercise prices for certain
investors of Series C, Series D and Series F warrants were reduced as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Series</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Warrant Shares Repriced</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Pre-reduced&nbsp;&nbsp;<BR>
Price</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Post-reduced <BR>
Price</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; font-size: 10pt; text-align: left">Series C</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: right">313,750</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: right">6.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: right">4.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Series D</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">312,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">9.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Series F</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">292,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">7.20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value relating to the modification
of exercise prices on all of the repriced warrants was treated as deemed dividend on the statement of stockholders&rsquo; equity
of $622,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>June 2017 Agent Warrants</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to an agency agreement, dated
May 12, 2017, by and between Katalyst Securities LLC and us, Katalyst agreed to act as our placement agent in connection with the
June 26, 2017 private placement offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the agreement, we agreed to
pay to Katalyst: (i) an aggregate cash fee for placement agent and financial advisory services equal to 10% of the gross proceeds
of the Offering; (ii) a non-accountable expense allowance in the amount of Seventy Thousand Dollars ($70,000); and (iii) five-year
warrants to purchase a number of shares of our common stock equal to 10% of the number of shares sold in the offering. The Katalyst
Warrants have the same terms as the private placement warrants issued in the offering. Based on the 1,503,567 shares of common
stock sold in the private placement, we issued five-year warrants to Katalyst providing for the purchase of up to 150,357 shares
of Company common stock for $3.97 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Previous Funding</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our previous funding has come from financings
that we conducted in January and March of 2015, from the exercises of stock warrants. In our August 2016 private placement, we
completed private placements of units with certain accredited investors. The units consisted of (i) one share of our common stock,
par value $0.001 per share and (ii) one five-year warrant to purchase one share of our common stock for $6.00. We issued and sold
an aggregate of 653,187 units at a purchase price per unit of $4.80 for an aggregate of $3,100,000. We incurred $0.8 million in
agency fees and legal costs. In addition, we issued five-year warrants to the placement agent in the offering providing for the
purchase of up to 65,327 shares of our common stock for $4.80 per share. In connection with the August 2016 private placement,
holders of an aggregate of 583,333 outstanding Series C Warrants and 416,667 Series C-1 Warrants, each providing for the purchase
of one share of our common stock for $6.00 per share, exercised their warrants for an aggregate exercise price of $6,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Future Capital Requirements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2017, we had working capital
of $8,566,000, compared to working capital of $6,185,000 as of December 31, 2016. We expect our expenses to continue at a similar
pace during the remainder of 2017 and into 2018 primarily to fund our Phase II clinical trials. Our collaborators at Mayo Clinic
recently announced a $3.8 million grant which will fully fund a Phase II trial in DCIS that we had planned for our HER2/neu vaccine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our capital requirements for 2017 and through
and beyond 2018 will depend on numerous factors, including the success of our research and development, the resources we devote
to develop and support our technologies and our success in pursuing strategic licensing and funded product development collaborations
with external partners. Subject to our ability to raise additional capital, we expect to incur substantial expenditures to further
develop our technologies including continued increases in costs related to research, nonclinical testing and clinical studies and
trials, as well as costs associated with our capital raising efforts and being a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe our existing cash could fund
our operations through the end of fiscal 2018. We will require additional substantial capital to conduct research and development,
to fund nonclinical testing and Phase II clinical trials of our licensed, patented technologies, and to begin cultivating collaborative
relationships for the Phase II and future Phase III clinical testing. Our plans could include seeking both equity and debt financing,
alliances or other partnership agreements with entities interested in our technologies, or other business transactions that would
generate sufficient resources to ensure continuation of our operations and research and development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to continue to seek additional
funding for our operations. Any such required additional capital may not be available on reasonable terms, if at all. If we were
unable to obtain additional financing, we may be required to reduce the scope of, delay or eliminate some or all of our planned
clinical testing and research and development activities, which could harm our business. The sale of additional equity or debt
securities may result in additional dilution to our shareholders. If we raise additional funds through the issuance of debt securities
or preferred stock, these securities could have rights senior to those holders of our common stock and could contain covenants
that would restrict our operations. We also will require additional capital beyond our currently forecasted amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of the numerous risks and uncertainties
associated with research, development and commercialization of our product candidates, we are unable to estimate the exact amounts
of our future working capital requirements. Our future funding requirements will depend on many factors, including, but not limited
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the number and characteristics of the product candidates we pursue;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the scope, progress, results and costs of researching and developing our product candidates, and conducting pre-clinical and clinical trials including the research and development expenditures we expect to make in connection with our license agreements with Mayo Foundation;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">our ability to maintain current research and development licensing agreements and to establish new strategic partnerships and collaborations, licensing or other arrangements and the financial terms of such agreements;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">our ability to achieve our milestones under our licensing arrangements and the payment obligations we may have;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the timing, receipt and amount of sales of, or royalties on, our future products, if any.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have based our estimates on assumptions
that may prove to be wrong. We may need to obtain additional funds sooner or in greater amounts than we currently anticipate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Various conditions outside of our control
may detract from our ability to raise additional capital needed to execute our plan of operations, including overall market conditions
in the international and local economies. We recognize that the United States economy has suffered through a period of uncertainty
during which the capital markets have been impacted, and that there is no certainty that these levels will stabilize or reverse
despite the optics of an improving economy. Any of these factors could have a material impact upon our ability to raise financing
and, as a result, upon our short-term or long-term liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Critical Accounting Policies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The condensed consolidated financial statements
are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported
amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported
amounts of expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances
are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates,
requiring adjustments to these balances in future periods. The critical accounting estimates that affect the consolidated financial
statements and the judgments and assumptions used are consistent with those described under Part II, Item 7 of our Annual Report
on Form 10-K for the year ended December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Going Concern</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have no sources of revenue to provide
incoming cash flows to sustain our future operations. As outlined above, our ability to pursue our planned business activities
is dependent upon our successful efforts to raise additional capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These factors raise substantial doubt regarding
our ability to continue as a going concern. Our condensed consolidated financial statements have been prepared on a going concern
basis, which implies that we will continue to realize our assets and discharge our liabilities in the normal course of business.
Our financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and
classification of liabilities that might be necessary should we be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audit report prepared by our independent
registered public accounting firm relating to our consolidated financial statements for the year ended December 31, 2016 included
an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not entered into any off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes of
financial condition, revenues, expenses, results of operations, liquidity, capital expenditures or capital resources that is material
to investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 0.5pt solid"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_008"></A>Item 3.</TD><TD>Quantitative and Qualitative Disclosures About Market Risk</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a smaller reporting company as defined
by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 0.5pt solid"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_009"></A>Item 4.</TD><TD>Controls and Procedures</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>(a)</B></TD><TD STYLE="text-align: justify"><B>Evaluation of Disclosure Controls and Procedures</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management, with the participation
of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and
procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered
by this report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that
information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to
management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding
required disclosure. Based on such evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that,
as of the end of the period covered by this report, our disclosure controls and procedures are not effective in recording, processing,
summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit
under the Exchange Act. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It should be noted that any system of controls is based in part
upon certain assumptions designed to obtain reasonable (and not absolute) assurance as to its effectiveness, and there can be no
assurance that any design will succeed in achieving its stated goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>(b)</B></TD><TD STYLE="text-align: justify"><B>Changes in Internal Control Over Financial Reporting</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no changes in our internal
control over financial reporting during the three months ended June 30, 2017 that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PART II &ndash; OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 0.5pt solid"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_010"></A>Item 1.</TD><TD>Legal Proceedings</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management is not aware of any material
legal proceedings and there are no pending material procedures that would affect the property of the Company. Management is not
aware of any legal proceedings contemplated by any government authority or any other party involving the Company. As of the date
of this Quarterly Report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an
adverse interest to us in any legal proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 0.5pt solid"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_011"></A>Item 1A.</TD><TD>Risk Factors</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For risk factors, see Item 1.A.-&ldquo;Risk
Factors&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2016 filed on March 14, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 0.5pt solid"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_012"></A>Item 2.</TD><TD>Unregistered Sales of Equity Securities and Use of Proceeds</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt; text-align: justify">(a)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Other than as set forth on Form 8-K filed with the SEC on June 26, 2017, we issued the following unrestricted securities during the period covered by this report to the named individual pursuant to exemptions under the Securities Act of 1933 including Section&nbsp;4(2): </TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 16, 2017, we issued 16,667 shares
of common stock to Collision Capital, LLC pursuant to a vendor agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 0.5pt solid">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.75in; font-size: 10pt"><A NAME="a_013"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 3.</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Defaults Upon Senior Securities</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 0.5pt solid"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_014"></A>Item 4.</TD><TD>Mine Safety Disclosure</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 0.5pt solid"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_015"></A>Item 5.</TD><TD>Other Information</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 0.5pt solid"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_016"></A>Item 6.</TD><TD>Exhibits</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following exhibits are included with
this Quarterly Report on Form 10-Q:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Incorporated by Reference</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">Exhibit<BR> number</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Exhibit description</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Form</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">File&nbsp;no.</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Exhibit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.3pt; text-align: center"><B>Filing</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.3pt; text-align: center"><B>date</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 4.3pt; text-align: center"><B>Filed</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>herewith</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: left">3.1</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: left">Amendment to Amended and Restated Bylaws</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: center">8-K</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: center">001-37939</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: center">3.1</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 9%; font: bold 10pt Times New Roman, Times, Serif; text-align: center">7/11/17</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 9%; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">4.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Form of PIPE Warrant</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">8-K</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">001-37939</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">4.1</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">6/22/17</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">4.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Form of Katalyst Warrant</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">8-K</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">001-37939</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">4.2</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">6/22/17</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">10.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Form of Subscription Agreement</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">8-K</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">001-37939</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">10.1</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">6/22/17</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">10.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Registration Rights Agreement</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">8-K</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">001-37939</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">10.2</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">6/22/17</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">10.3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Form of Warrant Exercise Agreement</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">8-K</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">001-37939</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">10.3</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">6/22/17</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">10.4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Agency Agreement</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">8-K</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">001-37939</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">10.4</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">6/22/17</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">10.5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;Amendment to Placement Agency Agreement</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>8-K&nbsp;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>001-37939&nbsp;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>10.5&nbsp;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>6/22/17</B></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">31.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1933, as amended.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">X</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">31.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Certification of Chief Financial Officer and Chief Accounting Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1933, as amended</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">X</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">32.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1933, as amended.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">X</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">32.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Certification of Chief Financial Officer and Chief Principal Accounting Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">X</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Exhibit 101</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">101.INS - XBRL Instance Document</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">101.SCH - XBRL Taxonomy Extension Schema
Document</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">101.CAL - XBRL Taxonomy Extension Calculation
Linkbase Document</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">101.DEF - XBRL Taxonomy Extension Definition
Linkbase Document</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">101.LAB - XBRL Taxonomy Extension Label
Linkbase Document</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">101.PRE - XBRL Taxonomy Extension Presentation
Linkbase Document</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">__________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_017"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the requirements of
the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TAPIMMUNE INC.</B></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 35%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Glynn Wilson</I></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Glynn Wilson</B></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, Chief Executive Officer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 7, 2017</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>v471682_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Glynn Wilson, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">I have reviewed this Report on Form 10-Q for the quarterly period ended June 30, 2017 of TapImmune
Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Based on my knowledge, this Report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this Report;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this
Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this Report;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting
in the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Disclosed in this Report any change in the registrant&rsquo;s internal control over financial reporting
that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case
of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
control over financial reporting; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(5)</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent
evaluation of the internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the
registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize
and report financial information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">Date:</TD><TD STYLE="text-align: justify">August 7, 2017</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Glynn Wilson</I></FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 35%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Glynn Wilson</B></FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>v471682_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Michael J. Loiacono, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">I have reviewed this Report on Form 10-Q for the quarterly period ended June 30, 2017 of TapImmune
Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Based on my knowledge, this Report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this Report;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this
Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this Report;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting
in the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Disclosed in this Report any change in the registrant&rsquo;s internal control over financial reporting
that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case
of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
control over financial reporting; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(5)</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent
evaluation of the internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the
registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize
and report financial information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">Date:</TD><TD STYLE="text-align: justify">August 7, 2017</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Michael J. Loiacono</I></FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 35%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Michael J. Loiacono</B></FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer and Chief Accounting Officer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>v471682_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned, Glynn Wilson, the Chief
Executive Officer of TapImmune Inc. (the &ldquo;Company&rdquo;) hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Report on Form 10-Q of TapImmune Inc., for the quarterly period
ended June 30, 2017, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and
that the information contained in the Report on Form 10-Q fairly presents in all material respects the financial condition and
results of operations of TapImmune Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 7, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 35%; padding: 0; text-align: justify; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Glynn Wilson</I></FONT></TD>
    <TD STYLE="width: 60%; padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Glynn Wilson</B></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>v471682_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL ACCOUNTING
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned, Michael J. Loiacono, the
Chief Financial Officer and Chief Accounting Officer of TapImmune Inc. (the &ldquo;Company&rdquo;) hereby certifies, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Report on Form 10-Q of TapImmune
Inc., for the quarterly period ended June 30, 2017, fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, and that the information contained in the Report on Form 10-Q fairly presents in all material respects the
financial condition and results of operations of TapImmune Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 7, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 35%; padding: 0; text-align: justify; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Michael J. Loiacono</I></FONT></TD>
    <TD STYLE="width: 60%; padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Michael J. Loiacono</B></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer and Chief Accounting Officer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
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M@9%"(Q8*\&&AL=$S0R87&,%B@F,E1SA(>!HJ.A$  0(% @0$ P8#!@<
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M>:5DFHU^]8]M,%=*79X]"3KUHK4FTEH.78N"[IN&+]FJHBJ&^Y3%W[R' 2F
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<6)Z]X>UOMTW]?A\]_LU#YB6Z>D3*9Z#YCA'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI8VAA96P@
M3&]I86-O;F\    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,S
M,0  DI(  @    ,S,0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MSM/^%K>)O^>MM_WX%'_"UO$W_/6V_P"_ KBZ*/JM#^1![:I_,SM/^%K>)O\
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MK;?]^!1_PM;Q-_SUMO\ OP*XNBCZK0_D0>VJ?S,[3_A:WB;_ )ZVW_?@4?\
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MM4M9_P"0#?\ _7M)_P"@FJA\2%+9GS-1117VQ\\%%%% !1110 4444 %%%%
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M&U2^)KYX-,FM(K"]NGNH'16MH=ZH2,?,>W6J?@JYFBTF'3+G3KZWEA1F:2:
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MM\Y#[B>N[(.\<GALCD^IJK11]5H?RK^OZ_+L@^OXG^=_U_7XON[VAJ=^-O\
MILK;6+?.0^XGKNR#O')X;(Y/J:!J=^-O^FRMM8M\Y#[B>N[(.\<GALCD^IJK
M11]5H?RK^OZ_+L@^OXG^=_U_7XON[N=WD=GE=I'8Y9G8DL?4D]:;1170DDK(
MXVW)W9JZW_JM+_Z\4_\ 0FK*K5UO_5:7_P!>*?\ H35E5%/X1RW"BBBM"0HH
MHH **** "BBB@ HHHH *L6'_ "$K;_KJO\Q5>K%A_P A*V_ZZK_,4I;,:W)=
M9_Y#U_\ ]?,G_H1JE5W6?^0]?_\ 7S)_Z$:I4H?"@ENPHHHJA!1110 4444
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MOR?^!5'_  K7PA_?D_\  JC^TJ/9_<'U2IY'B5%>V_\ "M?"']^3_P "J/\
MA6OA#^_)_P"!5']I4>S^X/JE3R/$J*]M_P"%:^$/[\G_ (%4?\*U\(?WY/\
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MU\(?WY/_  *H_P"%:^$/[\G_ (%4?VE1[/[@^J5/(\2HKVW_ (5KX0_OR?\
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M&/51Z?2M[0-?:!UCE;Y:X:M.5&?+(Z(34XW1Z%14-M<I<1!D.<U-4%!1110
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M&MV@?[+"@ 41Y^YD'=E<$DYS70P>!O#]L56&TG6W63S%L_MLYM5;=NX@+^6
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M^)/_ (FJ/Q#/_$AM_P#KZ7_T!Z\ZS7I8?"0JT^:39R5:\H2LCU/_ (3/0?\
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MRS-&:/[/I=W_ %\@^M3\CU/_ (3/0?\ G^/_ 'XD_P#B:/\ A,]!_P"?X_\
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M]OWYV)&50;2% P3@D\8%6[?QC%+=VL$^D:E:"^5C8RW"1!;HA=VU0')1BH)
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M7Y+O<]IKJ[;_ (]8O]P?RKE*ZNV_X]8O]P?RK*KLBXDE%%%8%A1110 5'/\
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M\,VOA;5;&?2S*EEJ,;.D$V=\1&,KSSC##KSUS7/V>H76F7D5]ITWD7,)W1R
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MCT*BH;:Y2XB#(<YJ:I*"IK?K)_US;^50U-;]9/\ KFW\J3V&0T444Q!1110
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MMWF<[L>^>];5_!<VOC7X7P7Y)NHK>Z28DY^<6R@_K6GV[=G^C_KYDK:_=/\
M+^ON.BU[XF>#_#.I&PUK6XH+M1EHDCDE*>S;%.T]\'!Q5/QU\1K#PSX'36=-
MN[:XGO5!T[>CR1SG()R5QC@GJ17)ZCXDN[GQ3XDBC\8:/X(BL+GRVB>PBEN+
M_"#]ZXD(+< !=H)(X],T=/#2_LJ7WEMYH F8,%VY47!)..PQSBL>=N#?E?\
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M_$3PII/B)-"U#688M2=E3R=CL%9N@9@"JGZD=1ZU*;YO^%BK8?V]A?[-\_\
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MF_\ =IN' (!.!V&<54\.Z4EW>:'YUQXE^U:5&=EO=:=%;P6A\HH5WB! Z\X
M1FSP>@R/1:*2C_7S;_4&[_UY)?H<3X,D%AHVG:%J&C7G]J6CN9I&L6\D2_,3
M.)R-AW9ZJ2WSXQUQS<*:S?7'AP3PZS'=6VK)+=6$>E)#9V*[F4[)!&"RX;&5
MD8$$DXS7K5%.VJ?:WX ]4UW"BBBJ$%%%% !1110 5U=M_P >L7^X/Y5RE=7;
M?\>L7^X/Y5A5V1<22BBBL"PHHK/U[4;C2=$N+VRT^749X0"EK%G=)E@., GO
MGIVIQ3DTD)M)79H5'/\ \>\G^X?Y5P,7QAT4VEU'J$%UI>HP1G-O<0%P90#\
M@V\\$?Q!?PKHO"FL7NO^"K?4]3@2"XN(W8I&I5<9(4@$DX( /6NB>&JTH\TU
M97_JQST\51JRY8.[_P N_8H4445J6%%%% !1110 4444 %%%% !1110 5-=?
M\?4GUJ&M>2W@>0LT62>OS&HD[,:5S(HK5^RV_P#SQ_\ 'C1]EM_^>/\ X\:.
M=#L95%:OV6W_ .>/_CQH^RV__/'_ ,>-'.@L95%:OV6W_P">/_CQH^RV_P#S
MQ_\ 'C1SH+&516K]EM_^>/\ X\:/LMO_ ,\?_'C1SH+&516K]EM_^>/_ (\:
M/LMO_P \?_'C1SH+&516K]EM_P#GC_X\:/LMO_SQ_P#'C1SH+&516K]EM_\
MGC_X\:/LMO\ \\?_ !XT<Z"QE45J_9;?_GC_ ./&C[+;_P#/'_QXT<Z"QE45
MJ_9;?_GC_P"/&C[+;_\ /'_QXT<Z"QE45J_9;?\ YX_^/&C[+;_\\?\ QXT<
MZ"QE45J_9;?_ )X_^/&C[+;_ //'_P >-'.@L95%:OV6W_YX_P#CQH^RV_\
MSQ_\>-'.@L95%:OV6W_YX_\ CQH^RV__ #Q_\>-'.@L4&_X\8O\ KH_\EJ&M
M@VT'V=!Y7 9B!N/H*9]EM_\ GC_X\:2F@L95%:OV6W_YX_\ CQH^RV__ #Q_
M\>-/G06,JBM7[+;_ //'_P >-'V6W_YX_P#CQHYT%C*HK5^RV_\ SQ_\>-'V
M6W_YX_\ CQHYT%C*HK5^RV__ #Q_\>-'V6W_ .>/_CQHYT%C*HK5^RV__/'_
M ,>-'V6W_P">/_CQHYT%C*HK5^RV_P#SQ_\ 'C1]EM_^>/\ X\:.=!8RJF'_
M !Y'_KH/Y&K_ -EM_P#GC_X\:?\ 9H/((\KC=G&X^E)S06,>BM7[+;_\\?\
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MO>U=^^QYN$HRC.[:]WW=%:^VYRE%%%9G:%%%% !1110 4444 %%%% !1110
M5MM]ZL2MMOO5E,I#:***@H**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH >?]2O^\?Z4RGG_ %*_[Q_I3*0!1113 **X
MF\N-8U3XI76B6VOWNEV-OI,5TJ6D-NQ:1I74DF6)SC ' Q4VB^(-0T[Q;?\
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M?46KONFEY:;'FX*M*3Y'-.R[--^>N_J8E%%%9'<%%%% !1110 4444 %%%%
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MHCQ%;:7'?0:K)>OYD3*@=8U (0(/N@ 9 [YJ>:T>9[))_>BG'WN5;W:^Y_\
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MRG_\L?\ @5(#G/&>OW7AW1X;JRCA>22X$1$P) !5CV(_NUQ/_"T-;_Y]]/\
M^_3_ /Q==#\4O^19M?\ K\7_ - >O*<U[N"P]*I1YI*[/-Q%6<:EDSM?^%H:
MW_S[Z?\ ]^G_ /BZ/^%H:W_S[Z?_ -^G_P#BZXK-&:[?JE#^5&'MZG<[7_A:
M&M_\^^G_ /?I_P#XNC_A:&M_\^^G_P#?I_\ XNN*S1FCZI0_E0>WJ=SM?^%H
M:W_S[Z?_ -^G_P#BZ/\ A:&M_P#/OI__ 'Z?_P"+KBLT9H^J4/Y4'MZG<[7_
M (6AK?\ S[Z?_P!^G_\ BZ/^%H:W_P ^^G_]^G_^+KBMWO1N]Z/J='^4/;U.
MYVO_  M#6_\ GWT__OT__P 71_PM#6_^??3_ /OT_P#\77%;J,T?4Z'\J#V]
M3N=L?BCKAQFWT_@8_P!4_P#\72?\+0UO_GWT_P#[]/\ _%UQ6:,T?4Z'\J#V
M]3N=K_PM#6_^??3_ /OT_P#\71_PM#6_^??3_P#OT_\ \77%9HS1]4H?RH/;
MU.YVO_"T-;_Y]]/_ ._3_P#Q='_"T-;_ .??3_\ OT__ ,77%;O>C=1]3H?R
MH/;U.YVO_"T-;_Y]]/\ ^_3_ /Q='_"T-;_Y]]/_ ._3_P#Q=<5FC-'U2A_*
M@]O4[G:_\+0UO_GWT_\ []/_ /%T?\+0UO\ Y]]/_P"_3_\ Q=<5FC-'U2A_
M*@]O4[G:_P#"T-;_ .??3_\ OT__ ,71_P +0UO_ )]]/_[]/_\ %UQ6:,T?
M5*'\J#V]3N=K_P +0UO_ )]]/_[]/_\ %T#XH:V#G[/I_P#WZ?\ ^+KBLT9H
M^J4/Y4'MZG<[8_%'6R2?L^G\_P#3)_\ XND_X6AK?_/OI_\ WZ?_ .+KBLT9
MH^J4/Y4'MZG<ZZ]^(NL7]A<6DT%B([B)HG*QN" PP<?/UYKE=U1YHS6L*,*:
MM!6(E.4OB9)NIT<QC?<OXCUJ'-&:J4(SCRRV)C)Q=T=-H^L/:R*\;';GD>E>
MFZ-K,=] OS#=BO#XIFB?<OXCUKH]&UE[617C8[<\CTKYO%866'E=?"SUJ-95
M5YGLM%8^C:S'?0+\PW8K8KC.@**** "GQ_Q?[IIE/C_B_P!TT@&4444P"BBB
M@ HHHH **** "BBN6\>>(SH>CK#:R^7>7C%(V'6-0/F?\!T]R*-Q-VU*?C#Q
MR-+WV>E,AG4[))RNX(W]Q5_B?U[#OZ56^&^IWNIR:C;ZK)))-E9HS*^YMIX/
ML.<< 8KCK+3_ +08Y77E1A5Z[%ZX^N>2>YKJM(!T34K;4U!\N,[)P.\;<$_A
MP?PKHE22AKN<L:TI5/(]$%H/2N>\=:/J][X5F;PU>S6>IVI\^ PMCS,=4([@
MCL>X%=FBHZ!D(96&01W%.\L"N).SN=C5U8\<^'_Q:&LW4>C>*8TL]3)VQ3#Y
M8YSZ8_A;V[UZA7GGQ'^#Z:[-)JOAPI;WS'?) 3M61O[RG^%OTK9^'^IZQ=Z"
M;+Q/9SVVJ6#>3*TR8\Y?X7!Z'CJ1W'O73/D:YH&%-S3Y9G5449'J**S-@HHH
MH **** "BBB@ K4C_P!6OT%9=:D?^K7Z"HD-#J***@85A^--*N-;\&:EI]GS
M/-#^[4'&X@A@OXXQ^-;E<!\2?B /#4$FEV!N(=5EB26&=8D:-06P<[CUPI[&
MM\/"I.K%4][F->I"G2<JFQA0_%"UM?"J>'I]$U!=82U%D+8QC:7V[!U.[G@X
MVYYQ[UVO@;2KK1?A[965^C1W"Q.[HW5-S,V/P!KE)?C9HYT=XXK?4A?& JLO
ME1!1)MX/WCQGGH?I78>$+S5-0\"VMUKV3?2Q.SEHPA(R=I(  'RX[5Z&*A.%
M)WARWDKZWN]=O(\W"3A*K%*?-9.VEK+3?SV_$I4445S'I!1110 4444 %%%%
M !1110 4444 %;;?>K$K;;[U93*0VBBBH*"BBB@#'\/>&+/PTVJ-8RSR'5+^
M2_F\Y@=LCXR%P!A>.,Y/O1X;\,V?A>TO+?3Y9Y$O+V6]D,[ D/(<L!@#CT[^
M];%%&WY?+^D#UW]3A];\(0Z-\/\ QG!HHN[NXUD7=XT1 =C-(F-J!5!QP,#D
M^]87A[X,Z-<>&M'74KO7H[0VT,MSH+W[K:&7:&;=$1N!WY8C(Y_*O5:*25G?
MT_ &[_C^)C:CX7L=3\1Z)K,SS1W&BF;[-'$5$;>8FQMPQG@#C!%8FO\ PPTO
M6M>EUFSU76]!O[A0MU+HU[]G^TXX7>,') ';'OFNTHHL%S+\.^'[3PSHR:=8
MR7$RJS223W4QEEFD8Y9W8]6)))Z#VIOB#PY:>)(K".^DFC%C?17T?DL!F2,Y
M4'(/R^O0^]:U%/K?^M ,+QCX/TOQSX=DT;6UD\AG619(6"R1..C*2" <$CH>
M":SM9^&VC:UHNDV,D]_:7&CQK%8ZE9W'E74("A3AP,<@8/'TQ7744K(+G"CP
M V@>&=?;2+W4?$&LWUB\$<FNW?V@N-K;8N<*%W,3SW8Y.*\ILM/\0V^F6MCX
M=7XJPZ] D:0+?.J:8DJXR#N^7RA@X!X(P.]?2%%*VM_Z_K4.G]?UT.*UKX:6
MFOZE%J\FKZQHNKM;K#=W.B7AM_M. ,;A@Y .<=.O.<#$NF?##P[I/AG6/#]J
MERVG:N[23Q2SEBI*A3M;K_"#R3S^5=A13:337<%=6\CBE^&&GMX'OO"U[KFN
MW]E>,A,UY>+++$$*D(A*X5?D'&.YJ]XU\ Z3X\TNUL=8ENH5M9?,CDM)%1^5
M*LI)4_*0>173T4WKN"TV_JYEZQX;TK7O#LFAZK:+/ITD:QF')& N-N".01@8
M(KG-#^%UEHVK6E]<>(_$NL?8COMK?5-2,L,3X*AP@4<@$@=L$\5V]%'6_472
MP4444#"BBB@!Y_U*_P"\?Z4RGG_4K_O'^E,I %%%%, K@9/$?BJ]U+Q6-*N=
M&M[?09O+CBNK*5VF_<K)\TBS*%^\1G8<>]=]7C3)X/N/%OCVU\8:]_9WG7BH
M(?[9DM?,C-M&"?*60"3OU5L].>E1)N[MV?YHI6TOW7ZGH>G^--.N/!>F>(M1
M+6,6HQ1M' 09)&=QD1HJ@M(W7 49(&<5=T?Q+I>NRW,.GSR?:+4@3V]S;R6\
MT>1D$QR*K $=#C!YP>#7F=C<:G:6/P^UWQ9;O!9:?)=PW$TL/E"V5U*6\LJ@
M 1C: "3@ L,XS6CJ@D\8>,-7O_"%Q'=VL?AJ?3S>P,&AEN)&W1QK(.&*\DXS
MMW 'DU4W9MI=_P %?_@?,F*NE=]OSM_P3KHO'WAN:Z@A2_DV7$WD079M9A:R
MR<_*MP4\IB2"!AN3P.:LZAXMT;3-3:PN[F3[0BJ\PBMI95MU;.UI712L0."<
MN5& 3T%><ZEK&F:S\%;;PII#H?$$MI;V2:.O_'S;SH5#%X_O1A"I8LP  &<]
M*L^+[^'PQKM[J_AGQ''%XC801W>@W$0D_M9@H6/9&<2!B''SQDK\N#T:F])6
M\_O_ *^8EJKG12^/U@^)DOAV2UNFM$L%F$D6EW,CF8RE>JJ08\8^?&W.?F[5
MVE<!=:A;:3\;(+K69XM/BOM 6WMWN9 B23"XR8U8X!8;UX'/-=_27PJ_G^;&
M_B?R_)!1113 *?\ \L?^!4RG_P#+'_@5(#AOBH<>%[;_ *_%_P#0'KR1WPIK
MUKXK?\BK;?\ 7XO_ * ]>0N?D-?3Y9_ 7J>/C/XAZ1=>#/!>BZ'IE[XCUK4K
M5KZ%778 P+;06 "QL0.>]<5J5K8W'B0V?@MKW5K7RPRDPLTA./F^7:#@?2O3
M_%GB33_#OA'PV^I>'K76Q/;J$6X*CRB(UR1E&ZY]NE<E\-K^/4_BT][;V,>G
MPS1RLEM$05C&WH, ?R%94*M7V<ZL[NR?56T_$JI"'-&$;:V]?\CEQI^I&P:^
M&FWAM%SNN/L[>6,'!RV,<'BF06UY=6KW-K97,\$9"O+'$S*A/0$@8!Y%>J>#
MO&6KZW\2-7T:_>%M.A65(;=(@HC".%'/4Y'7)/MBLWP)?R:#X$\77EDB-)8W
M,C1+(,KE1QFM7BYQ3YH*^EM>Y*HQ;5I::_@>?7%K>V=XEI=V-S!<R8V0RPLK
MMDX&%(R<FGWNG:GID*RZEIE[9Q,VT//;O&I/IDCKP:[WX:ZMJ6NW&O>(-39=
M2UBTLUCM08U4XPYV@*!U( SUJU\./$NM>,8=9LO%++>6/V<[G:%8PA/!7*@#
MID\\\4YXJ<'*\5[MKZ]^VGYBC1C*VN][?+N8$]G9#X&-J*V=O]L^UA?M'E+Y
MF/,QC=C/2M+QA8:/8^)/"L;Z(T]K<6SM/:Z=#MDG.T8X7!)SSU]:SF;=^SD3
M_P!/H_\ 1M=/KW_)1_ ?_7!__017,ZDE4;OUG^1LHIQ7I'\SS/4K:2Y\2:BN
MB:+J-O:6_P QMI86,D"8&2XY([GDU%-8ZC;V*7MQIUW%:. 5N'@98VSTPQ&#
MFO4_#+;?BWXS) 8+"IVL,@\+Q5+P3XLU7QIH?BB#Q \4\2VQ>-$B51&&#_*,
M=0,#&<GWK;ZW-*_+=)1OKKJ9^QBW:^KO^!YQ96=]J;.-,L;J\,8!<6\+2;<]
M,X'%.O=/U+3(T?4M-O+-';:K7$#1ACZ D5W.CPW<GP7TZ.PUFW\,W$MXSFZN
MKD6XN5RW1QSZ?79Z<UB_%#Q9%KFH6.EZ=J7VZULHP9Y8U'ER3\@LIQSQZ''/
M%;1Q$IUN2,=+OOT_#4S=)1AS-ZZ?B8NB64>K>(-/L)G=(KF=8W9,;@"><9[U
MW<_@?P.GB ^'QK^I1:NPPD4F"H8KN'/EA3QVW#/3K7%>#C_Q6NBC_I[C_G7?
M^+/%G@[PUXYNKJXT*[N_$$"*RS!OW9)0;>KX'&!G9D5CBIU554*;>S>EM[];
M]"Z,8<CE*V_4H>"O#$-AXP\0Z1K-O;7YLK8&-Y80P(/*L <X."*\\CL=2M]+
M2^NM.NXK23!2X>!A&P/3#$8.:]%^%^NW6O>-/$>LW:*DL]L'$8)(0 X5?P %
M6/!/BS5?&FA^*(/$$D4\2VQ>-$B51&&#_*,=0,#&<GWJ/;5J4YRDKV4;Z_D7
M[.$XQ2=M['G%E9WVILXTRQNKPQ@%Q;PM)MSTS@'%1723V%RUO?V\UK.H!,<T
M91AGIP>:[GPG=:QI'PYM[ZY\26WAW2I+AO)F6Q-U+,Q)!# Y 'RG&!GKFM;X
MB2 0>"]19'U:<7"9*VY1[H85O]7C(+$?=]ZZ'BK5O9VTU77I\K?CH9>QO3YK
MZ_U\SS>;3M3MK$7MQIEY%:$!A</;NL9!Z'<1CG/%)8V5_J@<Z9I]U>>7C?\
M9X&DVYZ9P#CH:]1U[5;GQ=X;UF\\+Z\)[5+0K=Z1=V@1X>,L5< ,#@'KN4G/
M/I)+=P>&_AQX=%GXA_X1V*:%'>X&FF[\YV0,0>"%)))YY...AK+Z[+EUC[S=
MK:Z:7UTO]Q?U=7WTMY?YGD<A>"X>WN8WAFC;:\<BE64^A!Z&K.F6L&H:K;VE
MW?1Z?!*V'N9<;8Q@G)R1Z8ZUT'Q2UC3-8NM$OM+=YYI(&6:Y-I) LP!&TKO
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M8ZED99%&&! /TKBOB%;ZMK%[H%YXL\+:W?>'GM&^W:)HTYG>.Z)ROF",KO4
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MLRV_YYK^55[>M_._O8O94_Y5]QXS_P (]_TZ_P Z/^$>_P"G7^=>S?V9;?\
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M_P"$>_Z=?YT?\(]_TZ_SKV;^S+;_ )YK^5']F6W_ #S7\J/;UOYW][#V5/\
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M"PNCJ&I7!OM2=<>:PPL0_NHO8>_6MVBBM-R4DM@HHHH&%%%% !1110 4444
M%:D?^K7Z"LNM2/\ U:_05$AH=1114#"L;Q=HTGB#PGJ&F0N$EGB_=D]-P(8
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M^V7/_/=_SH^V7/\ SW?\Z.1A<TJ*S?MES_SW?\Z/MES_ ,]W_.CD87-*G_\
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MV]?T_P R;Z7_ *ZGH(.1D44450!1110!,W_'C%_UT?\ DM0U,W_'C%_UT?\
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MI0E2NTF>=B)RC.R9O?\ "8Z]_P!! _\ ?F/_ .)H_P"$QU[_ *"!_P"_,?\
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MW\RKL62ZM4E8+G. 6!.,D\>]3S:1IMSI8TRXT^UEL%54%I) K1!5^Z-A&,#
MP,<8JY12LAE"ST+2-/\ *^P:796ODHT<?DVZ)L5CEE&!P">2.YJ:#3+&VT[^
MS[:RMX;+:4^S1Q*L>T]1M Q@Y.?K5FB@15;2]/?2_P"S7L;9K#8(_LIA4Q;1
MT79C&/;%,TS1=+T6-X]'TVST])#N=;6!8@Q]2% S5QF"*6;@ 9-96G^*M$U/
MP\-=M=1A&EY(-U/F%!AMISO QSQS1I<8Z#POH%KJ7]HVVAZ;#?;R_P!ICM(U
MDW'.3N SDY.3[U=@L;2VN;BXMK6&&:Y8-/+'&%:4@8!8CEB!QS535O$.EZ&E
MF^J70A6]N$MK<A&?S)&^Z/E!QGU/%:5"\A!1113 **Q?#OB(:ZVI02VQM+S3
M;Q[6> OOZ<HX.!PRD'IZCM6U26JN'D3-_P >,7_71_Y+4-3-_P >,7_71_Y+
M4-"&%%%%,13N=*LKS4K*_N8=]U8ES;R;V&S>NUN <'(]<T2Z393ZQ;ZK+#NO
M;:)X8I=[#:CD%AC.#G:.H[5<HI 90\,:0-#O-'%I_H%\TK7$/FO\YD)+\YR,
MDGH1CM4MUH6G7K:>UU;[SILHFM/G8>6X4J#P>>"1SFM"BBR_+\-ONZ!_7WF+
M>^$='OM2FOY(;B&XN%59VM;R:W$X7./,6-U#\''S \<=*V(HHX(4AAC6.*-0
MJ(BX50.  .PIU%&P&18>%M'TV&Z@M+1A:W>[S;22:22##$E@L3,44$L<A0!S
M3-.\(:+I=W!<VMO,\ELI2W^TW<TZVX(P1&LC,(^./E XXZ5KS2>3!))L=]BE
MMB#+-@= .YJOI6H?VKI5O??9+JR\]-WV>\B\N6/V9<G!H5N@WYENBBBF(*F'
M_'D?^N@_D:AJ8?\ 'D?^N@_D:3&<9\1CCP]!_P!?2_\ H#UYH[?(?I7I7Q(_
MY%V#_KZ7_P!!:O,7/R&OH<O_ (*]3R<7_$/4-5TOP'X7\.Z-=ZWHEW<R7\*G
M=;S.26V*22#(H'7M7#SVMOXF\6?9O NF3QP-$"EM/* V0/F.6<C]:]5UW7_$
M>A>$_#[>%]*_M%YK=1,#;23; (UP?D(QG)ZUQ_@.;4[KXQ27>N6C6=Y<122/
M"86BVY7LK<XXKFP]6HJ<ZK=[)[ROU[&E6$7.,$K7MT_4PO\ A#/%']EMJ']B
MS_9U4L<LN_ [[,[C^7(YZ53TK0M9URQFO-)L'NH(7".49<ACC VYR>O85W_@
M3Q%K&I?%C6K2_P!0GGMAYZI [?(@20*NU>@X].O>JO@V]GTCX?\ C2ZT]_)F
MMKB4PL!G80.#S6TL55BFG%7]VV]M2%1@VFF[:_@<9<^'=<M-<CT>;39#J$J!
MU@C99#M)QDE20!P>2>.]6=5\'>)=%L6O-1TB2.W4_,Z.DFWC.3L)P..IXKI_
MA->7^HQ>(;IKR2\UG[(BVTEU*9& ^? RW;=MXK0^&Y\3I%K#>,SJ']G"V)?^
MT]V,\YQOYV[<YQQ2J8JI3<DU'W;7WUOV_IA"C"26^M_E;N8T\A/[/3.IQF]'
M_HVM?QJS_P#"7>#ECTN+5F:U<"RE=568[1P2V1QUY]*PB<_LXY_Z?1_Z-KI]
M?_Y*/X#_ .N#_P#H(KFD[5&_.?Y&R5XI>4?S//;_ $36-8\8:P+#0H[)[4"2
M:P@FC(@7:.A& WKA1WI;[PCXDTW23J=[I$T5H%#,Q92R ]V4'<OOD#'>O0_#
M#E/BYXS93AEB4@^^%K(^&VNZIK^C^*EUJ_FOE:U+@3/D*65\A1T4>PP*W^M5
M(Q;25HJ-][Z_,S]C!NS;N[]NAQNB>'-<\1PR2Z+ITES%&=K2%U1<^@+$ GV'
MJ*=K?AK7/#=M%<:U8?9HI7\M&\Y'RV,X^5CV%=CI6A?VY\%=*L=0GNK%&NFF
MB>RM);LR*&;[Z1C(ZGOV!]JYSXFZ\^JZ]9Z?''J$-K80J@%ZCQM,W_/38V,9
M'<@$\UM#$3J5G"*5DW?1]/.]M?P,Y4HQI\S>NAF^'K2#4_$VF6=VI>WGN421
M0Q&Y2>1D<UZ#=:5\.X_&)\*OHU[#?281;A9G,:LR[A@F0G//=<9Z\5P7@X_\
M5MHO_7W'_.N[\9_$2V\,>,KVVL_"]E/J<4:[=2=@'RR#&0$W$ '&-PX]*SQ3
MJNJH4V_A>SMK?<NBH<CE*V_57'>!=$/A[Q[XFTB.1IT@M5\IF^\RMAAG'?G%
M<!+X.\3:5H?]IZAI$\5J%#LS,NY >[(#N7WR!CO77_"C4KW4_%/B'5-0<-=W
M%MYC,!@ YX 'H  /PI_PVUW5-?T?Q4NM7\U\K6I<"9R0I97R%'11[# K+VE:
ME.<W9V4;_EH7RPG&,=5>]CCM%\-:]XBA>;1],DN(4.#(65%)] 6(!/TZ57U?
M2=5T&^2SU:PEMYY!F->&#_[I7(/7L:['PII5]!\-[34+C4O$+VDTS&"Q\/(!
M*IR06=NK#Y>G0?C6S\01<PV_@J2R@N)[V.[00QWSKYKMA2%D.<;B0,GUK=XQ
MJOR635VNO3S_ . 9^P7L^;6^AP=]X/\ $NFZ0VIWND2Q6B('=BZ%E4]RH.X>
M^1QWJ/1?#&O^(;9KC1],DGA4X\QG6-2?8L1GIVZ5Z-KD%UXH\.ZSJ,+:]H5U
M':%;BPOPWV64!<ML#9'\.-R[3WQSS).(A\./#?V(>(_L_D(3_P (V5W[MG._
MOC.[IQGKVK+Z]/DU2YKVZZ:>NOWE_5X\V[M8\EU"UO-(U)['5;:2UN4ZHXZC
MU!Z$>XXJ335TZ;5+=-;GEM[!F_?2Q#+*,'IP>^.QKH_BKJ;:E-H3MI>H6,BP
M."^H(B2RKD 956)'(8\@=>!7+Z;IUSK&H6^GV,?F7%PVU 3@#U)]@.:[J51U
M*7-+33[O,YIQ4)\JU/2?#^A> ?'5I?6^AZ;?Z?<0*O[Z61MRYS@@;V4].0?_
M *]>60LR2RPNP8QN4)'0X.*]3U&SU'P!X8;1?">E:AJ&K7ZYN]0@M9&2+C'R
MD#J,G [=3Z5Y/! ]H[P3HT<L;%71U(96'4$'H:PPDI2<FI-QZ7=WZ^C-:R22
M35GUL6]U&ZH\T9KN.8DW4;JCS1F@"3=1NJ/-&: )-U*LA5LBHLT9I2BI*S&F
MT[HVM.U%[>17C;&#R*]$T36TO(E5F^:O+((BGS-U/:M*PO9+6960GK7RE>,(
M56J;NCVZ3E*"<EJ>O Y&1163HFH->6REASBM:H*"IK?K)_US;^50U-;]9/\
MKFW\J'L,AHHHIB"BBB@ HHHH **** ,F^M]2O69+._6T'(!$>37+WWPR\0ZA
MJ45Z=>@NC&FT+.K@XR3UYKNH%_>GZ_UK9M5X%<JG*,KHN4%*-F>=P^'M8TD
MW]D2@ZRP'S%_3D?E6Y92(8N,$&N\A'2LW4O#UO=[I;8"WN/[RCY6^H_K6OMW
M+XC'V"C\)@Z)K*Z'=BQO&QI\S_N)3T@8_P )]%/8]J[4'(S7F>I(\#26M]%A
MAPR-T(_J*KZ7XSO/#;""=6O].' 3=^]A'^R3]X>Q_.B5%O6(XU4M)'J4GW:S
M+KH:ATKQ9HFO1C^SK^)I.\,AV2+]5/-3W8.#Q7.TUN;II[&!=D^9UJ6HKO[_
M .=2UM2ZDR"BBBMR HHHH **** "NKMO^/6+_<'\JY2NKMO^/6+_ '!_*L*N
MR+B24445@6%8WBW6I/#WA._U2!%DEMX\QJXR-Q(49]LFMFN'USQ[X'U&QO='
MU/5CLD#0RA;>7*GIP=A&0>AYZ5M1IRG-6BVEO;L8UJD:<?>DEVN<E%J?Q-GU
M1+"/6[7[1)IW]HHODQ8*'^#/E_>Y^GO7?>"-4O-:\ 6M_J=T+JYF20O($"]&
M8 8  X QTK@-<OO!6HVVFC3?&MYI]UI]O]E6Z^RS,\D./NMM5?S],Y!KT3PA
M'I,/@>VB\/7#7-@D;A)G4J7;)W$@@$?-GM7IXOE]BGR<KO\ RV[]?/0\K!\W
MM[<_,K?S7[=+]'<I4445R'JA1110 4444 %%%% !1110 4444 %377_'U)]:
MAJ:Z_P"/J3ZTNHSFO'EY)I_P^UZZ@)$D=A,5(Z@[" :YC5M1O/"/P)TZZT.8
M0W-O:6:HY53G<4#<$$<@GMWKM?$6F?VUX9U+3#_R^6LD(/H64@?K7EVOW[ZG
M^S3 Q8I<0I;VLVX<I+%,L;9'U6H>[_[=_-_YE;\OS_0T]<O?'O@^WM_$NKZ_
M8ZA8_:(UOM)ALA&D*.P7]W*?G8@D8W8]_2M-CG]H.,C_ *%H_P#I156Y\)>-
M_$36NE^*M7T>70K>:.662TMW6YO0A!"R*?D4$C)VGC%="?#EV?BDOB020BR&
MD&Q\O<?,W^;OSC&-N/?.>U5'1KU?_I/^9-[I^B_-?H><>*_'NI:3JNH>9\2M
M,L[NW9S#I%GI!N8B%)VH\V"5<X 8?PDFK7Q GUCQ-X0\'ZW::J-.BO;NS)M%
MM5D"3N<K*&)R0O\ =Z'O6A;^ _&VE:7J/AS1=4T.+1+V29_MDMO(UYB3D@J/
MD)_AR><<^@&MJ/@;4[KX8:-H=K=6L6K:1]FEBE?<T+2Q8X/&=IYYQ^%9Q3Y=
M>\7_ )_U]UBG:[MY_P# _K[QOB"]\1^%-%\-P7.O?VC>7>NP6MS=_8XXO-A<
MME-@R!P ,CFHO$&J>+KSXH'PUX;U.VL+5]*6YEGGMUE,!\PJ71>-S'Y1ACMQ
MD]:NZMX<\3>(]%T :S+I*:CI^L0WUS]D,@A,49;A-P+%L$=<#/>M)/#MVOQ/
ME\1F2'[&^E"R";CYF\2;\XQC&/?/M5V;:OW?W<O^?XB;5M.W_MW^1REMXF\3
MZ5IWC;2=8U*.^U'0K,7-IJ:6R1EP\;,-T8RN01_CFM7Q#XCU6Q^"7]OVMUY>
MI_V?!-Y_EJ?G;9N.TC;SD]JLR>"I[SQ)XLN;R>);'7K&*T3RV)DCVHRL2",?
MQ<<FN9NO GQ!U'P7)X5OM;T5=.@@$-O+##)YURJ_<64L"$'"DE03\N,\DU/O
M<K76R_"__ ]2ERJ2?3_AOUN;7BO6?$R>)O#6D^&KJW@DU6WG,SW,09$VJA\S
M&,D@%L*" 21GBL>TN/B,WBR_\'-XCL9&C@CO!K;V"B6.)LC8L(^0DLN.>@R<
MY( ["\\.7=QXR\.:LDD(@TNWN(IE+'<QD10-HQ@C(.<D5);:!=0_$:^U]I(3
M:W&G16J(&/F!U=F)(QC&&'>KM[WW_K;]#--\OGI^ES \,>.)M.\/ZXWCR^C+
MZ#J!LYK^. @3*<;&*(#@G<!@#'\ZCU_XE6NI>![S5/ E_P">+>XCAN[W['(W
MV&-C\TWELH+[1SCD>O2N@\+>';O0]7\1W5W)"Z:IJ!NH1$Q)5-H&&R!@\=LU
M=\20^()=-1O"=U907T<H8I?QLT,R8(*,5^9>H.1SE<=":GWG!7[+]+E*U]//
M_@'*V'BF\T+X=ZOX@OO$EGXMAMD$EM<VT*PG<0/W;JG"X)7WP3D5PD?Q:N[&
M>UU'_A/;36WDF3[1HB:*\"*K'#".8KD[<\%NN.<]#W&E_#B]O-.\3_\ "53V
M$5WXB55EBTF-E@A*@XD&[EG+'<2>_?FI].T[XGPO;6%[JWAT6$+JKWT4$INI
M(U/]P_NPS 8/IDXY H][G3]/^#_5A:<MO7^OS(-?U3Q;>_% ^&_#6IVUA:R:
M4MS)//;K*8#YA4NB\;F/RC#';C/&:J6GB?Q?I-KXPTB[>/7]6T2&*>SN4MQ&
M9UD4GYHTXRN"<#DXQ75IX=NU^)\OB,R0_8WTH603<?,WB3?G&,8Q[Y]JSY_"
M^OP>)_$NLZ+?65M/J4%JMF959P&B^\LBXX5ONY!) .>HI6=O6_YNQ5US?=^E
M_P!2#X<ZGJ&JV\]U-XTL_%-H\*L/+LTMIK5\GY61>Q /W@#QQQ7&:_J&O^*/
MV=1K%WK6R0&4WB?98S]J43E57( V8P#D#G%=KX9\*>($\9W7B?Q7)H\=[)9_
M9%AT>.14D&X'?(S\EA@*.O %0Z?\/KQ/@S+X-OKJW6[DCE FB+-&&:4R+U .
M.1GCUHFFX/T_5_U^#"%DUZK\M?Q_S*>H7/BKPGHOA];SQ-_:<NH:Y:6[2?8(
MH=MNX.Z/ SGI][@UNZ?K][;?$O5] U>Y#V\EK'?::615VQCY9%R ,X;GG)P:
MS+CPOXQUS1]%@\0SZ(+G3-8MKS=9F4*\$8.<[ARY)Z8 JU\1_!FJ^)X["Y\-
MWEO9:E:^="99V8*8)HRD@^4$YZ$54KJ[7?\ "RM^/ZDQ2LD^WXW?Z?H<E>_$
M[5+3PO'JESJ<-C%K^IS1Z?<S6AD2PM$^7S-B#=(YQD Y&2,X%6/ GQ$FO?'%
MOH3>+(?%=M?0NXN/[,:RDMI$&=N, ,I&??([=^JU_P #2S:'HD?AB[BT_4O#
MY#6$DL>Z-L)M*.!SAAU(Y%6?#T'CI]5\[Q;>:'':1QD+;:5%(3*QQ\S-)RNW
M' 7KN.>@HBFI6Z?I;_/\?(&[QO\ UN9VDG[)\<-?MHN([W2K:ZD&/XU9D!_*
MNZKA_"J'5?B7XJUU<-;P>5I<#CD,8QNDP?9FQ]17<4X? OZZMK\+ _B?]=%^
MI,W_ !XQ?]='_DM9^J.T>CWCQL5=8'*LIP0=IYK0;_CQB_ZZ/_):S]41I-'O
M$C4L[0.%51DD[3Q43O[-V\RH?$CRZ&35++X-V'C!M;U&XUBWMX;@&2Z?RI4W
M!?*:+.QLJ2-Q!<DYSTQT"V]SK?Q2U:TNM3U"+3[6QM9EL[>[DA!D;S!G<C @
M<<@8#'&<X%5/!?@))O >A6VM7&J);QQQSS:/.P6+SAS\P9?, W?-LW!<C[O:
MNTM]#MK;Q'>ZU&\IN;V&*&1&(V!8]V,#&<_,<\UHU[WS_3_/_/<S7P?+]5_7
MX'+Z/:R>,[KQ!<:EJ>HP):ZC+I]I%8WLML+=8P!NQ&PWL22<ON[# '%8"^+K
MC4-!\)CQ'J[6%G=7=S!J-Y'/]E:8PE@AWJ045BHW%2!GC(S@]Q<>#X3J%[=Z
M9JNI:2=0(:\CLGCVS/C&_P"=&*,1@$H5/ /7FN?\1Z!;:;K'AF*+3;^+0-/A
MGB\S26N#/"[*-JMY)\PHV"21G+ 9//.=FDEZ?>NO];WU--V_G]W;^NQB++=V
MGP_\=:IIVJZI/;K+(-+O9M0FE_=*J\Q%F/RA]P#CDXZG%;'B1[[PYX:TR&RN
M]5O;W7+Z"VNKA+K,I#!F?R1(WEQ$X(&W:!GKD U-I6B7'B"#Q'I=TVKQ>&;Z
M..*T.H22?:0VTB4KY^9%7(7 <=<D#!KJM8\/V.N:,-.OA($C*O#-&^V2&1?N
MR(PZ,#R#^8(XJK:+Y?AO]_XBOK]_X[?<<QI=MXF@U?48],LM4L-/FTYS =:O
MH[HQ7@.$*D32/M(.2"<?+[\U_"M[<?9[K26DUC3_ !6M@Q>WU>=YX9I0H'GQ
ML2R% YQB,J.3E>!CK+?0)8X;A+W7-5OFGB,0DEE2(Q*>I7R40!O]H@D=B.:J
MV_@^%;Z>^O\ 5=2U"]DM3:)<S2)&\$9.3Y?E(@!)P=V">!S1RO;R_P ]OZV]
M$%_Z^[^O^'.?\(:BL2W&G:DVN6/B".Q+75MJ=R\R7# #=-"Q++MW$C]V5'/*
M\#%#2-6U'4_#_@#2)M2N4_MBV>:]N5F83S+%&&V"3.Y2Q(RP(; X(KLK+PG#
M!J<FHW^I7^J7K6QM4FNS$/)C)RP58T1<DXR2">!S4(\#Z:GA_2=+AGNXFT?:
M;&]1U$\) QG.W:<C((*D$'I19]?+]?\ @:?+87_!_)?U_P $QGFN?#WC*]T2
MTO;Z>QNM&EOHUNKEYWMI4(0E9')?:00<$G!'&,U@VDFHV'PKT#Q6=:U2XU3?
M:-(T]X[1RQO(J-&T6=A^5C\Q&[/.[->@67A:VMI;VYNKN[U"^O8?L\M[=,GF
M"+G"*$544 DGA1DG)S4+>"].;P7:>&3-=?8K00A)-Z^8?+<,N3MQU49XH2:W
M\OS;_)V!Z_C^2_6YT-3#_CR/_70?R-0U,/\ CR/_ %T'\C5,#BOB3_R+<'_7
MTO\ Z"U>7DY4BO4/B5_R+4/_ %]+_P"@M7EN:^AR_P#@_,\G%?Q#H8/B)XRM
M+:*VM=9V0PH(XU-M"V% P!DID\>M41XK\1_\)"=<.I9U+R_*$_DQ_=QC&W;M
M_2LS-&:Z51I)MJ*U\D8>TF^K+FF:[K.D:M/JFGWGE7]P7,DWE(V[<<MP00.?
M:DM]=UNUTJ_TZWO=EMJ+,UTGE(?,)Z\D9'X8JIFC-6X0>Z7W=MA*374ETV]O
MM'N8KO2[J2UN8ONR1GK[$="/8\&K^L>,?%6OV1L=6U>26U8Y:-(TC#^QV*,C
MV/%9>:,TI4X2:DTKH%.25DRRVL:N?#@T$7>-,W^9Y'EI][.<[L;NOO5JX\5>
M(KK5+#4)]0WW&G*5M7\F,>6",= N#^.:S,T9H]G#LON[[_>'/+N:5MXI\16>
MJWVIV^H[+V_&VXE\F,[Q]"N!T[ 57TC6=7T"WNHM(N_LXNT\N?\ =HV]>>/F
M!QU/2JN:,T>SA9JRU\NVP<TM[GJ.CZTD?PYTNP\(>)]+T6^MW_TP:G*J$D@E
MMN]6&,G/ _$<BL3XG>)[+5;'1M,BOX-5U&S!-W>VZ_NRQ49"D<')YXXX[=!P
MS1(QR12+$BG(%<T<)&-3VE^K?W^>YLZ[<.4MVEY<V%U!=V,GE7$#AXWV@[6'
M0X/!INH7U_K.KR:EJUQ]HNI0 \FQ5S@8'"@#H*BS1FNMQ3=[:F%W:Q?TS7M6
MT*2:31+O[,\Z>7(?+5]R^GS U%I&LZOH-O<Q:1=_9Q=IY<_[M&WKSQ\P..IZ
M55S1FDX1=[I:[C4FK69IZ-XM\2^'+$VFBZH]O 6W>68TD /MN!Q^%-O_ !3X
MDU86?]HZK),;*7SH&VJK(_KN !_,\5G9HS4^RI\W/RJ_HA\\K<M]#6UCQKXK
MUVQ>QU/5Y)+5S\\:1)'N]B44$CV/%,T;Q9XE\.V9MM%U62" \^4R+(J]>@<$
M+UYQC-9F:,TO8T^7DY5;M9![25^:^I-J>JZOK^H"]UN^DNY@,#=@*H]%48"_
M@*ET_4[W1[^.^TN?R+J+.R3:&QD$'@@CH:J9HS6BC%1Y;:$N3;OU.E_X67XX
M_P"@Y_Y*0_\ Q%<T\EQ<WT]W>2>;/<2-)(^ -S,<DX' Y/:C-&:B%*G#X(I>
MB*E.4OB=Q^:,TS-&:U('YHS3,T9H ?FC-,S1UH ?FKEO!M^9_O=AZ4EM;;/G
M?[W8>E6@,GBO#QN-O>G3?JSTL/A[>_, ,GBMS1-$>\E5F7Y:-$T1[R569?EK
MT&PL([.$*JC.*\A*YWMBV%DEG"%48XJW115DA4UOUD_ZYM_*H:FM^LG_ %S;
M^5#V&0T444Q!1110 4444 %%%% #H5 ;+,!]:T8[JU@">==0Q[VVKO<+D^G-
M9E9NOZ);>(-'EL+Q05?E6(SM;L:Q=)%<S.]B&*DKPKPUXF\0?#W6!I6LR2ZA
MH^<!9&+20K_>1CU _N^G3GBO;;>\AN[>.XMI%DAE4.CJ>&!Z&LYTW!A":F9G
MB;0QK&FMY.%NX@3$WK_LGV->*WD[F1DD!5E)5E/4$=J^@MX->9>-/"P;Q*+R
MW&(KM=S = XX/Y\&NC"U$GRLY\33;7,C@(-/^W7"Y3(!^]CFM[3[35[[5KFS
MTK5+FUCM;<*[F5BHD8CC&>H /TK0F@728X[:UC$VHS\00CM_M-Z 5T&A:0NC
M::L)(DGD)DN)?^>CGJ?Z"MJLE/0SH4W'4BT_1[NW -]JL]VP]> :UZ**Q44M
MCK;N%%%%4(**** "BBB@ KJ[;_CUB_W!_*N4KJ[;_CUB_P!P?RK"KLBXDE%%
M%8%A6!JNB>%=/L;K4]2T33/+B5I9I&LHV8]R>F236_6'XTTJXUOP9J6GV?,\
MT/[M0<;B"&"_CC'XUI2=II7LF9U(IQ>ESS@>+M%*?;A\+T_L?=G[=]C3&S.-
MV/+VY]M^,\9KT_2)M,N/#44^@Q0Q6$L1>)(8PBC.<_*.ASG/OFO-X?BA:VOA
M5/#T^B:@NL):BR%L8QM+[=@ZG=SP<;<\X]Z[7P-I5UHOP]LK*_1H[A8G=T;J
MFYF;'X UZ>,I\M.[7+KIK>ZUU_KN>7@JG-424N;372UGII^>GD5Z***YCT@H
MHHH **** "BBB@ HHHH **** "IKK_CZD^M0U-=?\?4GUI=1D-47T32I+6>V
MDTRS>WN)?.FB:W0K+)D'>PQ@MD Y//%7J*8@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** (;2RM;"$Q6-M#;1EV<I#&$!9CD
MG [D\DU-110!,W_'C%_UT?\ DM0U,W_'C%_UT?\ DM0TD,****8@HHHH ***
M* "BBB@ HHHH **** "IA_QY'_KH/Y&H:F'_ !Y'_KH/Y&DQF;J=I#>69CN(
M8YE'(61 P!]>:\ZO=!E^TMY5N%7/ 5<5ZB1GK49MXSU44[RZ,5EU1Y5_8%Q_
MSQ_2C^P+C_GC^E>J?9HO[HH^S1?W11S3[L+1['E?]@7'_/']*/[ N/\ GC^E
M>J?9HO[HH^S1?W11S3[L+1['E?\ 8%Q_SQ_2C^P+C_GC^E>J?9HO[HH^S1?W
M11S3[L+1['E?]@7'_/']*/[ N/\ GC^E>J?9HO[HH^S1?W11S3[L+1['E?\
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M/_/,?]]K_C1_9]S_ ,\Q_P!]K_C6A11SL+(S_P"S[G_GF/\ OM?\:/[/N?\
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M\Q_WVO\ C1_9]S_SS'_?:_XUH44<["R,_P#L^Y_YYC_OM?\ &C^S[G_GF/\
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M'E_^)H^KUOY']S#VM/\ F1T=%<Y_PG_AK_H(G_P'E_\ B:/^$_\ #7_01/\
MX#R__$T?5ZW\C^YA[6G_ #(Z.BN<_P"$_P##7_01/_@/+_\ $T?\)_X:_P"@
MB?\ P'E_^)H^KUOY']S#VM/^9'3/_#_NTRN>?X@>&3MQJ1X&/^/>7_XFF_\
M"?\ AK_H(G_P'E_^)H^KUOY']S#VM/\ F1T=%<Y_PG_AK_H(G_P'E_\ B:/^
M$_\ #7_01/\ X#R__$T?5ZW\C^YA[6G_ #(Z.BN<_P"$_P##7_01/_@/+_\
M$T?\)_X:_P"@B?\ P'E_^)H^KUOY']S#VM/^9'1T5SG_  G_ (:_Z")_\!Y?
M_B:/^$_\-?\ 01/_ (#R_P#Q-'U>M_(_N8>UI_S(Z.BN<_X3_P -?]!$_P#@
M/+_\31_PG_AK_H(G_P !Y?\ XFCZO6_D?W,/:T_YD='17.?\)_X:_P"@B?\
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M6UBP2*2YL[9I8UF!*$CU (./QK.TGQJ7^'MSKNM0I%>::)8KZW@!VB>(E2J
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M@84444 %1S_\>\G^X?Y5)4<__'O)_N'^5-;@<I1117:8A1110 4444 %%%%
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M7-&:BWCUHWCUI\HKDN:,U%O'K1O'K18+DN:,U&"S,JQJSNQ 55&2Q/8"M\>
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M_$V@S7UO91:WITEW=1B6W@6[C,DR$9#*N<L"!G([4Z^\1:)I<CIJ>L6%FZ%
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M)?H7*?\ \L?^!4RG_P#+'_@5 '"?%G_D4[?_ *_$_P#0'KQ[->Y>/=#N-?\
M#\=M:211O'.)2920,!6'8'GFO(;C0+FWF,;R1DCTS_A7OX'$4J='EG*S/,Q-
M*<ZEXHQ_*3=G'-/(#+@]*T/['F_YZ)^M']CS?\]$_6NWZYA_YD<WU>K_ "F8
M(D'04>2@'2M/^QYO^>B?K1_8\W_/1/UH^N8;^9!["K_*9?D1^E*88SU%:?\
M8\W_ #T3]:/['F_YZ)^M'US#?S(/85NQF^6F,8I!#&#G%:?]CS?\]$_6C^QY
MO^>B?K1]<PW\R#V%7^4S^,8[4WRT_NBM+^QYO^>B?K1_8\W_ #T3]:/KF'_F
M0?5ZO\IG!54Y Q0ZJ_WAFM$Z-.,?O$_6C^QYO^>B?K1]<P_\R#ZO5_E,WRDV
MXQQ2"% .E:?]CS?\]$_6C^QYO^>B?K1]<PW\R#V%7^4S!!&#TH,*$\BM/^QY
MO^>B?K1_8\W_ #T3]:/KF&_F0>PK?RF8(4'04GD1^E:G]CS?\]$_6C^QYO\
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MC_2F4\_ZE?\ >/\ 2F4@"BBBF 4444 %%%% !1110 4444 %%%% !3_^6/\
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M 9F@Z#;>'[.>"UDEF:XN9;J::<J7DDD;<22 !QP!QT %:=%% !1110 4444
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MWK+_ -\#_&LRBGR(+FG]NMO67_O@?XT?;K;UE_[X'^-9E%'(@N:?VZV]9?\
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MW&Q5V1A5(7@#/4\G)KJZX_P-H%QX7.MQZOK-KJ%S=WPNGF0A&)=% +(!A2S
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MQRIP!@?-SQRD'AG7[S4O"UW<Z5JL=QI]XDVI3ZAK F5V\M@S11"5D"[CV"$
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MJ)BD.9/+$C((FVIOX^\6Q@XKO4+%%W@!L<@'(!^M>*Z/;ZAIW@6QU_68C?\
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M9KJ,1=B?W11L3^Z*3-&:+ +Y:?W12J%7[HQ3<T9H ?FC-,S1FF _-&:9FC-
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M_AZ[J.DZ=K%L+?5["UOX%;>(KJ%95#=,X8$9Y//O46F>']&T5Y'T;2+'3VE
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MBB@ HHHH **** "BBB@ J:WZR?\ 7-OY5#4UOUD_ZYM_*D]AD-%%%,04444
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M<=B1VJN(0/XF_.GJNWH36"IR3+;31':VL%E;K!:1+%$O14&!4M%%=)F%%%%
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MHNP&?9[?_GW7_OIO\:?-! 9F+0*3GKN;_&BGR_ZQJ+L9#]GM_P#GW7_OIO\
M&C[/;_\ /NO_ 'TW^-/HHNQ#/L]O_P ^Z_\ ?3?XT?9[?_GW7_OIO\:?11=@
M,^SV_P#S[K_WTW^-'V>W_P"?=?\ OIO\:?11=@,^SV__ #[K_P!]-_C1]GM_
M^?=?^^F_QI]%%V S[/;_ //NO_?3?XT?9[?_ )]U_P"^F_QI]%%V S[/;_\
M/NO_ 'TW^-'V>W_Y]U_[Z;_&GT478#/L]O\ \^Z_]]-_C1]GM_\ GW7_ +Z;
M_&GT478#/L]O_P ^Z_\ ?3?XT?9[?_GW7_OIO\:?11=@,^SV_P#S[K_WTW^-
M'V>W_P"?=?\ OIO\:?11=@,^SV__ #[K_P!]-_C1]GM_^?=?^^F_QI]%%V S
M[/;_ //NO_?3?XT?9[?_ )]U_P"^F_QI]%%V S[/;_\ /NO_ 'TW^-'V>W_Y
M]U_[Z;_&GT478#/L]O\ \^Z_]]-_C1]GM_\ GW7_ +Z;_&GT478 8(/(4>0N
M-S8&YO0>],^SV_\ S[K_ -]-_C4Q_P!2O^\?Z4RB[&,^SV__ #[K_P!]-_C1
M]GM_^?=?^^F_QI]%%V(9]GM_^?=?^^F_QH^SV_\ S[K_ -]-_C3Z*+L!GV>W
M_P"?=?\ OIO\:/L]O_S[K_WTW^-/HHNP&?9[?_GW7_OIO\:/L]O_ ,^Z_P#?
M3?XT^BB[ 9]GM_\ GW7_ +Z;_&C[/;_\^Z_]]-_C3Z*+L!GV>W_Y]U_[Z;_&
MC[/;_P#/NO\ WTW^-/HHNP&?9[?_ )]U_P"^F_QI_D0>01Y"XW=-S>GUHI__
M "Q_X%1=C(?L]O\ \^Z_]]-_C1]GM_\ GW7_ +Z;_&GT478AGV>W_P"?=?\
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MN.#A6/?J/:NG%8>5*7-NF94:JFK=3M;+2K.TA"K;)T_O-_C5O[/;_P#/NO\
MWTW^--M[A+B,,ASFI:X[LV&?9[?_ )]U_P"^F_QH^SV__/NO_?3?XT^BB[ 9
M]GM_^?=?^^F_QI5M[<.,0+U_O-_C3J5?O#ZT78QLEO;F1B8%)R<G<W^--^SV
M_P#S[K_WTW^-2O\ ZQOJ:;1=@,^SV_\ S[K_ -]-_C1]GM_^?=?^^F_QI]%%
MV(9]GM_^?=?^^F_QH^SV_P#S[K_WTW^-/HHNP&?9[?\ Y]U_[Z;_ !H^SV__
M #[K_P!]-_C3Z*+L!GV>W_Y]U_[Z;_&C[/;_ //NO_?3?XT^BB[ 9]GM_P#G
MW7_OIO\ &C[/;_\ /NO_ 'TW^-/HHNP&?9[?_GW7_OIO\:?'! "V(%'RG^)O
M\:*?'_%_NFB[&0_9[?\ Y]U_[Z;_ !H^SV__ #[K_P!]-_C3Z*+L0S[/;_\
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M17 >H%%%% !1110 4444 %%%% !1110 4^7_ %C4RGR_ZQJ0#****8!1110
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MUI)2ALS/ZU33M+<]:HKR7_A:^K_\\=/_ ._3_P#Q='_"U]7/_+'3_P#OT_\
M\73_ +-Q'8/K=+N>M45Y)_PM?5_^>.G_ /?I_P#XNG#XJZP1D0Z?_P!^G_\
MBZ/[-Q'8/K=+N>LT5Y+_ ,+7U?\ YXZ?_P!^G_\ BZ&^*NK[2/)T_GTB?_XN
MC^S<1V#ZW2[GK;NGRC<,[?6DKSC4]9F@^%MEXCC2/^T)KORV;+[<;G'3=["L
MV'XH:YY*Y@L#QU,3_P#Q=2L#4E?DZ-K[A_68KXCUFBO*?^%H:W_S[Z?_ -^G
M_P#BZ/\ A:&M_P#/OI__ 'Z?_P"+H_L^OY!]:IGJU9OB/_D5M5_Z\IO_ $ U
MYW_PM#6_^??3_P#OT_\ \74%[\1=8O["XM)H+$1W$31.5C<$!A@X^?KS50P%
M9238I8FFTT<UNIT4[P2!XS@]QZU!NHW5[LH1FN66QYRDT[H]"\,>)\;8Y&XZ
M<]J] M[A+B,,ASFO 8+A[>4/&>>X]:[[PQXGQM21OEZ<]J^=Q6%E0E=?">I1
MK*HO,]%HJ*WN$N(PR'.:EKC.@*5?O#ZTE*OWA]: %?\ UC?4TVG/_K&^IIM(
M HHHI@%%%% !1110 4444 %%%% !3X_XO]TTRGQ_Q?[II ,HHHI@%%%% !11
M10 45POQ=T^'5_!]GIUV"8+O5[*"0 X.UIE4\_0UD?VQ<Z]X(T_PA<3$ZQ<W
M3Z1J3*<,(X/]?)P00&C"X/\ TU6IOHWV_P"!_FA[-?UW_P F>HT5Y=X4UN71
M/A)X4AL[NVMIKF$HGF64][(P7<2$MX<._'4[@%'7.:OZ?\0-2GT6RU*Z@MQ;
MPZTVEZG(;66#"D[8Y51SNB^9H]ROG&3]:K[3BOZU2_5"U2N_Z_JQZ%17"S^.
M-1DFO4TZWM6$VL+H^F-+NPTBH3-*Y!^95(<!1@DIC/.1IZ=K.LVGC!?#WB V
M=T;BS>\MKRR@>!<(RJZ/&SN0?G4AMV#G&!CE+7;^M+_EJ#TW_K6WYZ'3U#+>
M6T%Q#;SW$4<UP2(8W<!I"!D[0>3@<G%<3%86GBWXD>(;7Q'!%?V6CI;16EA<
MKOA!DC+M*8S\K,2=H8YP 0,9.7:II5EHWC;P59Z9 +>V%S>LD*L=D>8"<*"<
M*OHHP!V%%]+@SM+.]M=0M5N;"YANH'R%EAD#JV#@X(XX((HN;VULA$;RYAM_
M.D$47FR!=[GHHSU)[ <UY[HOB?5IM'\-6NA6.CV+:K<7L;K]G=88%B9\,J*P
MR>,D9&23RO6I9O%5W<:;;KJMCIMW>6?B>+3)'-N?+)W#$T:LQ*.%88Y.#GK0
MFFTEY?FE^J!Z)OU_)O\ 0]#JI?ZI9Z8;47LOEF[G6V@ 1F+R,"0, 'L"<]
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M#=> _%V@1Z/J&JWM[JVH0PP1:?*T+.\I"DS%?*7:<,26&,>N*]EK%\+^'?\
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MP?2KCI'^NR_KY_-I_%_7?^E\AU/_ .6/_ J93_\ EC_P*D!P_P 4O^19M?\
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MJ6^$HCOM/@D-S"5'ELLLI&0!D;03CGUJ]]H@\%_!N>;2-5TSQ/'=:Y@:A<V
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M@ HHHH **** "BBB@ I\O^L:F4^7_6-2 91113 **** "BBB@ HHHH ****
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M73FLUMK2:24J3(K[B[(NX'!_A&.!SUIKXE\_R?ZDOX7_ %U1U=%%%,84444
M%%%% !6I'_JU^@K+K4C_ -6OT%1(:'4445 PHHHH *:_^K;Z&G4U_P#5M]#0
M!ET445L2%%%% !1110 4444 %%%% !1110 4^7_6-3*?+_K&I ,HHHI@%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M//\ J5_WC_2F4\_ZE?\ >/\ 2F4@"BBBF 4444 %%%% !1110 4444 %%%%
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,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>tpiv-20170630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 2.0 on 04-Aug-2017 [07:27:56] {PM} EST - www.datatracks.com -->
<!-- Based on XBRL 2.1 -->
<xbrli:xbrl xmlns:tpiv="http://www.tapimmune.com/20170630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="tpiv-20170630.xsd" />

<!--Context Section-->
  <xbrli:context id="P01_01_2016To06_30_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To06_30_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2016To06_30_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2017To06_30_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2017To06_26_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-06-01</xbrli:startDate>

      <xbrli:endDate>2017-06-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_02_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-08-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_01_2016To09_16_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-09-01</xbrli:startDate>

      <xbrli:endDate>2016-09-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

<!--Dimension Section-->
  <xbrli:context id="PAsOn06_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_PromissoryNotesDueInTwoThousandTwelveMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:PromissoryNotesDueInTwoThousandTwelveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_08_2017To03_09_2017_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-08</xbrli:startDate>

      <xbrli:endDate>2017-03-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_09_2017_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_08_2017To03_09_2017_PresidentAndChiefOperatingOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">tpiv:PresidentAndChiefOperatingOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-08</xbrli:startDate>

      <xbrli:endDate>2017-03-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_09_2017_PresidentAndChiefOperatingOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">tpiv:PresidentAndChiefOperatingOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To06_30_2017_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tpiv:ConsultingAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_CrucellHollandBvMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tpiv:CrucellHollandBvMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To06_30_2017_CrucellHollandBvMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tpiv:CrucellHollandBvMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To06_30_2017_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To06_30_2016_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_MinimumMemberusgaapRangeAxis_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_MaximumMemberusgaapRangeAxis_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To06_30_2016_MinimumMemberusgaapRangeAxis_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To06_30_2016_MaximumMemberusgaapRangeAxis_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To07_06_2017_ChiefExecutiveOfficerAndPresidentMemberusgaapTitleOfIndividualAxis_MaximumMemberusgaapRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">tpiv:ChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-07-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To07_06_2017_ChiefFinancialOfficerTreasurerAndSecretaryMemberusgaapTitleOfIndividualAxis_MaximumMemberusgaapRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">tpiv:ChiefFinancialOfficerTreasurerAndSecretaryMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-07-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2017To06_26_2017_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-06-01</xbrli:startDate>

      <xbrli:endDate>2017-06-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_26_2017_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_26_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2017To06_26_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-06-01</xbrli:startDate>

      <xbrli:endDate>2017-06-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_31_2016_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_26_2017_SubsequentWarrantIssuanceMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SubsequentWarrantIssuanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_23_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesEWarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SeriesEWarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesEWarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SeriesEWarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_ScenarioPreviouslyReportedMemberusgaapStatementScenarioAxis_SharePurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_RestatementAdjustmentMemberusgaapStatementScenarioAxis_SharePurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To06_30_2017_ScenarioPreviouslyReportedMemberusgaapStatementScenarioAxis_SharePurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To06_30_2017_RestatementAdjustmentMemberusgaapStatementScenarioAxis_SharePurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2017To06_26_2017_SubsequentWarrantIssuanceMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SubsequentWarrantIssuanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-06-01</xbrli:startDate>

      <xbrli:endDate>2017-06-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_ClassOfWarrantOrRighttrancheOneMembertpivClassOfWarrantOrRightExerciseAxis_SeriesCWarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tpiv:ClassOfWarrantOrRightExerciseAxis">tpiv:ClassOfWarrantOrRighttrancheOneMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SeriesCWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_ClassOfWarrantOrRighttrancheOneMembertpivClassOfWarrantOrRightExerciseAxis_SeriesDWarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tpiv:ClassOfWarrantOrRightExerciseAxis">tpiv:ClassOfWarrantOrRighttrancheOneMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SeriesDWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_ClassOfWarrantOrRighttrancheOneMembertpivClassOfWarrantOrRightExerciseAxis_SeriesFWarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tpiv:ClassOfWarrantOrRightExerciseAxis">tpiv:ClassOfWarrantOrRighttrancheOneMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SeriesFWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_PrereducedPriceMembertpivClassOfWarrantOrRightExerciseAxis_SeriesCWarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tpiv:ClassOfWarrantOrRightExerciseAxis">tpiv:PrereducedPriceMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SeriesCWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_PrereducedPriceMembertpivClassOfWarrantOrRightExerciseAxis_SeriesDWarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tpiv:ClassOfWarrantOrRightExerciseAxis">tpiv:PrereducedPriceMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SeriesDWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_PrereducedPriceMembertpivClassOfWarrantOrRightExerciseAxis_SeriesFWarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tpiv:ClassOfWarrantOrRightExerciseAxis">tpiv:PrereducedPriceMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SeriesFWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_PostreducedPriceMembertpivClassOfWarrantOrRightExerciseAxis_SeriesCWarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tpiv:ClassOfWarrantOrRightExerciseAxis">tpiv:PostreducedPriceMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SeriesCWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_PostreducedPriceMembertpivClassOfWarrantOrRightExerciseAxis_SeriesDWarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tpiv:ClassOfWarrantOrRightExerciseAxis">tpiv:PostreducedPriceMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SeriesDWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_PostreducedPriceMembertpivClassOfWarrantOrRightExerciseAxis_SeriesFWarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tpiv:ClassOfWarrantOrRightExerciseAxis">tpiv:PostreducedPriceMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SeriesFWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2017To06_23_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesEWarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SeriesEWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-06-01</xbrli:startDate>

      <xbrli:endDate>2017-06-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_23_2017_ClassOfWarrantOrRighttrancheOneMembertpivClassOfWarrantOrRightExerciseAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesEWarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SeriesEWarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="tpiv:ClassOfWarrantOrRightExerciseAxis">tpiv:ClassOfWarrantOrRighttrancheOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_23_2017_ClassOfWarrantOrRighttrancheTwoMembertpivClassOfWarrantOrRightExerciseAxis_SeriesEWarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SeriesEWarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="tpiv:ClassOfWarrantOrRightExerciseAxis">tpiv:ClassOfWarrantOrRighttrancheTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_23_2017_ClassOfWarrantOrRighttrancheOneMembertpivClassOfWarrantOrRightExerciseAxis_SeriesEWarrantMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tpiv:ClassOfWarrantOrRightExerciseAxis">tpiv:ClassOfWarrantOrRighttrancheOneMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tpiv:SeriesEWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To07_06_2017_ChiefExecutiveOfficerAndPresidentMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">tpiv:ChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-07-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To07_06_2017_ChiefFinancialOfficerTreasurerAndSecretaryMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">tpiv:ChiefFinancialOfficerTreasurerAndSecretaryMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-07-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="USD_Warrant">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>tpiv:Warrant</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>

<!--Element Section-->
  <dei:DocumentType contextRef="P01_01_2017To06_30_2017" id="Factid_1">10-Q</dei:DocumentType>

  <dei:AmendmentFlag contextRef="P01_01_2017To06_30_2017" id="Factid_2">false</dei:AmendmentFlag>

  <dei:DocumentPeriodEndDate contextRef="P01_01_2017To06_30_2017" id="Factid_3">2017-06-30</dei:DocumentPeriodEndDate>

  <dei:DocumentFiscalYearFocus contextRef="P01_01_2017To06_30_2017" id="Factid_4">2017</dei:DocumentFiscalYearFocus>

  <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2017To06_30_2017" id="Factid_5">Q2</dei:DocumentFiscalPeriodFocus>

  <dei:EntityRegistrantName contextRef="P01_01_2017To06_30_2017" id="Factid_6">TAPIMMUNE INC.</dei:EntityRegistrantName>

  <dei:EntityCentralIndexKey contextRef="P01_01_2017To06_30_2017" id="Factid_7">0001094038</dei:EntityCentralIndexKey>

  <dei:CurrentFiscalYearEndDate contextRef="P01_01_2017To06_30_2017" id="Factid_8">--12-31</dei:CurrentFiscalYearEndDate>

  <dei:EntityFilerCategory contextRef="P01_01_2017To06_30_2017" id="Factid_9">Smaller Reporting Company</dei:EntityFilerCategory>

  <dei:TradingSymbol contextRef="P01_01_2017To06_30_2017" id="Factid_10">TPIV</dei:TradingSymbol>

  <dei:EntityCommonStockSharesOutstanding contextRef="PAsOn08_02_2017" id="Factid_11" unitRef="shares" decimals="INF">10158993</dei:EntityCommonStockSharesOutstanding>

  <us-gaap:Cash contextRef="PAsOn06_30_2017" id="Factid_12" unitRef="USD" decimals="0">9962615</us-gaap:Cash>

  <us-gaap:Cash contextRef="PAsOn12_31_2016" id="Factid_13" unitRef="USD" decimals="0">7851243</us-gaap:Cash>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn06_30_2017" id="Factid_14" unitRef="USD" decimals="0">179181</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn12_31_2016" id="Factid_15" unitRef="USD" decimals="0">70149</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:Assets contextRef="PAsOn06_30_2017" id="Factid_16" unitRef="USD" decimals="0">10141796</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn12_31_2016" id="Factid_17" unitRef="USD" decimals="0">7921392</us-gaap:Assets>

  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="PAsOn06_30_2017" id="Factid_18" unitRef="USD" decimals="0">1561075</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="PAsOn12_31_2016" id="Factid_19" unitRef="USD" decimals="0">1224940</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

  <us-gaap:OtherLiabilitiesCurrent contextRef="PAsOn06_30_2017" id="Factid_20" unitRef="USD" decimals="0">0</us-gaap:OtherLiabilitiesCurrent>

  <us-gaap:OtherLiabilitiesCurrent contextRef="PAsOn12_31_2016" id="Factid_21" unitRef="USD" decimals="0">492365</us-gaap:OtherLiabilitiesCurrent>

  <us-gaap:DerivativeLiabilitiesCurrent contextRef="PAsOn06_30_2017" id="Factid_22" unitRef="USD" decimals="0">10000</us-gaap:DerivativeLiabilitiesCurrent>

  <us-gaap:DerivativeLiabilitiesCurrent contextRef="PAsOn12_31_2016" id="Factid_23" unitRef="USD" decimals="0">14500</us-gaap:DerivativeLiabilitiesCurrent>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn06_30_2017" id="Factid_24" unitRef="USD" decimals="0">5000</us-gaap:NotesPayableCurrent>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn12_31_2016" id="Factid_25" unitRef="USD" decimals="0">5000</us-gaap:NotesPayableCurrent>

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn06_30_2017" id="Factid_26" unitRef="USD" xsi:nil="true" />

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2016" id="Factid_27" unitRef="USD" xsi:nil="true" />

  <us-gaap:CommonStockValue contextRef="PAsOn06_30_2017" id="Factid_28" unitRef="USD" decimals="0">10159</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2016" id="Factid_29" unitRef="USD" decimals="0">8421</us-gaap:CommonStockValue>

  <us-gaap:AdditionalPaidInCapital contextRef="PAsOn06_30_2017" id="Factid_30" unitRef="USD" decimals="0">159306674</us-gaap:AdditionalPaidInCapital>

  <us-gaap:AdditionalPaidInCapital contextRef="PAsOn12_31_2016" id="Factid_31" unitRef="USD" decimals="0">151991974</us-gaap:AdditionalPaidInCapital>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn06_30_2017" id="Factid_32" unitRef="USD" decimals="0">-150751112</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2016" id="Factid_33" unitRef="USD" decimals="0">-145815808</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2017" id="Factid_34" unitRef="USD" decimals="0">8565721</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016" id="Factid_35" unitRef="USD" decimals="0">6184587</us-gaap:StockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn06_30_2017" id="Factid_36" unitRef="USD" decimals="0">10141796</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2016" id="Factid_37" unitRef="USD" decimals="0">7921392</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:PreferredStockValue contextRef="PAsOn06_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_38" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn06_30_2017_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_39" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_40" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2016_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_41" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:AssetsCurrent contextRef="PAsOn06_30_2017" id="Factid_42" unitRef="USD" decimals="0">10141796</us-gaap:AssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2016" id="Factid_43" unitRef="USD" decimals="0">7921392</us-gaap:AssetsCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn06_30_2017" id="Factid_44" unitRef="USD" decimals="0">1576075</us-gaap:LiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2016" id="Factid_45" unitRef="USD" decimals="0">1736805</us-gaap:LiabilitiesCurrent>

  <us-gaap:Liabilities contextRef="PAsOn06_30_2017" id="Factid_46" unitRef="USD" decimals="0">1576075</us-gaap:Liabilities>

  <us-gaap:Liabilities contextRef="PAsOn12_31_2016" id="Factid_47" unitRef="USD" decimals="0">1736805</us-gaap:Liabilities>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P04_01_2017To06_30_2017" id="Factid_48" unitRef="USD" decimals="0">1202725</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P04_01_2016To06_30_2016" id="Factid_49" unitRef="USD" decimals="0">1248165</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P04_01_2017To06_30_2017" id="Factid_50" unitRef="USD" decimals="0">1190517</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P04_01_2016To06_30_2016" id="Factid_51" unitRef="USD" decimals="0">1177408</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:OperatingIncomeLoss contextRef="P04_01_2017To06_30_2017" id="Factid_52" unitRef="USD" decimals="0">-2393242</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P04_01_2016To06_30_2016" id="Factid_53" unitRef="USD" decimals="0">-2425573</us-gaap:OperatingIncomeLoss>

  <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="P04_01_2017To06_30_2017" id="Factid_54" unitRef="USD" decimals="0">7500</us-gaap:DerivativeGainLossOnDerivativeNet>

  <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="P04_01_2016To06_30_2016" id="Factid_55" unitRef="USD" decimals="0">8237000</us-gaap:DerivativeGainLossOnDerivativeNet>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2017To06_30_2017" id="Factid_56" unitRef="USD" decimals="0">-1893377</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2016To06_30_2016" id="Factid_57" unitRef="USD" decimals="0">5974140</us-gaap:NetIncomeLoss>

  <us-gaap:OperatingExpenses contextRef="P04_01_2017To06_30_2017" id="Factid_58" unitRef="USD" decimals="0">2393242</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P04_01_2016To06_30_2016" id="Factid_59" unitRef="USD" decimals="0">2425573</us-gaap:OperatingExpenses>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2017To06_30_2017" id="Factid_60" unitRef="USD" decimals="0">2191817</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2016To06_30_2016" id="Factid_61" unitRef="USD" decimals="0">2233916</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2017To06_30_2017" id="Factid_62" unitRef="USD" decimals="0">2618310</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2016To06_30_2016" id="Factid_63" unitRef="USD" decimals="0">1945396</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2017To06_30_2017" id="Factid_64" unitRef="USD" decimals="0">-4810127</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2016To06_30_2016" id="Factid_65" unitRef="USD" decimals="0">-4179312</us-gaap:OperatingIncomeLoss>

  <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="P01_01_2017To06_30_2017" id="Factid_66" unitRef="USD" decimals="0">4500</us-gaap:DerivativeGainLossOnDerivativeNet>

  <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="P01_01_2016To06_30_2016" id="Factid_67" unitRef="USD" decimals="0">5241000</us-gaap:DerivativeGainLossOnDerivativeNet>

  <us-gaap:OperatingExpenses contextRef="P01_01_2017To06_30_2017" id="Factid_68" unitRef="USD" decimals="0">4810127</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P01_01_2016To06_30_2016" id="Factid_69" unitRef="USD" decimals="0">4179312</us-gaap:OperatingExpenses>

  <us-gaap:SharesIssued contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_70" unitRef="shares" decimals="INF">8421185</us-gaap:SharesIssued>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_71" unitRef="USD" decimals="0">8421</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_72" unitRef="USD" decimals="0">151991974</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_73" unitRef="USD" decimals="0">-145815808</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_74" unitRef="USD" decimals="0">10159</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_75" unitRef="USD" decimals="0">159306674</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_76" unitRef="USD" decimals="0">-150751112</us-gaap:StockholdersEquity>

  <us-gaap:SharesIssued contextRef="PAsOn06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_77" unitRef="shares" decimals="INF">10158993</us-gaap:SharesIssued>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To06_30_2017" id="Factid_78" unitRef="USD" decimals="0">-4313262</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_79" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_80" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_81" unitRef="USD" decimals="0">-4313262</us-gaap:NetIncomeLoss>

  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="P01_01_2017To06_30_2017" id="Factid_82" unitRef="USD" decimals="0">647387</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>

  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="P01_01_2017To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_83" unitRef="USD" decimals="0">66</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>

  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="P01_01_2017To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_84" unitRef="USD" decimals="0">647321</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>

  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="P01_01_2017To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_85" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>

  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross contextRef="P01_01_2017To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_86" unitRef="shares" decimals="INF">66315</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2016To06_30_2016" id="Factid_87" unitRef="USD" decimals="0">1224401</us-gaap:NetIncomeLoss>

  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="P01_01_2017To06_30_2017" id="Factid_88" unitRef="USD" decimals="0">-4500</us-gaap:IncreaseDecreaseInDerivativeLiabilities>

  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="P01_01_2016To06_30_2016" id="Factid_89" unitRef="USD" decimals="0">-5241000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2017To06_30_2017" id="Factid_90" unitRef="USD" decimals="0">647387</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2016To06_30_2016" id="Factid_91" unitRef="USD" decimals="0">544934</us-gaap:ShareBasedCompensation>

  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="P01_01_2017To06_30_2017" id="Factid_92" unitRef="USD" decimals="0">109032</us-gaap:IncreaseDecreaseInPrepaidExpense>

  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="P01_01_2016To06_30_2016" id="Factid_93" unitRef="USD" decimals="0">-47409</us-gaap:IncreaseDecreaseInPrepaidExpense>

  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="P01_01_2017To06_30_2017" id="Factid_94" unitRef="USD" decimals="0">336135</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="P01_01_2016To06_30_2016" id="Factid_95" unitRef="USD" decimals="0">570033</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P01_01_2017To06_30_2017" id="Factid_96" unitRef="USD" decimals="0">-3935637</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P01_01_2016To06_30_2016" id="Factid_97" unitRef="USD" decimals="0">-2783908</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:ProceedsFromRepaymentsOfNotesPayable contextRef="P01_01_2017To06_30_2017" id="Factid_98" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromRepaymentsOfNotesPayable>

  <us-gaap:ProceedsFromRepaymentsOfNotesPayable contextRef="P01_01_2016To06_30_2016" id="Factid_99" unitRef="USD" decimals="0">-25000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P01_01_2017To06_30_2017" id="Factid_100" unitRef="USD" decimals="0">6047009</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P01_01_2016To06_30_2016" id="Factid_101" unitRef="USD" decimals="0">-25000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:CashPeriodIncreaseDecrease contextRef="P01_01_2017To06_30_2017" id="Factid_102" unitRef="USD" decimals="0">2111372</us-gaap:CashPeriodIncreaseDecrease>

  <us-gaap:CashPeriodIncreaseDecrease contextRef="P01_01_2016To06_30_2016" id="Factid_103" unitRef="USD" decimals="0">-2808908</us-gaap:CashPeriodIncreaseDecrease>

  <us-gaap:Cash contextRef="PAsOn12_31_2015" id="Factid_104" unitRef="USD" decimals="0">6576564</us-gaap:Cash>

  <us-gaap:Cash contextRef="PAsOn06_30_2016" id="Factid_105" unitRef="USD" decimals="0">3767656</us-gaap:Cash>

  <tpiv:ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation contextRef="P01_01_2017To06_30_2017" id="Factid_106" unitRef="USD" decimals="0">0</tpiv:ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation>

  <tpiv:ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation contextRef="P01_01_2016To06_30_2016" id="Factid_107" unitRef="USD" decimals="0">191000</tpiv:ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation>

  <us-gaap:CashEquivalentsAtCarryingValue contextRef="PAsOn06_30_2017" id="Factid_108" unitRef="USD" decimals="0">9963000</us-gaap:CashEquivalentsAtCarryingValue>

  <us-gaap:OptionIndexedToIssuersEquityShares contextRef="P04_01_2017To06_30_2017" id="Factid_109" unitRef="shares" decimals="INF">455000</us-gaap:OptionIndexedToIssuersEquityShares>

  <us-gaap:OptionIndexedToIssuersEquityShares contextRef="P04_01_2016To06_30_2016" id="Factid_110" unitRef="shares" decimals="INF">251000</us-gaap:OptionIndexedToIssuersEquityShares>

  <tpiv:CommonStockWarrantsEquityTreatment contextRef="P04_01_2017To06_30_2017" id="Factid_111" unitRef="shares" decimals="INF">6540000</tpiv:CommonStockWarrantsEquityTreatment>

  <tpiv:CommonStockWarrantsEquityTreatment contextRef="P04_01_2016To06_30_2016" id="Factid_112" unitRef="shares" decimals="INF">213000</tpiv:CommonStockWarrantsEquityTreatment>

  <tpiv:CommonStockWarrantsLiabilityTreatment contextRef="P04_01_2017To06_30_2017" id="Factid_113" unitRef="shares" decimals="INF">3500</tpiv:CommonStockWarrantsLiabilityTreatment>

  <tpiv:CommonStockWarrantsLiabilityTreatment contextRef="P04_01_2016To06_30_2016" id="Factid_114" unitRef="shares" decimals="INF">2283000</tpiv:CommonStockWarrantsLiabilityTreatment>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P04_01_2017To06_30_2017" id="Factid_115" unitRef="shares" decimals="INF">6998500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P04_01_2016To06_30_2016" id="Factid_116" unitRef="shares" decimals="INF">2747000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:OptionIndexedToIssuersEquityShares contextRef="P01_01_2017To06_30_2017" id="Factid_117" unitRef="shares" decimals="INF">455000</us-gaap:OptionIndexedToIssuersEquityShares>

  <us-gaap:OptionIndexedToIssuersEquityShares contextRef="P01_01_2016To06_30_2016" id="Factid_118" unitRef="shares" decimals="INF">297000</us-gaap:OptionIndexedToIssuersEquityShares>

  <tpiv:CommonStockWarrantsEquityTreatment contextRef="P01_01_2017To06_30_2017" id="Factid_119" unitRef="shares" decimals="INF">6540000</tpiv:CommonStockWarrantsEquityTreatment>

  <tpiv:CommonStockWarrantsEquityTreatment contextRef="P01_01_2016To06_30_2016" id="Factid_120" unitRef="shares" decimals="INF">213000</tpiv:CommonStockWarrantsEquityTreatment>

  <tpiv:CommonStockWarrantsLiabilityTreatment contextRef="P01_01_2017To06_30_2017" id="Factid_121" unitRef="shares" decimals="INF">3500</tpiv:CommonStockWarrantsLiabilityTreatment>

  <tpiv:CommonStockWarrantsLiabilityTreatment contextRef="P01_01_2016To06_30_2016" id="Factid_122" unitRef="shares" decimals="INF">2068000</tpiv:CommonStockWarrantsLiabilityTreatment>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2017To06_30_2017" id="Factid_123" unitRef="shares" decimals="INF">6998500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2016To06_30_2016" id="Factid_124" unitRef="shares" decimals="INF">2578000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="PAsOn06_30_2017_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_125" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>

  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="PAsOn06_30_2017_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_126" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>

  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="PAsOn06_30_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_127" unitRef="USD" decimals="0">10000</us-gaap:DerivativeFairValueOfDerivativeLiability>

  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="PAsOn06_30_2017_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis" id="Factid_128" unitRef="USD" decimals="0">10000</us-gaap:DerivativeFairValueOfDerivativeLiability>

  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="PAsOn12_31_2016_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_129" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>

  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="PAsOn12_31_2016_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_130" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>

  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="PAsOn12_31_2016_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_131" unitRef="USD" decimals="0">14500</us-gaap:DerivativeFairValueOfDerivativeLiability>

  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="PAsOn12_31_2016_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis" id="Factid_132" unitRef="USD" decimals="0">14500</us-gaap:DerivativeFairValueOfDerivativeLiability>

  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="PAsOn12_31_2016" id="Factid_133" unitRef="USD" decimals="0">14500</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>

  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="P01_01_2017To06_30_2017" id="Factid_134" unitRef="USD" decimals="0">-4500</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>

  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="PAsOn06_30_2017" id="Factid_135" unitRef="USD" decimals="0">10000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn06_30_2017_PromissoryNotesDueInTwoThousandTwelveMemberusgaapDebtInstrumentAxis" id="Factid_136" unitRef="pure" decimals="1">0.1</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross contextRef="P03_08_2017To03_09_2017_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_137" unitRef="shares" decimals="INF">12761</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>

  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="P03_08_2017To03_09_2017_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_138" unitRef="USD" decimals="0">55000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>

  <us-gaap:SharePrice contextRef="PAsOn03_09_2017_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_139" unitRef="USD_per_Share" decimals="2">4.31</us-gaap:SharePrice>

  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="P03_08_2017To03_09_2017_PresidentAndChiefOperatingOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_140" unitRef="USD" decimals="0">22500</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>

  <us-gaap:SharePrice contextRef="PAsOn03_09_2017_PresidentAndChiefOperatingOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_141" unitRef="USD_per_Share" decimals="2">4.31</us-gaap:SharePrice>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P01_01_2017To06_30_2017_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis" id="Factid_142" unitRef="shares" decimals="INF">48334</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="P01_01_2017To06_30_2017_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis" id="Factid_143" unitRef="USD" decimals="0">205000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>

  <us-gaap:ShareBasedCompensation contextRef="P04_01_2017To06_30_2017" id="Factid_144" unitRef="USD" decimals="0">271000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P04_01_2016To06_30_2016" id="Factid_145" unitRef="USD" decimals="0">331000</us-gaap:ShareBasedCompensation>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="PAsOn06_30_2017" id="Factid_146" unitRef="USD" decimals="0">680000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2017To06_30_2017" id="Factid_147">P8M5D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn06_30_2017" id="Factid_148" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2016" id="Factid_149" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn06_30_2017" id="Factid_150" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2016" id="Factid_151" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn06_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_152" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_153" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn06_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_154" unitRef="shares" decimals="INF">1250000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_155" unitRef="shares" decimals="INF">1250000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn06_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_156" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_157" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn06_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_158" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_159" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn06_30_2017_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_160" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2016_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_161" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn06_30_2017_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_162" unitRef="shares" decimals="INF">1500000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2016_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_163" unitRef="shares" decimals="INF">1500000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn06_30_2017_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_164" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2016_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_165" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn06_30_2017_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_166" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2016_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_167" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn06_30_2017" id="Factid_168" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2016" id="Factid_169" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn06_30_2017" id="Factid_170" unitRef="shares" decimals="INF">41666667</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2016" id="Factid_171" unitRef="shares" decimals="INF">41666667</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn06_30_2017" id="Factid_172" unitRef="shares" decimals="INF">10158993</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn06_30_2017" id="Factid_173" unitRef="shares" decimals="INF">10158993</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2016" id="Factid_174" unitRef="shares" decimals="INF">8421185</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2016" id="Factid_175" unitRef="shares" decimals="INF">8421185</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="P04_01_2017To06_30_2017" id="Factid_176" unitRef="USD" decimals="0">492365</us-gaap:GainsLossesOnExtinguishmentOfDebt>

  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="P04_01_2016To06_30_2016" id="Factid_177" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>

  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="P01_01_2017To06_30_2017" id="Factid_178" unitRef="USD" decimals="0">492365</us-gaap:GainsLossesOnExtinguishmentOfDebt>

  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="P01_01_2016To06_30_2016" id="Factid_179" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>

  <us-gaap:RevenueFromGrants contextRef="P04_01_2017To06_30_2017" id="Factid_180" unitRef="USD" decimals="0">0</us-gaap:RevenueFromGrants>

  <us-gaap:RevenueFromGrants contextRef="P04_01_2016To06_30_2016" id="Factid_181" unitRef="USD" decimals="0">231200</us-gaap:RevenueFromGrants>

  <us-gaap:RevenueFromGrants contextRef="P01_01_2017To06_30_2017" id="Factid_182" unitRef="USD" decimals="0">0</us-gaap:RevenueFromGrants>

  <us-gaap:RevenueFromGrants contextRef="P01_01_2016To06_30_2016" id="Factid_183" unitRef="USD" decimals="0">231200</us-gaap:RevenueFromGrants>

  <us-gaap:OtherIncome contextRef="P04_01_2017To06_30_2017" id="Factid_184" unitRef="USD" decimals="0">0</us-gaap:OtherIncome>

  <us-gaap:OtherIncome contextRef="P01_01_2017To06_30_2017" id="Factid_185" unitRef="USD" decimals="0">0</us-gaap:OtherIncome>

  <us-gaap:OtherIncome contextRef="P01_01_2016To06_30_2016" id="Factid_186" unitRef="USD" decimals="0">1828</us-gaap:OtherIncome>

  <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="P04_01_2017To06_30_2017" id="Factid_187" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnRestructuringOfDebt>

  <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="P04_01_2016To06_30_2016" id="Factid_188" unitRef="USD" decimals="0">-70315</us-gaap:GainsLossesOnRestructuringOfDebt>

  <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="P01_01_2017To06_30_2017" id="Factid_189" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnRestructuringOfDebt>

  <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="P01_01_2016To06_30_2016" id="Factid_190" unitRef="USD" decimals="0">-70315</us-gaap:GainsLossesOnRestructuringOfDebt>

  <us-gaap:OtherIncome contextRef="P04_01_2016To06_30_2016" id="Factid_191" unitRef="USD" decimals="0">1828</us-gaap:OtherIncome>

  <us-gaap:EarningsPerShareBasic contextRef="P04_01_2017To06_30_2017" id="Factid_192" unitRef="USD_per_Share" decimals="2">-0.22</us-gaap:EarningsPerShareBasic>

  <us-gaap:EarningsPerShareBasic contextRef="P04_01_2016To06_30_2016" id="Factid_193" unitRef="USD_per_Share" decimals="2">1.01</us-gaap:EarningsPerShareBasic>

  <us-gaap:EarningsPerShareBasic contextRef="P01_01_2017To06_30_2017" id="Factid_194" unitRef="USD_per_Share" decimals="2">-0.51</us-gaap:EarningsPerShareBasic>

  <us-gaap:EarningsPerShareBasic contextRef="P01_01_2016To06_30_2016" id="Factid_195" unitRef="USD_per_Share" decimals="2">0.21</us-gaap:EarningsPerShareBasic>

  <us-gaap:EarningsPerShareDiluted contextRef="P04_01_2017To06_30_2017" id="Factid_196" unitRef="USD_per_Share" decimals="2">-0.22</us-gaap:EarningsPerShareDiluted>

  <us-gaap:EarningsPerShareDiluted contextRef="P04_01_2016To06_30_2016" id="Factid_197" unitRef="USD_per_Share" decimals="2">0.35</us-gaap:EarningsPerShareDiluted>

  <us-gaap:EarningsPerShareDiluted contextRef="P01_01_2017To06_30_2017" id="Factid_198" unitRef="USD_per_Share" decimals="2">-0.51</us-gaap:EarningsPerShareDiluted>

  <us-gaap:EarningsPerShareDiluted contextRef="P01_01_2016To06_30_2016" id="Factid_199" unitRef="USD_per_Share" decimals="2">-0.19</us-gaap:EarningsPerShareDiluted>

  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="P04_01_2017To06_30_2017" id="Factid_200" unitRef="shares" decimals="INF">8576634</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>

  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="P04_01_2016To06_30_2016" id="Factid_201" unitRef="shares" decimals="INF">5935000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>

  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="P01_01_2017To06_30_2017" id="Factid_202" unitRef="shares" decimals="INF">8503521</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>

  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="P01_01_2016To06_30_2016" id="Factid_203" unitRef="shares" decimals="INF">5908917</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>

  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="P04_01_2017To06_30_2017" id="Factid_204" unitRef="shares" decimals="INF">8576634</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>

  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="P04_01_2016To06_30_2016" id="Factid_205" unitRef="shares" decimals="INF">6524750</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>

  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="P01_01_2017To06_30_2017" id="Factid_206" unitRef="shares" decimals="INF">8503521</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>

  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="P01_01_2016To06_30_2016" id="Factid_207" unitRef="shares" decimals="INF">6652417</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>

  <tpiv:StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement contextRef="P01_01_2017To06_30_2017" id="Factid_208" unitRef="USD" decimals="0">6190003</tpiv:StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement>

  <tpiv:StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement contextRef="P01_01_2017To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_209" unitRef="USD" decimals="0">1504</tpiv:StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement>

  <tpiv:StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement contextRef="P01_01_2017To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_210" unitRef="USD" decimals="0">6188499</tpiv:StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement>

  <tpiv:StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement contextRef="P01_01_2017To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_211" unitRef="USD" decimals="0">0</tpiv:StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement>

  <tpiv:StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement contextRef="P01_01_2017To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_212" unitRef="shares" decimals="INF">1503567</tpiv:StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement>

  <tpiv:ExerciseOfWarrantsAmount contextRef="P01_01_2017To06_30_2017" id="Factid_213" unitRef="USD" decimals="0">666666</tpiv:ExerciseOfWarrantsAmount>

  <tpiv:ExerciseOfWarrantsAmount contextRef="P01_01_2017To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_214" unitRef="USD" decimals="0">168</tpiv:ExerciseOfWarrantsAmount>

  <tpiv:ExerciseOfWarrantsAmount contextRef="P01_01_2017To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_215" unitRef="USD" decimals="0">666498</tpiv:ExerciseOfWarrantsAmount>

  <tpiv:ExerciseOfWarrantsAmount contextRef="P01_01_2017To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_216" unitRef="USD" decimals="0">0</tpiv:ExerciseOfWarrantsAmount>

  <tpiv:ExerciseOfWarrantsShare contextRef="P01_01_2017To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_217" unitRef="shares" decimals="INF">167926</tpiv:ExerciseOfWarrantsShare>

  <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2017To06_30_2017" id="Factid_218">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &lt;font style="TEXT-TRANSFORM: uppercase"&gt;Note 5: NET (LOSS) InCOME PER SHARE&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Basic (loss) income per common share is computed by dividing net (loss) income by the weighted average number of common shares outstanding during the reporting period. Diluted income per common share is computed similar to basic income per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Income (loss) per-share amounts for all prior periods have been retroactively adjusted to reflect the Company&amp;#8217;s 1-for-12 reverse stock split, which was effective September 16, 2016.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following table sets forth the computation of net loss per share:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;Six&amp;#160;Months&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;Numerator:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Net (loss) income&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(1,893,377)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5,974,140&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(4,313,262)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,224,401&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Less: non-cash income from change in fair value of common stock warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;3,697,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,492,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Net (loss) income - diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(1,893,377)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,277,140&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(4,313,262)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(1,267,599)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;Denominator:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Weighted average common shares outstanding - basic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;8,576,634&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5,935,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;8,503,521&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5,908,917&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Dilutive effect of warrants, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;565,417&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;743,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Dilutive effect of stock options, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;24,333&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Weighted average common shares outstanding - diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;8,576,634&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,524,750&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;8,503,521&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,652,417&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;Net (loss) income per share data:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Basic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(0.22)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.01&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(0.51)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0.21&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(0.22)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0.35&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(0.51)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(0.19)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;Six&amp;#160;Months&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Common stock options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;455,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;251,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;455,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;297,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Common stock warrants - equity treatment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,540,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;213,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,540,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;213,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Common stock warrants - liability treatment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;3,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,283,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;3,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,068,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Potentially dilutive securities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,998,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,747,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,998,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,578,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>

  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2017To06_30_2017" id="Factid_219">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The following table sets forth the computation of net loss per share:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;Six&amp;#160;Months&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;Numerator:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Net (loss) income&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(1,893,377)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5,974,140&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(4,313,262)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,224,401&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Less: non-cash income from change in fair value of common stock warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;3,697,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,492,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Net (loss) income - diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(1,893,377)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,277,140&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(4,313,262)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(1,267,599)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;Denominator:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Weighted average common shares outstanding - basic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;8,576,634&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5,935,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;8,503,521&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5,908,917&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Dilutive effect of warrants, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;565,417&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;743,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Dilutive effect of stock options, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;24,333&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Weighted average common shares outstanding - diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;8,576,634&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,524,750&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;8,503,521&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,652,417&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;Net (loss) income per share data:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Basic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(0.22)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.01&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(0.51)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0.21&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(0.22)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0.35&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(0.51)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(0.19)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>

  <tpiv:NetLossPerShareTableTextBlockTableTextBlock contextRef="P01_01_2017To06_30_2017" id="Factid_220">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;Six&amp;#160;Months&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Common stock options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;455,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;251,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;455,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;297,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Common stock warrants - equity treatment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,540,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;213,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,540,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;213,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Common stock warrants - liability treatment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;3,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,283,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;3,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,068,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Potentially dilutive securities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,998,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,747,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,998,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,578,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tpiv:NetLossPerShareTableTextBlockTableTextBlock>

  <us-gaap:DilutiveSecurities contextRef="P04_01_2017To06_30_2017" id="Factid_221" unitRef="USD" decimals="0">0</us-gaap:DilutiveSecurities>

  <us-gaap:DilutiveSecurities contextRef="P04_01_2016To06_30_2016" id="Factid_222" unitRef="USD" decimals="0">-3697000</us-gaap:DilutiveSecurities>

  <us-gaap:DilutiveSecurities contextRef="P01_01_2017To06_30_2017" id="Factid_223" unitRef="USD" decimals="0">0</us-gaap:DilutiveSecurities>

  <us-gaap:DilutiveSecurities contextRef="P01_01_2016To06_30_2016" id="Factid_224" unitRef="USD" decimals="0">-2492000</us-gaap:DilutiveSecurities>

  <us-gaap:NetIncomeLossAttributableToParentDiluted contextRef="P04_01_2017To06_30_2017" id="Factid_225" unitRef="USD" decimals="0">-1893377</us-gaap:NetIncomeLossAttributableToParentDiluted>

  <us-gaap:NetIncomeLossAttributableToParentDiluted contextRef="P04_01_2016To06_30_2016" id="Factid_226" unitRef="USD" decimals="0">2277140</us-gaap:NetIncomeLossAttributableToParentDiluted>

  <us-gaap:NetIncomeLossAttributableToParentDiluted contextRef="P01_01_2017To06_30_2017" id="Factid_227" unitRef="USD" decimals="0">-4313262</us-gaap:NetIncomeLossAttributableToParentDiluted>

  <us-gaap:NetIncomeLossAttributableToParentDiluted contextRef="P01_01_2016To06_30_2016" id="Factid_228" unitRef="USD" decimals="0">-1267599</us-gaap:NetIncomeLossAttributableToParentDiluted>

  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="P04_01_2017To06_30_2017" id="Factid_229" unitRef="shares" decimals="INF">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>

  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="P04_01_2016To06_30_2016" id="Factid_230" unitRef="shares" decimals="INF">565417</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>

  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="P01_01_2017To06_30_2017" id="Factid_231" unitRef="shares" decimals="INF">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>

  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="P01_01_2016To06_30_2016" id="Factid_232" unitRef="shares" decimals="INF">743500</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>

  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="P04_01_2017To06_30_2017" id="Factid_233" unitRef="shares" decimals="INF">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>

  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="P04_01_2016To06_30_2016" id="Factid_234" unitRef="shares" decimals="INF">24333</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>

  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="P01_01_2017To06_30_2017" id="Factid_235" unitRef="shares" decimals="INF">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>

  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="P01_01_2016To06_30_2016" id="Factid_236" unitRef="shares" decimals="INF">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>

  <us-gaap:ProceedsFromWarrantExercises contextRef="P01_01_2017To06_30_2017" id="Factid_237" unitRef="USD" decimals="0">638666</us-gaap:ProceedsFromWarrantExercises>

  <us-gaap:ProceedsFromWarrantExercises contextRef="P01_01_2016To06_30_2016" id="Factid_238" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromWarrantExercises>

  <tpiv:ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement contextRef="P01_01_2017To06_30_2017" id="Factid_239" unitRef="USD" decimals="0">5408343</tpiv:ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement>

  <tpiv:ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement contextRef="P01_01_2016To06_30_2016" id="Factid_240" unitRef="USD" decimals="0">0</tpiv:ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement>

  <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="P01_01_2017To06_30_2017" id="Factid_241">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="TEXT-TRANSFORM: uppercase"&gt;&lt;b&gt;Note 6: Research Agreement OBLIGATIONS&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;b&gt;Crucell Holland B. V. (&amp;#8220;Crucell&amp;#8221;) &amp;#150; Research License and Option Agreement&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In 2003 and further amended in 2008, the Company acquired a research license and option agreement from Crucell Holland B.V. for use of an adenovirus technology. The Company has not made use of the technology in its current work and has not asked for nor received any work product from Crucell. Crucell was acquired by Johnson and Johnson in 2010.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;As of December 31, 2016, the Company had accrued $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;492,365&lt;/font&gt; under the amended agreement.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Upon further legal review and analysis of the agreement undertaken during the quarter, the Company concluded that the statute of limitations has run out on the obligation, and a legal opinion received by the Company confirms the amounts are not currently owed. As such, as of June 30, 2017, the Company was no longer obligated to make the payments under the agreement and therefore, the Company recorded a debt extinguishment gain of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;492,365&lt;/font&gt; and reduced the liability amount owed to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>

  <tpiv:NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement contextRef="P01_01_2017To06_30_2017" id="Factid_242" unitRef="USD" decimals="0">622042</tpiv:NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement>

  <tpiv:NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement contextRef="P01_01_2016To06_30_2016" id="Factid_243" unitRef="USD" decimals="0">0</tpiv:NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement>

  <us-gaap:NatureOfOperations contextRef="P01_01_2017To06_30_2017" id="Factid_244">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &lt;font style="TEXT-TRANSFORM: uppercase"&gt;Note 1: Nature of Operations&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;TapImmune Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;we&amp;#8221;), a Nevada corporation incorporated in 1992, is a biotechnology company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NatureOfOperations>

  <us-gaap:BasisOfAccounting contextRef="P01_01_2017To06_30_2017" id="Factid_245">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &lt;font style="TEXT-TRANSFORM: uppercase"&gt;NOTE 2: Basis of Presentation&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The results for the condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2017 or for any future interim period. The condensed consolidated balance sheet at June 30, 2017 has been derived from unaudited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2016, and notes thereto included in the Company&amp;#8217;s annual report on Form 10-K filed on March 14, 2017.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfAccounting>

  <tpiv:LiquidityAndFinancialConditionTextBlock contextRef="P01_01_2017To06_30_2017" id="Factid_246">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &lt;font style="TEXT-TRANSFORM: uppercase"&gt;NOTE 3: LIQUIDITY AND FINANCIAL CONDITION&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company&amp;#8217;s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company&amp;#8217;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity and debt financings and warrant exercises.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company&amp;#8217;s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;As of June 30, 2017, the Company had cash of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9,963,000&lt;/font&gt;. The Company had net losses and negative cash flows from operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company&amp;#8217;s ability to continue as a going concern.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tpiv:LiquidityAndFinancialConditionTextBlock>

  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2017To06_30_2017" id="Factid_247">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &lt;font style="TEXT-TRANSFORM: uppercase"&gt;Note 4: SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;There have been no material changes in the Company&amp;#8217;s significant accounting policies to those previously disclosed in the Company&amp;#8217;s annual report on Form 10-K, which was filed with the SEC on March 14, 2017.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;New Accounting Pronouncement&lt;/i&gt;s&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;i&gt;&lt;u&gt;Accounting for Certain Financial Instruments with Down Round Features&lt;/u&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"&gt;On July 13, 2017, the FASB has issued a two-part Accounting Standards Update (&amp;#8220;ASU&amp;#8221;), No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features and (ii) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company will be evaluating the impact of adopting this standard on the consolidated financial statements and disclosures.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;u&gt;Compensation-Stock Compensation&lt;/u&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In May 2017, the FASB issued ASU 2017-09, Compensation&amp;#151;Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the consolidated financial statements and disclosures, but does not expect it to have a significant impact.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>

  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2017To06_30_2017" id="Factid_248">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;b&gt;&lt;i&gt;New Accounting Pronouncement&lt;/i&gt;s&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;i&gt;&lt;u&gt;Accounting for Certain Financial Instruments with Down Round Features&lt;/u&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"&gt;On July 13, 2017, the FASB has issued a two-part Accounting Standards Update (&amp;#8220;ASU&amp;#8221;), No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features and (ii) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company will be evaluating the impact of adopting this standard on the consolidated financial statements and disclosures.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;u&gt;Compensation-Stock Compensation&lt;/u&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In May 2017, the FASB issued ASU 2017-09, Compensation&amp;#151;Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the consolidated financial statements and disclosures, but does not expect it to have a significant impact.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>

  <us-gaap:DerivativesAndFairValueTextBlock contextRef="P01_01_2017To06_30_2017" id="Factid_249">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &lt;font style="TEXT-TRANSFORM: uppercase"&gt;Note 7: WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company&amp;#8217;s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the six months ended June 30, 2017 and 2016 is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="30%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"&gt; &lt;div&gt;Six&amp;#160;Months&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="30%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="30%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"&gt; &lt;div&gt;Stock price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;3.88&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6.12&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"&gt; &lt;div&gt;Exercise price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.20 - $300.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: calibri; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"&gt; &lt;div&gt;Contractual term (years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.03&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0.28 - 4.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"&gt; &lt;div&gt;Volatility (annual)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;78&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;68% - 151&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"&gt; &lt;div&gt;Risk-free rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"&gt; &lt;div&gt;Dividend yield (per share)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management&amp;#8217;s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Financial Liabilities Measured at Fair Value on a Recurring Basis&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"&gt; &lt;div&gt; Fair&amp;#160;value&amp;#160;measured&amp;#160;at&amp;#160;June&amp;#160;30,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Quoted&amp;#160;prices&amp;#160;in&amp;#160;active&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Significant&amp;#160;other&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Significant&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;markets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;observable&amp;#160;inputs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;unobservable&amp;#160;inputs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Fair&amp;#160;value&amp;#160;at&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;(Level&amp;#160;1)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;(Level&amp;#160;2)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;(Level&amp;#160;3)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;June&amp;#160;30,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;10,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;10,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"&gt; &lt;div&gt; Fair&amp;#160;value&amp;#160;measured&amp;#160;at&amp;#160;December&amp;#160;31,&amp;#160;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Quoted&amp;#160;prices&amp;#160;in&amp;#160;active&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Significant&amp;#160;other&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Significant&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;markets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;observable&amp;#160;inputs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;unobservable&amp;#160;inputs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Fair&amp;#160;value&amp;#160;at&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;(Level&amp;#160;1)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;(Level&amp;#160;2)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;(Level&amp;#160;3)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;14,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;14,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;There were no transfers between Level 1, 2 or 3 during the&amp;#160;six months ended June 30, 2017.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following table presents changes in Level 3 liabilities measured at fair value for the&amp;#160;six months ended June 30, 2017:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Warrant&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Balance - December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;14,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Change in fair value of warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(4,500)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Balance &amp;#150; June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;10,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DerivativesAndFairValueTextBlock>

  <tpiv:ValuationMethodology contextRef="P01_01_2017To06_30_2017" id="Factid_250">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company&amp;#8217;s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the six months ended June 30, 2017 and 2016 is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="30%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"&gt; &lt;div&gt;Six&amp;#160;Months&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="30%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="30%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"&gt; &lt;div&gt;Stock price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;3.88&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6.12&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"&gt; &lt;div&gt;Exercise price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.20 - $300.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: calibri; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"&gt; &lt;div&gt;Contractual term (years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.03&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0.28 - 4.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"&gt; &lt;div&gt;Volatility (annual)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;78&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;68% - 151&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"&gt; &lt;div&gt;Risk-free rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"&gt; &lt;div&gt;Dividend yield (per share)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tpiv:ValuationMethodology>

  <tpiv:FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis contextRef="P01_01_2017To06_30_2017" id="Factid_251">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"&gt; &lt;div&gt; Fair&amp;#160;value&amp;#160;measured&amp;#160;at&amp;#160;June&amp;#160;30,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Quoted&amp;#160;prices&amp;#160;in&amp;#160;active&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Significant&amp;#160;other&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Significant&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;markets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;observable&amp;#160;inputs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;unobservable&amp;#160;inputs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Fair&amp;#160;value&amp;#160;at&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;(Level&amp;#160;1)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;(Level&amp;#160;2)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;(Level&amp;#160;3)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;June&amp;#160;30,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;10,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;10,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"&gt; &lt;div&gt; Fair&amp;#160;value&amp;#160;measured&amp;#160;at&amp;#160;December&amp;#160;31,&amp;#160;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Quoted&amp;#160;prices&amp;#160;in&amp;#160;active&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Significant&amp;#160;other&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Significant&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;markets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;observable&amp;#160;inputs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;unobservable&amp;#160;inputs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;Fair&amp;#160;value&amp;#160;at&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;(Level&amp;#160;1)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;(Level&amp;#160;2)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;(Level&amp;#160;3)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;14,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;14,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tpiv:FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis>

  <tpiv:MeasuredAtFairValue contextRef="P01_01_2017To06_30_2017" id="Factid_252">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The following table presents changes in Level 3 liabilities measured at fair value for the&amp;#160;six months ended June 30, 2017:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Warrant&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Balance - December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;14,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Change in fair value of warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(4,500)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Balance &amp;#150; June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;10,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tpiv:MeasuredAtFairValue>

  <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="PAsOn12_31_2016_CrucellHollandBvMemberdeiLegalEntityAxis" id="Factid_253" unitRef="USD" decimals="0">492365</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>

  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="P01_01_2017To06_30_2017_CrucellHollandBvMemberdeiLegalEntityAxis" id="Factid_254" unitRef="USD" decimals="0">492365</us-gaap:GainsLossesOnExtinguishmentOfDebt>

  <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet contextRef="P01_01_2017To06_30_2017_CrucellHollandBvMemberdeiLegalEntityAxis" id="Factid_255" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>

  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2017To06_30_2017" id="Factid_256">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="TEXT-TRANSFORM: uppercase; FONT-WEIGHT: bold"&gt;Note 10: STOCK-BASED COMPENSATION&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company recorded $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;271,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;331,000&lt;/font&gt; of stock-based compensation expense for the three months ended June 30, 2017 and 2016, respectively. The Company recorded $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;647,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;545,000&lt;/font&gt; of stock-based compensation expense for the six months ended June 30, 2017 and 2016, respectively. Stock-based compensation expense is included in general and administrative expense on the condensed consolidated statements of operations.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;At June 30, 2017, the total stock-based compensation cost related to unvested awards not yet recognized was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;680,000&lt;/font&gt;. The expected weighted average period compensation costs to be recognized was &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 0.68&lt;/font&gt; years.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Future option grants will impact the compensation expense recognized.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>

  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="P01_01_2017To06_30_2017_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_257" unitRef="pure" decimals="0">0</us-gaap:FairValueAssumptionsExpectedDividendRate>

  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="P01_01_2016To06_30_2016_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_258" unitRef="pure" decimals="0">0</us-gaap:FairValueAssumptionsExpectedDividendRate>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P01_01_2017To06_30_2017_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_259">P1Y11D</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2017To06_30_2017_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_260" unitRef="pure" decimals="2">0.78</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2017To06_30_2017_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_261" unitRef="pure" decimals="4">0.0100</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:SharePrice contextRef="PAsOn06_30_2017_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_262" unitRef="USD_per_Share" decimals="2">3.88</us-gaap:SharePrice>

  <us-gaap:FairValueAssumptionsExercisePrice contextRef="PAsOn06_30_2017_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_263" unitRef="USD_per_Share" decimals="2">1.20</us-gaap:FairValueAssumptionsExercisePrice>

  <us-gaap:SharePrice contextRef="PAsOn06_30_2016_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_264" unitRef="USD_per_Share" decimals="2">6.12</us-gaap:SharePrice>

  <tpiv:PromissoryNoteTextBlock contextRef="P01_01_2017To06_30_2017" id="Factid_265">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="TEXT-TRANSFORM: uppercase"&gt;&lt;b&gt;Note 8: Promissory note&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;At June 30, 2017 and December 31, 2016, the Company had an outstanding promissory note in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,000&lt;/font&gt;. The promissory note outstanding and due at June 30, 2017 bears &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt;% annual interest.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tpiv:PromissoryNoteTextBlock>

  <us-gaap:FairValueAssumptionsExercisePrice contextRef="PAsOn06_30_2016_MinimumMemberusgaapRangeAxis_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_266" unitRef="USD_per_Share" decimals="2">1.20</us-gaap:FairValueAssumptionsExercisePrice>

  <us-gaap:FairValueAssumptionsExercisePrice contextRef="PAsOn06_30_2016_MaximumMemberusgaapRangeAxis_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_267" unitRef="USD_per_Share" decimals="2">300.00</us-gaap:FairValueAssumptionsExercisePrice>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P01_01_2016To06_30_2016_MinimumMemberusgaapRangeAxis_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_268">P3M11D</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P01_01_2016To06_30_2016_MaximumMemberusgaapRangeAxis_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_269">P4Y2M12D</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2016To06_30_2016_MinimumMemberusgaapRangeAxis_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_270" unitRef="pure" decimals="2">0.68</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2016To06_30_2016_MaximumMemberusgaapRangeAxis_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_271" unitRef="pure" decimals="2">1.51</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2016To06_30_2016_SharePurchaseWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_272" unitRef="pure" decimals="4">0.0100</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P01_01_2017To06_30_2017" id="Factid_273" unitRef="USD" decimals="0">781660</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P01_01_2017To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_274" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P01_01_2017To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_275" unitRef="USD" decimals="0">781660</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P01_01_2017To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_276" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <tpiv:AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants contextRef="P01_01_2017To06_30_2017" id="Factid_277" unitRef="USD" decimals="0">28000</tpiv:AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants>

  <tpiv:AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants contextRef="P01_01_2017To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_278" unitRef="USD" decimals="0">0</tpiv:AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants>

  <tpiv:AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants contextRef="P01_01_2017To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_279" unitRef="USD" decimals="0">28000</tpiv:AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants>

  <tpiv:AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants contextRef="P01_01_2017To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_280" unitRef="USD" decimals="0">0</tpiv:AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P01_01_2017To06_30_2017" id="Factid_281" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P01_01_2017To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_282" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P01_01_2017To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_283" unitRef="USD" decimals="0">622042</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P01_01_2017To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_284" unitRef="USD" decimals="0">-622042</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <tpiv:BonusOnBaseSalariespercentage contextRef="P07_01_2017To07_06_2017_ChiefExecutiveOfficerAndPresidentMemberusgaapTitleOfIndividualAxis_MaximumMemberusgaapRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_285" unitRef="pure" decimals="1">0.5</tpiv:BonusOnBaseSalariespercentage>

  <tpiv:BonusOnBaseSalariespercentage contextRef="P07_01_2017To07_06_2017_ChiefFinancialOfficerTreasurerAndSecretaryMemberusgaapTitleOfIndividualAxis_MaximumMemberusgaapRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_286" unitRef="pure" decimals="1">0.3</tpiv:BonusOnBaseSalariespercentage>

  <us-gaap:OfficersCompensation contextRef="P07_01_2017To07_06_2017_ChiefExecutiveOfficerAndPresidentMemberusgaapTitleOfIndividualAxis_MaximumMemberusgaapRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_287" unitRef="USD" decimals="0">140000</us-gaap:OfficersCompensation>

  <us-gaap:OfficersCompensation contextRef="P07_01_2017To07_06_2017_ChiefFinancialOfficerTreasurerAndSecretaryMemberusgaapTitleOfIndividualAxis_MaximumMemberusgaapRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_288" unitRef="USD" decimals="0">60000</us-gaap:OfficersCompensation>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P06_01_2017To06_26_2017_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_289" unitRef="USD" decimals="0">1503567</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:SharesIssuedPricePerShare contextRef="PAsOn06_26_2017_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_290" unitRef="USD_per_Share" decimals="2">3.97</us-gaap:SharesIssuedPricePerShare>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn06_26_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_291" unitRef="USD_per_Share" decimals="2">3.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P06_01_2017To06_26_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_292" unitRef="USD" decimals="-5">6200000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:LegalFees contextRef="P06_01_2017To06_26_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_293" unitRef="USD" decimals="-5">800000</us-gaap:LegalFees>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn08_31_2016_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_294" unitRef="USD_per_Share" decimals="2">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn06_26_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_295" unitRef="shares" decimals="INF">653187</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn06_26_2017_SubsequentWarrantIssuanceMemberusgaapClassOfWarrantOrRightAxis" id="Factid_296" unitRef="shares" decimals="INF">150357</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn06_26_2017_SubsequentWarrantIssuanceMemberusgaapClassOfWarrantOrRightAxis" id="Factid_297" unitRef="USD_per_Share" decimals="2">3.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <tpiv:LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities contextRef="PAsOn06_26_2017_SubsequentWarrantIssuanceMemberusgaapClassOfWarrantOrRightAxis" id="Factid_298" unitRef="pure" decimals="1">0.1</tpiv:LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities>

  <us-gaap:LossContingencyDamagesSoughtValue contextRef="P06_01_2017To06_26_2017" id="Factid_299" unitRef="USD" decimals="0">57000</us-gaap:LossContingencyDamagesSoughtValue>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn06_23_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesEWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_300" unitRef="USD_per_Share" decimals="2">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn06_30_2016_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesEWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_301" unitRef="USD_per_Share" decimals="2">3.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <tpiv:ValuationMethodologyTableTextBlock contextRef="P01_01_2017To06_30_2017" id="Factid_302">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company&amp;#8217;s common stock purchase warrants that are included in the modification is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="6"&gt; &lt;div&gt;Weighted&amp;#160;Average&amp;#160;Inputs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;Before&amp;#160;Modification&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;After&amp;#160;Modification&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Exercise price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;8.32&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;4.04&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Contractual term (years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;3.34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;3.34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Volatility (annual)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;200&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;200&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Risk-free rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;1.50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;1.50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Dividend yield (per share)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tpiv:ValuationMethodologyTableTextBlock>

  <us-gaap:FairValueAssumptionsExercisePrice contextRef="PAsOn06_30_2017_ScenarioPreviouslyReportedMemberusgaapStatementScenarioAxis_SharePurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_303" unitRef="USD_per_Share" decimals="2">8.32</us-gaap:FairValueAssumptionsExercisePrice>

  <us-gaap:FairValueAssumptionsExercisePrice contextRef="PAsOn06_30_2017_RestatementAdjustmentMemberusgaapStatementScenarioAxis_SharePurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_304" unitRef="USD_per_Share" decimals="2">4.04</us-gaap:FairValueAssumptionsExercisePrice>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P01_01_2017To06_30_2017_ScenarioPreviouslyReportedMemberusgaapStatementScenarioAxis_SharePurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_305">P3Y4M2D</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P01_01_2017To06_30_2017_RestatementAdjustmentMemberusgaapStatementScenarioAxis_SharePurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_306">P3Y4M2D</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2017To06_30_2017_ScenarioPreviouslyReportedMemberusgaapStatementScenarioAxis_SharePurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_307" unitRef="pure" decimals="0">2</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2017To06_30_2017_RestatementAdjustmentMemberusgaapStatementScenarioAxis_SharePurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_308" unitRef="pure" decimals="0">2</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2017To06_30_2017_ScenarioPreviouslyReportedMemberusgaapStatementScenarioAxis_SharePurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_309" unitRef="pure" decimals="4">0.0150</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2017To06_30_2017_RestatementAdjustmentMemberusgaapStatementScenarioAxis_SharePurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_310" unitRef="pure" decimals="4">0.0150</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="P01_01_2017To06_30_2017_ScenarioPreviouslyReportedMemberusgaapStatementScenarioAxis_SharePurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_311" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>

  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="P01_01_2017To06_30_2017_RestatementAdjustmentMemberusgaapStatementScenarioAxis_SharePurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_312" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>

  <tpiv:EquityUnitIssuedPricePerUnit contextRef="P06_01_2017To06_26_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_313" unitRef="USD_Warrant" decimals="3">4.095</tpiv:EquityUnitIssuedPricePerUnit>

  <tpiv:ClassOfWarrantOrRightExpirationPeriod contextRef="P06_01_2017To06_26_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_314">P5Y</tpiv:ClassOfWarrantOrRightExpirationPeriod>

  <tpiv:ClassOfWarrantOrRightExpirationPeriod contextRef="P06_01_2017To06_26_2017_SubsequentWarrantIssuanceMemberusgaapClassOfWarrantOrRightAxis" id="Factid_315">P5Y</tpiv:ClassOfWarrantOrRightExpirationPeriod>

  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross contextRef="P03_08_2017To03_09_2017_PresidentAndChiefOperatingOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_316" unitRef="shares" decimals="INF">5220</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>

  <tpiv:NumberOfUnitsSold contextRef="P06_01_2017To06_26_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_317" unitRef="shares" decimals="INF">1503567</tpiv:NumberOfUnitsSold>

  <us-gaap:StockholdersEquityReverseStockSplit contextRef="P09_01_2016To09_16_2016" id="Factid_318">1-for-12 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>

  <tpiv:ClassOfWarrantOrRightWarrantPrice contextRef="PAsOn06_26_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_319" unitRef="USD_Warrant" decimals="3">0.125</tpiv:ClassOfWarrantOrRightWarrantPrice>

  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2017To06_30_2017" id="Factid_320">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &lt;font style="TEXT-TRANSFORM: uppercase"&gt;Note 9: STOCKHOLDERS&amp;#8217; EQUITY&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; Reverse Stock Split&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On September 16, 2016, the Company effected a one for twelve reverse stock-split of our issued and outstanding common stock and has retroactively adjusted our common shares outstanding, options and warrants amounts outstanding. The Company has presented its share data for and as of all periods presented on this basis. The par value was not adjusted as a result of the one for twelve reverse stock split. All prior period share transactions included in the Company&amp;#8217;s stock transactions and balances have been retroactively restated.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;strong&gt;2017 Common Stock Transactions&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;u&gt;June 2017 Private Placement Transaction&lt;/u&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On June 26, 2017, the Company completed private placement of units with certain accredited investors. In the private placement transaction, the Company sold &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,503,567&lt;/font&gt; shares of common stock for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.97&lt;/font&gt; per share and five-year warrants to purchase an equal number of shares of common stock, at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.97&lt;/font&gt; per share, for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.125&lt;/font&gt; per warrant, with one common share and one warrant being sold together as a unit for a total of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.095&lt;/font&gt; per unit. The Company issued and sold an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,503,567&lt;/font&gt; million units for aggregate gross proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.2&lt;/font&gt; million. The Company incurred $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.8&lt;/font&gt; million in agency fees and legal costs. In connection with the offering, the Company reduced the exercise price for the warrants to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 653,187&lt;/font&gt; shares of common stock issued to investors in the private placement that closed in August 2016 from $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.00&lt;/font&gt; per share to $3.97 per share.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In addition, the Company issued five-year warrants to the placement agent in the offering providing for the purchase of up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 150,357&lt;/font&gt; shares of Company common stock for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.97&lt;/font&gt; per share.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Pursuant to a Registration Rights Agreement to be entered into at the closing of the private placement offering, promptly, but no later than 90 calendar days after the closing of the offering, the Company is required to file a registration statement with the Securities and Exchange Commission registering for resale (a) the common stock issued in the offering; (b) the shares of common stock issuable upon the exercise of the private placement warrants; and (c) the shares of common stock issuable upon the exercise of the warrants issued to Katalyst Securities LLC, which acted as placement agent for the offering. The Company is required to use its commercially reasonable efforts to ensure that the Registration Statement is declared effective within 90 calendar days after filing with the Securities and Exchange Commission, on or before December 23, 2017.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In accordance with the registration rights agreements, should the Company fail to meet the above criteria, the Company is subject to pay the investors liquidated damages. The liquidated damages shall be a cash sum payment calculated at a rate of ten percent (&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10&lt;/font&gt;%) per annum of the aggregate purchase price for the registrable securities or aggregate amount upon exercise of the placement agent warrants.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In accordance with U.S. GAAP, a contingent obligation to make future payments must be recorded if the transfer of consideration under a registration payment arrangement is probable and can be reasonably estimated. The Company has determined that should it be required to pay liquidated damages to the investors of the private placements, the aggregate contingent liability it would be required to record would be approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;57,000&lt;/font&gt; per month for each month it fails or is estimated to fail to meet the above criteria.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;At the June 26, 2017 private placement closing, and on June 30, 2017, the Company concluded that it is not probable that it will be required to remit any payments to the investors for failing to obtain an effective registration statement or failing to maintain its effectiveness.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;u&gt;June 2017 Exercise and Repricing of Warrants Held by Existing Institutional Investors&lt;/u&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On June 23, 2017, certain existing institutional shareholders of the Company who hold various outstanding warrants (i.e. C, D, E and F) to purchase Company common stock, entered into warrant repricing and exercise agreements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;Series E repriced and exercised warrants&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 168,000&lt;/font&gt; of Series E warrants were repriced from $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15.00&lt;/font&gt; per share to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.97&lt;/font&gt; per share and exercised immediately for gross proceeds of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.7&lt;/font&gt; million. Series E warrants to purchase approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 187,000&lt;/font&gt; shares of Company common stock being reduced from $15.00 per share to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.50&lt;/font&gt; per share.&lt;/div&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;Series C, D &amp;amp; F repriced warrants&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Additionally, the exercise prices for certain investors of Series C, Series D and Series F warrants were reduced as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="17%"&gt; &lt;div&gt;Series&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Number of Warrant Shares Repriced&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Pre-reduced Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Post-reduced Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;Series C&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;313,750&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;Series D&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;312,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;9.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;Series F&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;292,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;7.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The fair value relating to the modification of exercise prices on all of the repriced warrants was treated as deemed dividend on the statement of stockholders&amp;#8217; equity of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;622,000&lt;/font&gt;.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company&amp;#8217;s common stock purchase warrants that are included in the modification is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="6"&gt; &lt;div&gt;Weighted&amp;#160;Average&amp;#160;Inputs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;Before&amp;#160;Modification&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;After&amp;#160;Modification&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Exercise price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;8.32&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;4.04&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Contractual term (years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;3.34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;3.34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Volatility (annual)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;200&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;200&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Risk-free rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;1.50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;1.50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Dividend yield (per share)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;u&gt;2017 Management Compensation&lt;/u&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On March 9, 2017, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 12,761&lt;/font&gt; shares of stock in relation to the discretionary 2016 bonus awarded to Dr. Glynn Wilson. The fair value of the common stock of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;55,000&lt;/font&gt; was recognized as stock-based compensation in general and administrative expenses. The issuance was based on the closing price or our common stock of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.31&lt;/font&gt; per share, on the day immediately preceding the date the 2016 bonus award was approved by the Board of Directors.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On March 9, 2017, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5,220&lt;/font&gt; shares of stock in relation to the discretionary 2016 bonus awarded to our former Chief Operating Officer. The fair value of the common stock of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;22,500&lt;/font&gt; was recognized as stock-based compensation in general and administrative expenses. The issuance was based on the closing price or our common stock of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.31&lt;/font&gt; per share, on the day immediately preceding the date the 2016 bonus award was approved by the Board of Directors.&lt;/div&gt; &lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;u&gt;Consulting Arrangements&lt;/u&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;During the six months ended June 30, 2017, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 48,334&lt;/font&gt; shares of common stock as part of consulting agreements. The fair value of the common stock of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;205,000&lt;/font&gt; was recognized as stock-based compensation in general and administrative expenses.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn06_30_2017_ClassOfWarrantOrRighttrancheOneMembertpivClassOfWarrantOrRightExerciseAxis_SeriesCWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_321" unitRef="shares" decimals="INF">313750</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn06_30_2017_ClassOfWarrantOrRighttrancheOneMembertpivClassOfWarrantOrRightExerciseAxis_SeriesDWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_322" unitRef="shares" decimals="INF">312500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn06_30_2017_ClassOfWarrantOrRighttrancheOneMembertpivClassOfWarrantOrRightExerciseAxis_SeriesFWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_323" unitRef="shares" decimals="INF">292500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn06_30_2017_PrereducedPriceMembertpivClassOfWarrantOrRightExerciseAxis_SeriesCWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_324" unitRef="USD_per_Share" decimals="2">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn06_30_2017_PrereducedPriceMembertpivClassOfWarrantOrRightExerciseAxis_SeriesDWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_325" unitRef="USD_per_Share" decimals="2">9.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn06_30_2017_PrereducedPriceMembertpivClassOfWarrantOrRightExerciseAxis_SeriesFWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_326" unitRef="USD_per_Share" decimals="2">7.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn06_30_2017_PostreducedPriceMembertpivClassOfWarrantOrRightExerciseAxis_SeriesCWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_327" unitRef="USD_per_Share" decimals="2">4.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn06_30_2017_PostreducedPriceMembertpivClassOfWarrantOrRightExerciseAxis_SeriesDWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_328" unitRef="USD_per_Share" decimals="2">4.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn06_30_2017_PostreducedPriceMembertpivClassOfWarrantOrRightExerciseAxis_SeriesFWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_329" unitRef="USD_per_Share" decimals="2">4.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn06_23_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesEWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_330" unitRef="shares" decimals="INF">168000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ProceedsFromWarrantExercises contextRef="P06_01_2017To06_23_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesEWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_331" unitRef="USD" decimals="-5">700000</us-gaap:ProceedsFromWarrantExercises>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn06_23_2017_ClassOfWarrantOrRighttrancheOneMembertpivClassOfWarrantOrRightExerciseAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesEWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_332" unitRef="shares" decimals="INF">187000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn06_23_2017_ClassOfWarrantOrRighttrancheTwoMembertpivClassOfWarrantOrRightExerciseAxis_SeriesEWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_333" unitRef="USD_per_Share" decimals="2">4.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn06_23_2017_ClassOfWarrantOrRighttrancheOneMembertpivClassOfWarrantOrRightExerciseAxis_SeriesEWarrantMemberusgaapClassOfWarrantOrRightAxis" id="Factid_334" unitRef="USD_per_Share" decimals="2">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="P01_01_2017To06_30_2017" id="Factid_335">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Additionally, the exercise prices for certain investors of Series C, Series D and Series F warrants were reduced as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="17%"&gt; &lt;div&gt;Series&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Number of Warrant Shares Repriced&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Pre-reduced Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Post-reduced Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;Series C&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;313,750&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;Series D&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;312,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;9.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;Series F&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;292,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;7.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>

  <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2017To06_30_2017" id="Factid_336">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="TEXT-TRANSFORM: uppercase; FONT-WEIGHT: bold"&gt;Note 11: SUBSEQUENT EVENT&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On July 6, 2017, the Board of Directors of&amp;#160;the Company&amp;#160;approved the 2017 bonus program for Dr. Glynn Wilson, our Chief Executive Officer and President, and Mr. Michael J. Loiacono, our Chief Financial Officer, Treasurer and Secretary, as recommended by the Compensation Committee of the Board of Directors. Under such bonus program, Dr. Wilson and Mr. Loiacono are eligible for bonuses of up to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;140,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;60,000&lt;/font&gt;, respectively, equaling up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 50&lt;/font&gt;% and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 30&lt;/font&gt;%, of their respective base salaries.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The bonus amount of up to $140,000 to Dr. Wilson is to be allocated upon the achievement of the following objectives:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div&gt;(i)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;up to 40% of the bonus amount for meeting scientific, technical and clinical objectives;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div&gt;(ii)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;up to 20% of the bonus amount for financial performance and corporate objectives related to our raising capital; and&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div&gt;(iii)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;up to 40% of the bonus amount designated to be discretionary as determined by the Board.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In order for Dr. Wilson to achieve his eligible bonus of $140,000, he would need 100% attainment in each of the above objectives&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The bonus amount of up to $60,000 to Mr. Loiacono is to be allocated upon the achievement of the following objectives:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div&gt;(i)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;up to 33.3% of the bonus amount for meeting corporate and operational objectives;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div&gt;(ii)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;up to 33.3% of the bonus amount for financial performance objectives including related to our raising capital; and&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div&gt;(iii)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;up to 33.3% of the bonus amount designated to be discretionary as determined by the Board.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In order for Mr. Loiacono to achieve his eligible bonus of $60,000, he would need 100% attainment in each of the above objectives.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The bonuses will be paid in a combination of cash and common stock at the discretion of the Compensation Committee.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>

  <tpiv:BonusPayableDescription contextRef="P07_01_2017To07_06_2017_ChiefExecutiveOfficerAndPresidentMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_337">The bonus amount of up to $140,000 to Dr. Wilson is to be allocated upon the achievement of the following objectives: (i) up to 40% of the bonus amount for meeting scientific, technical and clinical objectives; (ii) up to 20% of the bonus amount for financial performance and corporate objectives related to our raising capital; and (iii) up to 40% of the bonus amount designated to be discretionary as determined by the Board. In order for Dr. Wilson to achieve his eligible bonus of $140,000, he would need 100% attainment in each of the above objectives.</tpiv:BonusPayableDescription>

  <tpiv:BonusPayableDescription contextRef="P07_01_2017To07_06_2017_ChiefFinancialOfficerTreasurerAndSecretaryMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_338">The bonus amount of up to $60,000 to Mr. Loiacono is to be allocated upon the achievement of the following objectives: (i) up to 33.3% of the bonus amount for meeting corporate and operational objectives; (ii) up to 33.3% of the bonus amount for financial performance objectives including related to our raising capital; and (iii) up to 33.3% of the bonus amount designated to be discretionary as determined by the Board. In order for Mr. Loiacono to achieve his eligible bonus of $60,000, he would need 100% attainment in each of the above objectives.</tpiv:BonusPayableDescription>

<!--FootNote Section Ref-->

  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
  </link:footnoteLink>
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>tpiv-20170630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 04-Aug-2017 [07:27:56] {PM} EST - www.datatracks.com -->
<schema targetNamespace="http://www.tapimmune.com/20170630" elementFormDefault="qualified" xmlns:tpiv="http://www.tapimmune.com/20170630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.tapimmune.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>101 - Document - Document And Entity Information</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
        <link:definition>104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/CondensedConsolidatedStatementOfStockholdersEquity" id="CondensedConsolidatedStatementOfStockholdersEquity">
        <link:definition>105 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS&#39; EQUITY</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/NatureOfOperations" id="NatureOfOperations">
        <link:definition>107 - Disclosure - NATURE OF OPERATIONS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/BasisOfPresentation" id="BasisOfPresentation">
        <link:definition>108 - Disclosure - BASIS OF PRESENTATION</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/LiquidityAndFinancialCondition" id="LiquidityAndFinancialCondition">
        <link:definition>109 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
        <link:definition>110 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/NetLossIncomePerShare" id="NetLossIncomePerShare">
        <link:definition>111 - Disclosure - NET (LOSS) INCOME PER SHARE</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/ResearchAgreementObligations" id="ResearchAgreementObligations">
        <link:definition>112 - Disclosure - RESEARCH AGREEMENT OBLIGATIONS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurements" id="WarrantLiabilityAndFairValueMeasurements">
        <link:definition>113 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/PromissoryNote" id="PromissoryNote">
        <link:definition>114 - Disclosure - PROMISSORY NOTE</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>115 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/StockbasedCompensation" id="StockbasedCompensation">
        <link:definition>116 - Disclosure - STOCK-BASED COMPENSATION</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/SubsequentEvent" id="SubsequentEvent">
        <link:definition>117 - Disclosure - SUBSEQUENT EVENT</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
        <link:definition>118 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/NetLossIncomePerShareTables" id="NetLossIncomePerShareTables">
        <link:definition>119 - Disclosure - NET (LOSS) INCOME PER SHARE (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsTables" id="WarrantLiabilityAndFairValueMeasurementsTables">
        <link:definition>120 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <link:definition>121 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/LiquidityAndFinancialConditionAdditionalInformationDetail" id="LiquidityAndFinancialConditionAdditionalInformationDetail">
        <link:definition>122 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/NetLossIncomePerShareComputationOfIncomeLossPerShareDetail" id="NetLossIncomePerShareComputationOfIncomeLossPerShareDetail">
        <link:definition>123 - Disclosure - NET (LOSS) INCOME PER SHARE - Computation of income (loss) per share (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/NetLossIncomePerSharePotentiallyDilutiveSecuritiesDetail" id="NetLossIncomePerSharePotentiallyDilutiveSecuritiesDetail">
        <link:definition>124 - Disclosure - NET (LOSS) INCOME PER SHARE - Potentially Dilutive Securities (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/NetLossIncomePerShareAdditionalInformationDetail" id="NetLossIncomePerShareAdditionalInformationDetail">
        <link:definition>125 - Disclosure - NET (LOSS) INCOME PER SHARE - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/ResearchAgreementObligationsAdditionalInformationDetail" id="ResearchAgreementObligationsAdditionalInformationDetail">
        <link:definition>126 - Disclosure - RESEARCH AGREEMENT OBLIGATIONS - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionValuationMethodologyDetail" id="WarrantLiabilityAndFairValueMeasurementsConversionOptionValuationMethodologyDetail">
        <link:definition>127 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Valuation Methodology (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="WarrantLiabilityAndFairValueMeasurementsConversionOptionFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>128 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueDetail" id="WarrantLiabilityAndFairValueMeasurementsConversionOptionScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueDetail">
        <link:definition>129 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/PromissoryNoteAdditionalInformationDetail" id="PromissoryNoteAdditionalInformationDetail">
        <link:definition>130 - Disclosure - PROMISSORY NOTE - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/StockholdersEquitySummaryOfNumberOfPricereducedAndPriceretainedWarrantsDetail" id="StockholdersEquitySummaryOfNumberOfPricereducedAndPriceretainedWarrantsDetail">
        <link:definition>131 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Summary of number of price-reduced and price-retained warrants (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/StockholdersEquityConversionOptionValuationMethodologyDetail" id="StockholdersEquityConversionOptionValuationMethodologyDetail">
        <link:definition>132 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Conversion Option - Valuation Methodology (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/StockholdersEquityAdditionalInformationDetail" id="StockholdersEquityAdditionalInformationDetail">
        <link:definition>133 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/StockbasedCompensationAdditionalInformationDetail" id="StockbasedCompensationAdditionalInformationDetail">
        <link:definition>134 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/SubsequentEventAdditionalInformationDetail" id="SubsequentEventAdditionalInformationDetail">
        <link:definition>135 - Disclosure - SUBSEQUENT EVENT - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:linkbaseRef xlink:type="simple" xlink:href="tpiv-20170630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="tpiv-20170630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="tpiv-20170630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="tpiv-20170630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>

  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />

  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />

  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />

  <import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />

  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />

  <import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />

  <element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_DocumentAndEntityInformationAbstract" />

  <element name="StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement" />

  <element name="ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation" />

  <element name="SharePurchaseWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_SharePurchaseWarrantsMember" />

  <element name="CommonStockCapitalSharesReservedForFutureIssuanceTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable" />

  <element name="ConsultingAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_ConsultingAgreementsMember" />

  <element name="LiquidityAndFinancialConditionTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_LiquidityAndFinancialConditionTextBlock" />

  <element name="DerivativesAndFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_DerivativesAndFairValueAbstract" />

  <element name="ValuationMethodology" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_ValuationMethodology" />

  <element name="FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" />

  <element name="MeasuredAtFairValue" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_MeasuredAtFairValue" />

  <element name="PromissoryNotesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_PromissoryNotesAbstract" />

  <element name="PromissoryNoteTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_PromissoryNoteTextBlock" />

  <element name="StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement" />

  <element name="ExerciseOfWarrantsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="tpiv_ExerciseOfWarrantsAmount" />

  <element name="ExerciseOfWarrantsShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_ExerciseOfWarrantsShare" />

  <element name="AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants" />

  <element name="ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement" />

  <element name="ClassOfWarrantOrRightExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_ClassOfWarrantOrRightExpirationPeriod" />

  <element name="EquityUnitIssuedPricePerUnit" type="us-types:perUnitItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_EquityUnitIssuedPricePerUnit" />

  <element name="CommonStockWarrantsEquityTreatment" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_CommonStockWarrantsEquityTreatment" />

  <element name="CommonStockWarrantsLiabilityTreatment" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_CommonStockWarrantsLiabilityTreatment" />

  <element name="NotestofinancialstatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_NotestofinancialstatementsAbstract" />

  <element name="NetLossPerShareTableTextBlockTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_NetLossPerShareTableTextBlockTableTextBlock" />

  <element name="ClassOfWarrantOrRightExerciseAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="tpiv_ClassOfWarrantOrRightExerciseAxis" />

  <element name="SeriesEWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_SeriesEWarrantMember" />

  <element name="SubsequentWarrantIssuanceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_SubsequentWarrantIssuanceMember" />

  <element name="PromissoryNotesDueInTwoThousandTwelveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_PromissoryNotesDueInTwoThousandTwelveMember" />

  <element name="NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement" />

  <element name="PresidentAndChiefOperatingOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_PresidentAndChiefOperatingOfficerMember" />

  <element name="CrucellHollandBvMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_CrucellHollandBvMember" />

  <element name="ChiefFinancialOfficerTreasurerAndSecretaryMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_ChiefFinancialOfficerTreasurerAndSecretaryMember" />

  <element name="ChiefExecutiveOfficerAndPresidentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_ChiefExecutiveOfficerAndPresidentMember" />

  <element name="BonusOnBaseSalariespercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_BonusOnBaseSalariespercentage" />

  <element name="BonusPayableDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_BonusPayableDescription" />

  <element name="ClassOfWarrantOrRightWarrantPrice" type="us-types:perUnitItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tpiv_ClassOfWarrantOrRightWarrantPrice" />

  <element name="LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities" />

  <element name="ValuationMethodologyTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_ValuationMethodologyTableTextBlock" />

  <element name="ClassOfWarrantOrRightExerciseDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_ClassOfWarrantOrRightExerciseDomain" />

  <element name="ClassOfWarrantOrRighttrancheOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_ClassOfWarrantOrRighttrancheOneMember" />

  <element name="SeriesCWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_SeriesCWarrantMember" />

  <element name="SeriesDWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_SeriesDWarrantMember" />

  <element name="SeriesFWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_SeriesFWarrantMember" />

  <element name="CommonStockCapitalSharesReservedForFutureIssuanceLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" />

  <element name="ClassOfWarrantOrRighttrancheTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_ClassOfWarrantOrRighttrancheTwoMember" />

  <element name="NumberOfUnitsSold" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_NumberOfUnitsSold" />

  <element name="PrereducedPriceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_PrereducedPriceMember" />

  <element name="PostreducedPriceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_PostreducedPriceMember" />
</schema>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>tpiv-20170630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 04-Aug-2017 [07:27:56] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#NetLossIncomePerShareComputationOfIncomeLossPerShareDetail" roleURI="http://www.tapimmune.com/role/NetLossIncomePerShareComputationOfIncomeLossPerShareDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#NetLossIncomePerSharePotentiallyDilutiveSecuritiesDetail" roleURI="http://www.tapimmune.com/role/NetLossIncomePerSharePotentiallyDilutiveSecuritiesDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#NetLossIncomePerShare" roleURI="http://www.tapimmune.com/role/NetLossIncomePerShare" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#StockholdersEquity" roleURI="http://www.tapimmune.com/role/StockholdersEquity" />

  <calculationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_NotesPayableCurrent" use="optional" order="40" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt" use="optional" order="30" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="50" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="70" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xlink:label="loc_tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_RevenueFromGrants" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OtherIncome" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="20" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/NetLossIncomePerShareComputationOfIncomeLossPerShareDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaap_DilutiveSecurities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:to="loc_us-gaap_DilutiveSecurities" use="optional" order="20" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/NetLossIncomePerShareComputationOfIncomeLossPerShareDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/NetLossIncomePerSharePotentiallyDilutiveSecuritiesDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityShares" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityShares" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityShares" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CommonStockWarrantsEquityTreatment" xlink:label="loc_tpiv_CommonStockWarrantsEquityTreatment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="loc_tpiv_CommonStockWarrantsEquityTreatment" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CommonStockWarrantsLiabilityTreatment" xlink:label="loc_tpiv_CommonStockWarrantsLiabilityTreatment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="loc_tpiv_CommonStockWarrantsLiabilityTreatment" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Cash" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="20" weight="1" />
  </calculationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>tpiv-20170630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 04-Aug-2017 [07:27:56] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#DocumentAndEntityInformation" roleURI="http://www.tapimmune.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#CondensedConsolidatedStatementOfStockholdersEquity" roleURI="http://www.tapimmune.com/role/CondensedConsolidatedStatementOfStockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#LiquidityAndFinancialConditionAdditionalInformationDetail" roleURI="http://www.tapimmune.com/role/LiquidityAndFinancialConditionAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#WarrantLiabilityAndFairValueMeasurementsConversionOptionValuationMethodologyDetail" roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionValuationMethodologyDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#WarrantLiabilityAndFairValueMeasurementsConversionOptionFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#WarrantLiabilityAndFairValueMeasurementsConversionOptionScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueDetail" roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#PromissoryNoteAdditionalInformationDetail" roleURI="http://www.tapimmune.com/role/PromissoryNoteAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.tapimmune.com/role/StockholdersEquityAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#SubsequentEventAdditionalInformationDetail" roleURI="http://www.tapimmune.com/role/SubsequentEventAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#NetLossIncomePerShareComputationOfIncomeLossPerShareDetail" roleURI="http://www.tapimmune.com/role/NetLossIncomePerShareComputationOfIncomeLossPerShareDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#NetLossIncomePerSharePotentiallyDilutiveSecuritiesDetail" roleURI="http://www.tapimmune.com/role/NetLossIncomePerSharePotentiallyDilutiveSecuritiesDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#NetLossIncomePerShareAdditionalInformationDetail" roleURI="http://www.tapimmune.com/role/NetLossIncomePerShareAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#ResearchAgreementObligationsAdditionalInformationDetail" roleURI="http://www.tapimmune.com/role/ResearchAgreementObligationsAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#StockbasedCompensationAdditionalInformationDetail" roleURI="http://www.tapimmune.com/role/StockbasedCompensationAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#StockholdersEquitySummaryOfNumberOfPricereducedAndPriceretainedWarrantsDetail" roleURI="http://www.tapimmune.com/role/StockholdersEquitySummaryOfNumberOfPricereducedAndPriceretainedWarrantsDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#StockholdersEquityConversionOptionValuationMethodologyDetail" roleURI="http://www.tapimmune.com/role/StockholdersEquityConversionOptionValuationMethodologyDetail" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1142" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1142" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1143" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1142" xlink:to="loc_us-gaap_ClassOfStockDomain_1143" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1143_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1142" xlink:to="loc_us-gaap_ClassOfStockDomain_1143_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentType_5" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentFlag_6" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_7" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_8" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_10" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityRegistrantName_10" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_11" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_12" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_12" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_13" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFilerCategory_13" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1101" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_TradingSymbol_1101" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1102" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1102" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_16" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_StatementTable_16" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_17" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_16" xlink:to="loc_us-gaap_StatementClassOfStockAxis_17" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_18" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_17" xlink:to="loc_us-gaap_ClassOfStockDomain_18" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_18_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_17" xlink:to="loc_us-gaap_ClassOfStockDomain_18_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_19" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_18" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_19" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_20" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_18" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_20" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_22" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_AssetsAbstract_22" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_23" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_AssetsCurrentAbstract_23" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_24" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_Cash_24" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_25" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_25" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1050" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_AssetsCurrent_1050" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_26" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_Assets_26" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_28" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_28" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_29" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_29" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_30" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_30" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_31" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_31" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_32" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_NotesPayableCurrent_32" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_34" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_LiabilitiesCurrent_34" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_1051" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_Liabilities_1051" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_355" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_CommitmentsAndContingencies_355" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_35" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27" xlink:to="loc_us-gaap_StockholdersEquityAbstract_35" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_36" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_PreferredStockValue_36" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_37" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_CommonStockValue_37" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_38" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_AdditionalPaidInCapital_38" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_39" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_39" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_40" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_StockholdersEquity_40" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_41" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_41" use="optional" order="28" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_44" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_StatementTable_44" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_45" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_44" xlink:to="loc_us-gaap_StatementClassOfStockAxis_45" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_46" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_45" xlink:to="loc_us-gaap_ClassOfStockDomain_46" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_46_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_45" xlink:to="loc_us-gaap_ClassOfStockDomain_46_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_47" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_46" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_47" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_48" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_46" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_48" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_50" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_50" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_51" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_51" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_52" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_PreferredStockSharesIssued_52" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_53" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_53" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_54" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_54" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_55" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_55" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_56" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_CommonStockSharesIssued_56" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_57" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_57" use="optional" order="14" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_651" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_60" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_651" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_60" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_60" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_62" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_60" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_62" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1053" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_60" xlink:to="loc_us-gaap_OperatingExpenses_1053" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_63" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_60" xlink:to="loc_us-gaap_OperatingIncomeLoss_63" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_651" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_65" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_65" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_364" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_364" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_67" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" xlink:to="loc_us-gaap_RevenueFromGrants_67" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_1103" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_1103" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_69" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" xlink:to="loc_us-gaap_OtherIncome_69" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_70" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" xlink:to="loc_us-gaap_NetIncomeLoss_70" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_71" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_651" xlink:to="loc_us-gaap_EarningsPerShareBasic_71" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_72" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_651" xlink:to="loc_us-gaap_EarningsPerShareDiluted_72" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_73" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_651" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_73" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_651" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_648" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_651" xlink:to="loc_us-gaap_StatementTable_648" use="optional" order="17" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_649" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_648" xlink:to="loc_us-gaap_StatementClassOfStockAxis_649" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_650" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_649" xlink:to="loc_us-gaap_ClassOfStockDomain_650" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_650_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_649" xlink:to="loc_us-gaap_ClassOfStockDomain_650_default" use="optional" order="20" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/CondensedConsolidatedStatementOfStockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_83" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_77" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_StatementTable_77" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_78" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_77" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_78" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_79" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_78" xlink:to="loc_us-gaap_EquityComponentDomain_79" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_79_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_78" xlink:to="loc_us-gaap_EquityComponentDomain_79_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_80" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79" xlink:to="loc_us-gaap_CommonStockMember_80" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_81" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_81" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_82" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79" xlink:to="loc_us-gaap_RetainedEarningsMember_82" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_84" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_StockholdersEquity_84" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_85" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_SharesIssued_85" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement" xlink:label="loc_tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement_388" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement_388" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement" xlink:label="loc_tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement_387" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement_387" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_389" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_389" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ExerciseOfWarrantsAmount" xlink:label="loc_tpiv_ExerciseOfWarrantsAmount_399" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_tpiv_ExerciseOfWarrantsAmount_399" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ExerciseOfWarrantsShare" xlink:label="loc_tpiv_ExerciseOfWarrantsShare_400" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_tpiv_ExerciseOfWarrantsShare_400" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants" xlink:label="loc_tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants_1121" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants_1121" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_402" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_402" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_88" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_88" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_89" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_89" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_90" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_NetIncomeLoss_90" use="optional" order="19" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_656" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_653" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_656" xlink:to="loc_us-gaap_StatementTable_653" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_654" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_653" xlink:to="loc_us-gaap_StatementClassOfStockAxis_654" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_655" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_654" xlink:to="loc_us-gaap_ClassOfStockDomain_655" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_655_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_654" xlink:to="loc_us-gaap_ClassOfStockDomain_655_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_95" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_656" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_95" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_96" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_95" xlink:to="loc_us-gaap_NetIncomeLoss_96" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_95" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_98" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_98" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_1108" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_1108" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_100" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" xlink:to="loc_us-gaap_ShareBasedCompensation_100" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_403" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_403" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_101" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_95" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_101" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_102" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_101" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_102" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_103" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_101" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_103" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_104" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_95" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_104" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_105" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_656" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_105" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_107" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_105" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_107" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xlink:label="loc_tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement_1110" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_105" xlink:to="loc_tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement_1110" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_108" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_105" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_108" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_110" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_105" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_110" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_111" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_656" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_111" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_112" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_656" xlink:to="loc_us-gaap_Cash_112" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_114" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_656" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_114" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_418" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_114" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_418" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation" xlink:label="loc_tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation_115" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_418" xlink:to="loc_tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation_115" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement" xlink:label="loc_tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement_1112" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_418" xlink:to="loc_tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement_1112" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_419" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_418" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_419" use="optional" order="27" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/LiquidityAndFinancialConditionAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_455" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_122" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_455" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_122" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_441" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_455" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_441" use="optional" order="2" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_449" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_441" xlink:to="loc_us-gaap_StatementClassOfStockAxis_449" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_450" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_449" xlink:to="loc_us-gaap_ClassOfStockDomain_450" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_450_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_449" xlink:to="loc_us-gaap_ClassOfStockDomain_450_default" use="optional" order="5" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionValuationMethodologyDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_150" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_150" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_151" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_150" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_151" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_152" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_151" xlink:to="loc_us-gaap_EquityComponentDomain_152" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_152_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_151" xlink:to="loc_us-gaap_EquityComponentDomain_152_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SharePurchaseWarrantsMember" xlink:label="loc_tpiv_SharePurchaseWarrantsMember_153" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_152" xlink:to="loc_tpiv_SharePurchaseWarrantsMember_153" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_154" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_150" xlink:to="loc_us-gaap_RangeAxis_154" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1065" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_154" xlink:to="loc_us-gaap_RangeMember_1065" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1065_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_154" xlink:to="loc_us-gaap_RangeMember_1065_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1066" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1065" xlink:to="loc_us-gaap_MaximumMember_1066" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1067" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1065" xlink:to="loc_us-gaap_MinimumMember_1067" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_155" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" xlink:to="loc_us-gaap_SharePrice_155" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_570" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_570" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_157" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_157" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_158" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_158" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_159" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_159" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_160" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_160" use="optional" order="16" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_170" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_163" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_170" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_163" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_164" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_163" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_164" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_165" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_164" xlink:to="loc_us-gaap_HedgingRelationshipDomain_165" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_165_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_164" xlink:to="loc_us-gaap_HedgingRelationshipDomain_165_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="loc_us-gaap_FairValueHedgingMember_166" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_165" xlink:to="loc_us-gaap_FairValueHedgingMember_166" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_167" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_163" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_167" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_168" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_167" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_168" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_168_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_167" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_168_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_951" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_168" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_951" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_952" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_168" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_952" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_169" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_168" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_169" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_171" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_170" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_171" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_541" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_538" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_541" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_538" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_539" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_538" xlink:to="loc_us-gaap_StatementClassOfStockAxis_539" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_540" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_539" xlink:to="loc_us-gaap_ClassOfStockDomain_540" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_540_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_539" xlink:to="loc_us-gaap_ClassOfStockDomain_540_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_542" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_541" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_542" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_545" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_541" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_545" use="optional" order="6" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/PromissoryNoteAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_184" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_180" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_184" xlink:to="loc_us-gaap_DebtInstrumentTable_180" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_181" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_180" xlink:to="loc_us-gaap_DebtInstrumentAxis_181" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_182" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_181" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_182" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_182_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_181" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_182_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PromissoryNotesDueInTwoThousandTwelveMember" xlink:label="loc_tpiv_PromissoryNotesDueInTwoThousandTwelveMember_979" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_182" xlink:to="loc_tpiv_PromissoryNotesDueInTwoThousandTwelveMember_979" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_185" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_184" xlink:to="loc_us-gaap_NotesPayableCurrent_185" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_186" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_184" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_186" use="optional" order="7" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/StockholdersEquityAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:label="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:label="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_199" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_TitleOfIndividualAxis_199" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_200" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_199" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_200" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_200_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_199" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_200_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_201" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_200" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_201" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PresidentAndChiefOperatingOfficerMember" xlink:label="loc_tpiv_PresidentAndChiefOperatingOfficerMember_1068" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_200" xlink:to="loc_tpiv_PresidentAndChiefOperatingOfficerMember_1068" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_202" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_TypeOfArrangementAxis_202" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_202" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_202" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ConsultingAgreementsMember" xlink:label="loc_tpiv_ConsultingAgreementsMember_204" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_tpiv_ConsultingAgreementsMember_204" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_205" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_205" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_391" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_205" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_391" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_391_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_205" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_391_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_392" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_391" xlink:to="loc_us-gaap_PrivatePlacementMember_392" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_430" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_430" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_430_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_430_default" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_429" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_429" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_621" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_429" xlink:to="loc_us-gaap_EquityComponentDomain_621" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_621_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_429" xlink:to="loc_us-gaap_EquityComponentDomain_621_default" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1136" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_621" xlink:to="loc_us-gaap_CommonStockMember_1136" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1193" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_621" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1193" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_620" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_620" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_629" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_620" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_629" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_629_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_620" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_629_default" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_628" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_StatementClassOfStockAxis_628" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_810" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_628" xlink:to="loc_us-gaap_ClassOfStockDomain_810" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_810_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_628" xlink:to="loc_us-gaap_ClassOfStockDomain_810_default" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_809" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_809" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_835" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_809" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_835" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_835_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_809" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_835_default" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SeriesEWarrantMember" xlink:label="loc_tpiv_SeriesEWarrantMember_847" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_835" xlink:to="loc_tpiv_SeriesEWarrantMember_847" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SubsequentWarrantIssuanceMember" xlink:label="loc_tpiv_SubsequentWarrantIssuanceMember_850" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_835" xlink:to="loc_tpiv_SubsequentWarrantIssuanceMember_850" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightExerciseAxis" xlink:label="loc_tpiv_ClassOfWarrantOrRightExerciseAxis_834" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_tpiv_ClassOfWarrantOrRightExerciseAxis_834" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightExerciseDomain" xlink:label="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1185" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseAxis_834" xlink:to="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1185" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightExerciseDomain" xlink:label="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1185_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseAxis_834" xlink:to="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1185_default" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRighttrancheOneMember" xlink:label="loc_tpiv_ClassOfWarrantOrRighttrancheOneMember_1186" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1185" xlink:to="loc_tpiv_ClassOfWarrantOrRighttrancheOneMember_1186" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRighttrancheTwoMember" xlink:label="loc_tpiv_ClassOfWarrantOrRighttrancheTwoMember_1187" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1185" xlink:to="loc_tpiv_ClassOfWarrantOrRighttrancheTwoMember_1187" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_207" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_207" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_210" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_210" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_394" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_394" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightExpirationPeriod" xlink:label="loc_tpiv_ClassOfWarrantOrRightExpirationPeriod_411" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_tpiv_ClassOfWarrantOrRightExpirationPeriod_411" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_415" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_LegalFees_415" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_416" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_416" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_EquityUnitIssuedPricePerUnit" xlink:label="loc_tpiv_EquityUnitIssuedPricePerUnit_425" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_tpiv_EquityUnitIssuedPricePerUnit_425" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_990" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_990" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_1069" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_1069" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_1070" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_1070" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1071" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_SharePrice_1071" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1130" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1130" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1137" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1137" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightWarrantPrice" xlink:label="loc_tpiv_ClassOfWarrantOrRightWarrantPrice_1140" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_tpiv_ClassOfWarrantOrRightWarrantPrice_1140" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1141" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1141" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities" xlink:label="loc_tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities_1144" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities_1144" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_1145" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_1145" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1189" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1189" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_NumberOfUnitsSold" xlink:label="loc_tpiv_NumberOfUnitsSold_1190" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_tpiv_NumberOfUnitsSold_1190" use="optional" order="57" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/SubsequentEventAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1132" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_216" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1132" xlink:to="loc_us-gaap_SubsequentEventTable_216" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_217" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_216" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_217" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_218" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_217" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_218" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_218_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_217" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_218_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_219" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_218" xlink:to="loc_us-gaap_SubsequentEventMember_219" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_220" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_216" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_220" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_221" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_220" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_221" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_221_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_220" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_221_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_223" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_216" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_223" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_224" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_223" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_224" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_224_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_223" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_224_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_226" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_216" xlink:to="loc_us-gaap_StatementScenarioAxis_226" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_227" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_226" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_227" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_227_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_226" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_227_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_231" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_216" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_231" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_232" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_231" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_232" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_232_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_231" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_232_default" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_236" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_216" xlink:to="loc_us-gaap_TitleOfIndividualAxis_236" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1126" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_236" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1126" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1126_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_236" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1126_default" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ChiefFinancialOfficerTreasurerAndSecretaryMember" xlink:label="loc_tpiv_ChiefFinancialOfficerTreasurerAndSecretaryMember_1127" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1126" xlink:to="loc_tpiv_ChiefFinancialOfficerTreasurerAndSecretaryMember_1127" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ChiefExecutiveOfficerAndPresidentMember" xlink:label="loc_tpiv_ChiefExecutiveOfficerAndPresidentMember_1128" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1126" xlink:to="loc_tpiv_ChiefExecutiveOfficerAndPresidentMember_1128" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1125" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_216" xlink:to="loc_us-gaap_RangeAxis_1125" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1133" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_1125" xlink:to="loc_us-gaap_RangeMember_1133" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1133_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_1125" xlink:to="loc_us-gaap_RangeMember_1133_default" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1134" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1133" xlink:to="loc_us-gaap_MaximumMember_1134" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_BonusOnBaseSalariespercentage" xlink:label="loc_tpiv_BonusOnBaseSalariespercentage_1129" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1132" xlink:to="loc_tpiv_BonusOnBaseSalariespercentage_1129" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_1131" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1132" xlink:to="loc_us-gaap_OfficersCompensation_1131" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_BonusPayableDescription" xlink:label="loc_tpiv_BonusPayableDescription_1135" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1132" xlink:to="loc_tpiv_BonusPayableDescription_1135" use="optional" order="29" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/NetLossIncomePerShareComputationOfIncomeLossPerShareDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_503" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_500" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_StatementTable_500" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_501" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_500" xlink:to="loc_us-gaap_StatementClassOfStockAxis_501" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_502" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_501" xlink:to="loc_us-gaap_ClassOfStockDomain_502" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_502_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_501" xlink:to="loc_us-gaap_ClassOfStockDomain_502_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1106" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1106" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_504" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1106" xlink:to="loc_us-gaap_NetIncomeLoss_504" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaap_DilutiveSecurities_586" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1106" xlink:to="loc_us-gaap_DilutiveSecurities_586" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_587" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1106" xlink:to="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_587" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1107" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1107" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_505" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1107" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_505" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_506" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1107" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_506" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_507" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1107" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_507" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_508" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1107" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_508" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_509" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_509" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_510" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_509" xlink:to="loc_us-gaap_EarningsPerShareBasic_510" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_511" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_509" xlink:to="loc_us-gaap_EarningsPerShareDiluted_511" use="optional" order="16" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/NetLossIncomePerSharePotentiallyDilutiveSecuritiesDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_518" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_515" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_518" xlink:to="loc_us-gaap_StatementTable_515" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_516" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_515" xlink:to="loc_us-gaap_StatementClassOfStockAxis_516" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_517" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_516" xlink:to="loc_us-gaap_ClassOfStockDomain_517" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_517_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_516" xlink:to="loc_us-gaap_ClassOfStockDomain_517_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityShares" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityShares_525" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_518" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityShares_525" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CommonStockWarrantsEquityTreatment" xlink:label="loc_tpiv_CommonStockWarrantsEquityTreatment_527" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_518" xlink:to="loc_tpiv_CommonStockWarrantsEquityTreatment_527" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CommonStockWarrantsLiabilityTreatment" xlink:label="loc_tpiv_CommonStockWarrantsLiabilityTreatment_528" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_518" xlink:to="loc_tpiv_CommonStockWarrantsLiabilityTreatment_528" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_530" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_518" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_530" use="optional" order="8" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/NetLossIncomePerShareAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_536" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_533" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_536" xlink:to="loc_us-gaap_StatementTable_533" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_534" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_533" xlink:to="loc_us-gaap_StatementClassOfStockAxis_534" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_535" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_534" xlink:to="loc_us-gaap_ClassOfStockDomain_535" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_535_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_534" xlink:to="loc_us-gaap_ClassOfStockDomain_535_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_537" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_536" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_537" use="optional" order="5" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/ResearchAgreementObligationsAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1113" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_778" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1113" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_778" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_779" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_778" xlink:to="loc_us-gaap_StatementClassOfStockAxis_779" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_780" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_779" xlink:to="loc_us-gaap_ClassOfStockDomain_780" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_780_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_779" xlink:to="loc_us-gaap_ClassOfStockDomain_780_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_781" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_778" xlink:to="loc_dei_LegalEntityAxis_781" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1114" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_781" xlink:to="loc_dei_EntityDomain_1114" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1114_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_781" xlink:to="loc_dei_EntityDomain_1114_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CrucellHollandBvMember" xlink:label="loc_tpiv_CrucellHollandBvMember_1115" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1114" xlink:to="loc_tpiv_CrucellHollandBvMember_1115" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_782" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1113" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_782" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1116" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1113" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1116" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_1117" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1113" xlink:to="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_1117" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/StockbasedCompensationAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1009" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_871" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1009" xlink:to="loc_us-gaap_StatementTable_871" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_872" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_871" xlink:to="loc_us-gaap_StatementClassOfStockAxis_872" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_873" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_872" xlink:to="loc_us-gaap_ClassOfStockDomain_873" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_873_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_872" xlink:to="loc_us-gaap_ClassOfStockDomain_873_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_874" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_871" xlink:to="loc_us-gaap_AwardTypeAxis_874" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_884" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_874" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_884" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_884_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_874" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_884_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_883" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_871" xlink:to="loc_us-gaap_PlanNameAxis_883" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1010" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_883" xlink:to="loc_us-gaap_PlanNameDomain_1010" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1010_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_883" xlink:to="loc_us-gaap_PlanNameDomain_1010_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_876" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1009" xlink:to="loc_us-gaap_ShareBasedCompensation_876" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1081" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1009" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1081" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1082" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1009" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1082" use="optional" order="13" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/StockholdersEquitySummaryOfNumberOfPricereducedAndPriceretainedWarrantsDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_1158" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1152" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1158" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1152" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1153" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1152" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1153" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1155" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1153" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1155" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1155_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1153" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1155_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SeriesCWarrantMember" xlink:label="loc_tpiv_SeriesCWarrantMember_1162" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1155" xlink:to="loc_tpiv_SeriesCWarrantMember_1162" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SeriesDWarrantMember" xlink:label="loc_tpiv_SeriesDWarrantMember_1163" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1155" xlink:to="loc_tpiv_SeriesDWarrantMember_1163" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SeriesFWarrantMember" xlink:label="loc_tpiv_SeriesFWarrantMember_1165" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1155" xlink:to="loc_tpiv_SeriesFWarrantMember_1165" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightExerciseAxis" xlink:label="loc_tpiv_ClassOfWarrantOrRightExerciseAxis_1154" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1152" xlink:to="loc_tpiv_ClassOfWarrantOrRightExerciseAxis_1154" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightExerciseDomain" xlink:label="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1159" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseAxis_1154" xlink:to="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1159" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightExerciseDomain" xlink:label="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1159_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseAxis_1154" xlink:to="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1159_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRighttrancheOneMember" xlink:label="loc_tpiv_ClassOfWarrantOrRighttrancheOneMember_1160" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1159" xlink:to="loc_tpiv_ClassOfWarrantOrRighttrancheOneMember_1160" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PrereducedPriceMember" xlink:label="loc_tpiv_PrereducedPriceMember_1194" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1159" xlink:to="loc_tpiv_PrereducedPriceMember_1194" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PostreducedPriceMember" xlink:label="loc_tpiv_PostreducedPriceMember_1195" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1159" xlink:to="loc_tpiv_PostreducedPriceMember_1195" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1166" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1158" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1166" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1167" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1158" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1167" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/StockholdersEquityConversionOptionValuationMethodologyDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1180" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1170" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1180" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1170" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1171" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1170" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1171" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1178" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1171" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1178" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1178_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1171" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1178_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SharePurchaseWarrantsMember" xlink:label="loc_tpiv_SharePurchaseWarrantsMember_1179" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1178" xlink:to="loc_tpiv_SharePurchaseWarrantsMember_1179" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_1177" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1170" xlink:to="loc_us-gaap_StatementScenarioAxis_1177" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_1181" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_1177" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_1181" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_1181_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_1177" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_1181_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_1182" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_1181" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_1182" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_1183" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_1181" xlink:to="loc_us-gaap_RestatementAdjustmentMember_1183" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_1172" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1180" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_1172" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_1173" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1180" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_1173" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_1174" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1180" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_1174" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1175" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1180" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1175" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_1176" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1180" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_1176" use="optional" order="15" />
  </definitionLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>tpiv-20170630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 04-Aug-2017 [07:27:56] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />

  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_DocumentAndEntityInformationAbstract" xlink:label="loc_tpiv_DocumentAndEntityInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_DocumentAndEntityInformationAbstract" xlink:to="lab_tpiv_DocumentAndEntityInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash at beginning of period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash at end of period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses and deposits</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#39; EQUITY</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Total accounts payable and accrued liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Research agreement obligations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other current liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative Liability, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Warrant liability</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative liability - warrants</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes Payable, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesPayableCurrent" xml:lang="en-US">Promissory note</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayableCurrent" xml:lang="en-US">Outstanding promissory notes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders&#39; equity:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value, 41,666,667 shares authorized, 10,158,993 and 8,421,185 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders&#39; equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning Balance, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders&#39; equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Ending Balance, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders&#39; equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders&#39; equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock par value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock shares authorized/designated</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock shares par value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock par value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock shares authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock shares issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock shares outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xml:lang="en-US">Costs and Expenses [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xml:lang="en-US">Operating expenses:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense):</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Change in fair value of warrant liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Debt extinguishment gain</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Debt extinguishment gain</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromGrants" xml:lang="en-US">Revenue from Grants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromGrants" xml:lang="en-US">Grant income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromGrants" xlink:to="lab_us-gaap_RevenueFromGrants" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xml:lang="en-US">Shares issued in debt settlement agreements</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xml:lang="en-US">Shares issued in debt settlement agreements</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="lab_us-gaap_GainsLossesOnRestructuringOfDebt" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncome" xml:lang="en-US">Other Income</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIncome" xml:lang="en-US">Other income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic net (loss) income per share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic net loss per share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted net (loss) income per share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted net loss per share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of common shares outstanding, basic</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of common shares outstanding, Basic</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average common shares outstanding - basic</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders&#39; Equity [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid In Capital [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Beginning Balance, Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Ending Balance, Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement" xlink:label="loc_tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement" xml:lang="en-US">Stock And Warrants Issued During Period, Value, Under Private Placement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement" xml:lang="en-US">Common stock and warrants issued in private placement, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement" xml:lang="en-US">Represent value of new stock and warrants issued in private placement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement" xlink:to="lab_tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (loss) income</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (loss) income</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (loss) income</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Reconciliation of net (loss) income to net cash used in operating activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xml:lang="en-US">Changes in fair value of warrant liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses and deposits</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operating activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash Flows from Operating Activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xml:lang="en-US">Proceeds from (Repayments of) Notes Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xml:lang="en-US">Repayment of promissory note</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash Flows from Financing Activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Cash, Period Increase (Decrease)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation" xlink:label="loc_tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation" xml:lang="en-US">Reclassification Of Accrued Liability Upon Issuance Of Common Shares Relating To Compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation" xml:lang="en-US">Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilson&#8217;s compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation" xml:lang="en-US">Reclassification of accrued liability upon issuance of common shares relating to compensation.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation" xlink:to="lab_tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xml:lang="en-US">Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SharePurchaseWarrantsMember" xlink:label="loc_tpiv_SharePurchaseWarrantsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_SharePurchaseWarrantsMember" xml:lang="en-US">Share Purchase Warrants [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tpiv_SharePurchaseWarrantsMember" xml:lang="en-US">Share Purchase Warrants [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_SharePurchaseWarrantsMember" xml:lang="en-US">Share Purchase Warrants [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_SharePurchaseWarrantsMember" xlink:to="lab_tpiv_SharePurchaseWarrantsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis" xlink:to="lab_us-gaap_RangeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Stock price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExercisePrice" xml:lang="en-US">Fair Value Assumptions, Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExercisePrice" xml:lang="en-US">Exercise price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExercisePrice" xml:lang="en-US">Exercise price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_FairValueAssumptionsExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Contractual term (years)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Contractual term (years)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility (annual)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility (annual)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNetAbstract" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNetAbstract" xml:lang="en-US">Derivative, Fair Value, Net [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeNetAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xml:lang="en-US">Hedging Relationship [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xml:lang="en-US">Hedging Relationship [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xml:lang="en-US">Hedging Relationship [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xml:lang="en-US">Hedging Relationship [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="loc_us-gaap_FairValueHedgingMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueHedgingMember" xml:lang="en-US">Fair Value Hedging [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueHedgingMember" xml:lang="en-US">Fair Value [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Quoted prices in active markets (Level 1)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xml:lang="en-US">Derivatives, Fair Value [Line Items]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xml:lang="en-US">Derivatives, Fair Value [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xml:lang="en-US">Derivative liability - warrants</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaap_NotesPayableAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableAbstract" xml:lang="en-US">Notes Payable [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableAbstract" xlink:to="lab_us-gaap_NotesPayableAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Annual interest rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:label="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance [Table]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance [Table]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:to="lab_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Chief Executive Officer [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Chief Executive Officer, President and Chairman [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Chief Executive Officer, President and Chairman [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChiefExecutiveOfficerMember" xlink:to="lab_us-gaap_ChiefExecutiveOfficerMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ConsultingAgreementsMember" xlink:label="loc_tpiv_ConsultingAgreementsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_ConsultingAgreementsMember" xml:lang="en-US">Consulting Agreements [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tpiv_ConsultingAgreementsMember" xml:lang="en-US">Consulting Agreements [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_ConsultingAgreementsMember" xml:lang="en-US">Consulting Agreements [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_ConsultingAgreementsMember" xlink:to="lab_tpiv_ConsultingAgreementsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Fair value of common stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Common shares issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xml:lang="en-US">Equity Interest Type [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xml:lang="en-US">Equity Interest Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">NATURE OF OPERATIONS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaap_BasisOfAccounting" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccounting" xml:lang="en-US">Basis of Accounting [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccounting" xml:lang="en-US">BASIS OF PRESENTATION</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TextBlockAbstract" xml:lang="en-US">Text Block [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_LiquidityAndFinancialConditionTextBlock" xlink:label="loc_tpiv_LiquidityAndFinancialConditionTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_LiquidityAndFinancialConditionTextBlock" xml:lang="en-US">Liquidity And Financial Condition [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tpiv_LiquidityAndFinancialConditionTextBlock" xml:lang="en-US">LIQUIDITY AND FINANCIAL CONDITION</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_LiquidityAndFinancialConditionTextBlock" xml:lang="en-US">Liquidity and financial condition text block.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_LiquidityAndFinancialConditionTextBlock" xlink:to="lab_tpiv_LiquidityAndFinancialConditionTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_DerivativesAndFairValueAbstract" xlink:label="loc_tpiv_DerivativesAndFairValueAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_DerivativesAndFairValueAbstract" xml:lang="en-US">Derivatives and Fair Value [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_DerivativesAndFairValueAbstract" xlink:to="lab_tpiv_DerivativesAndFairValueAbstract" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ValuationMethodology" xlink:label="loc_tpiv_ValuationMethodology" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_ValuationMethodology" xml:lang="en-US">Valuation Methodology</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tpiv_ValuationMethodology" xml:lang="en-US">Valuation Methodology</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_ValuationMethodology" xml:lang="en-US">Valuation methodology.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_ValuationMethodology" xlink:to="lab_tpiv_ValuationMethodology" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" xlink:label="loc_tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" xml:lang="en-US">Financial Assets And Liabilities Measured At Fair Value On Recurring Basis</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" xml:lang="en-US">Financial assets and liabilities measured at fair value on recurring basis.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" xlink:to="lab_tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_MeasuredAtFairValue" xlink:label="loc_tpiv_MeasuredAtFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_MeasuredAtFairValue" xml:lang="en-US">Measured At Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tpiv_MeasuredAtFairValue" xml:lang="en-US">Schedule of Changes in Level 3 Liabilities Measured at Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_MeasuredAtFairValue" xml:lang="en-US">Measured at fair value.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_MeasuredAtFairValue" xlink:to="lab_tpiv_MeasuredAtFairValue" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PromissoryNotesAbstract" xlink:label="loc_tpiv_PromissoryNotesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_PromissoryNotesAbstract" xml:lang="en-US">Promissory Notes [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_PromissoryNotesAbstract" xlink:to="lab_tpiv_PromissoryNotesAbstract" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PromissoryNoteTextBlock" xlink:label="loc_tpiv_PromissoryNoteTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_PromissoryNoteTextBlock" xml:lang="en-US">Promissory Note [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tpiv_PromissoryNoteTextBlock" xml:lang="en-US">PROMISSORY NOTES</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_PromissoryNoteTextBlock" xml:lang="en-US">Promissory Note [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_PromissoryNoteTextBlock" xlink:to="lab_tpiv_PromissoryNoteTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">SUBSEQUENT EVENT</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average number of common shares outstanding, Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average number of common shares outstanding, diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average common shares outstanding - diluted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement" xlink:label="loc_tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement" xml:lang="en-US">Stock And Warrants Issued During Period, Share, Under Private Placement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement" xml:lang="en-US">Common stock and warrants issued in private placement, Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement" xml:lang="en-US">Represent the number of new stock and warrants issued in private placement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement" xlink:to="lab_tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">offering costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Fees and legal costs relating to private placement</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price of warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ExerciseOfWarrantsAmount" xlink:label="loc_tpiv_ExerciseOfWarrantsAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_ExerciseOfWarrantsAmount" xml:lang="en-US">Exercise Of Warrants Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tpiv_ExerciseOfWarrantsAmount" xml:lang="en-US">Exercise of warrants, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_ExerciseOfWarrantsAmount" xml:lang="en-US">Exercise of warrants amount.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_ExerciseOfWarrantsAmount" xlink:to="lab_tpiv_ExerciseOfWarrantsAmount" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ExerciseOfWarrantsShare" xlink:label="loc_tpiv_ExerciseOfWarrantsShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_ExerciseOfWarrantsShare" xml:lang="en-US">Exercise Of Warrants share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tpiv_ExerciseOfWarrantsShare" xml:lang="en-US">Exercise of warrants, Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_ExerciseOfWarrantsShare" xml:lang="en-US">Exercise of warrants share.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_ExerciseOfWarrantsShare" xlink:to="lab_tpiv_ExerciseOfWarrantsShare" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants" xlink:label="loc_tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants" xml:lang="en-US">Adjustments To Additional Paid In Capital, Legal Costs Relating to Exercise of Warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants" xml:lang="en-US">Legal costs relating to exercise of warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants" xml:lang="en-US">Amount of decrease in additional paid in capital (APIC) resulting from exercise of warrants.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants" xlink:to="lab_tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Fair value of repriced warrants as inducement</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Stock-based compensation, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xlink:label="loc_tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Common Stock and Warrants in Private Placement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xml:lang="en-US">Proceeds from issuance of common stock and warrants in private placement, net of offering costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity due to issue of common stock and warrants in a private placement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xlink:to="lab_tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from Warrant Exercises</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from exercise of stock warrants, net of offering costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightExpirationPeriod" xlink:label="loc_tpiv_ClassOfWarrantOrRightExpirationPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_ClassOfWarrantOrRightExpirationPeriod" xml:lang="en-US">Class Of Warrant Or Right Expiration Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_ClassOfWarrantOrRightExpirationPeriod" xml:lang="en-US">Class of warrant or right expiration period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_ClassOfWarrantOrRightExpirationPeriod" xlink:to="lab_tpiv_ClassOfWarrantOrRightExpirationPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of warrant or right, number of securities called by warrants or rights</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of Warrant Shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental schedule of non-cash financing activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_EquityUnitIssuedPricePerUnit" xlink:label="loc_tpiv_EquityUnitIssuedPricePerUnit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_EquityUnitIssuedPricePerUnit" xml:lang="en-US">Equity Unit Issued Price Per Unit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_EquityUnitIssuedPricePerUnit" xml:lang="en-US">Equity units issued price per unit.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_EquityUnitIssuedPricePerUnit" xlink:to="lab_tpiv_EquityUnitIssuedPricePerUnit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">STOCK-BASED COMPENSATION</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaap_DilutiveSecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DilutiveSecurities" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DilutiveSecurities" xml:lang="en-US">Less: noncash income from change in fair value of common stock warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DilutiveSecurities" xml:lang="en-US">Less: non-cash income from change in fair value of common stock warrants</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecurities" xlink:to="lab_us-gaap_DilutiveSecurities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToParentDiluted" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToParentDiluted" xml:lang="en-US">Net income (loss) - diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToParentDiluted" xml:lang="en-US">Net (loss) income - diluted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:to="lab_us-gaap_NetIncomeLossAttributableToParentDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xml:lang="en-US">Dilutive effect of warrants, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US">Dilutive effect of stock options, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Diluted [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xml:lang="en-US">Numerator:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityShares" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityShares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityShares" xml:lang="en-US">Option Indexed to Issuer&#39;s Equity, Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityShares" xml:lang="en-US">Common stock options</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityShares" xml:lang="en-US">Common stock options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityShares" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityShares" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CommonStockWarrantsEquityTreatment" xlink:label="loc_tpiv_CommonStockWarrantsEquityTreatment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_CommonStockWarrantsEquityTreatment" xml:lang="en-US">Common Stock Warrants Equity Treatment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tpiv_CommonStockWarrantsEquityTreatment" xml:lang="en-US">Common stock warrants - equity treatment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tpiv_CommonStockWarrantsEquityTreatment" xml:lang="en-US">Common stock warrants - equity treatment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_CommonStockWarrantsEquityTreatment" xml:lang="en-US">Common stock warrants - equity treatment.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_CommonStockWarrantsEquityTreatment" xlink:to="lab_tpiv_CommonStockWarrantsEquityTreatment" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CommonStockWarrantsLiabilityTreatment" xlink:label="loc_tpiv_CommonStockWarrantsLiabilityTreatment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_CommonStockWarrantsLiabilityTreatment" xml:lang="en-US">Common Stock Warrants Liability Treatment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tpiv_CommonStockWarrantsLiabilityTreatment" xml:lang="en-US">Common stock warrants - liability treatment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tpiv_CommonStockWarrantsLiabilityTreatment" xml:lang="en-US">Common stock warrants - liability treatment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_CommonStockWarrantsLiabilityTreatment" xml:lang="en-US">Common stock warrants - liability treatment.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_CommonStockWarrantsLiabilityTreatment" xlink:to="lab_tpiv_CommonStockWarrantsLiabilityTreatment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Potentially dilutive securities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_NotestofinancialstatementsAbstract" xlink:label="loc_tpiv_NotestofinancialstatementsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_NotestofinancialstatementsAbstract" xml:lang="en-US">NotesToFinancialStatements [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tpiv_NotestofinancialstatementsAbstract" xml:lang="en-US">Notes To Financial Statements</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_NotestofinancialstatementsAbstract" xlink:to="lab_tpiv_NotestofinancialstatementsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders&#39; Equity, Reverse Stock Split</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class of Warrant or Right [Table]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class of Warrant or Right [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield (per share)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield (per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by (used in) financing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xml:lang="en-US">Stock-based compensation, Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share Applicable To Common Stockholders</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">NET INCOME (LOSS) PER SHARE</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Reconciliation of Numerator and Denominator Used in Calculation of Earnings Per Share Applicable to Common Stockholders</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_NetLossPerShareTableTextBlockTableTextBlock" xlink:label="loc_tpiv_NetLossPerShareTableTextBlockTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_NetLossPerShareTableTextBlockTableTextBlock" xml:lang="en-US">Net Loss Per Share [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tpiv_NetLossPerShareTableTextBlockTableTextBlock" xml:lang="en-US">Net Loss Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_NetLossPerShareTableTextBlockTableTextBlock" xml:lang="en-US">Net Loss Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_NetLossPerShareTableTextBlockTableTextBlock" xlink:to="lab_tpiv_NetLossPerShareTableTextBlockTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xml:lang="en-US">Research and Development [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xml:lang="en-US">RESEARCH AGREEMENT OBLIGATIONS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued Liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders&#39; Equity Note [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders&#39; Equity Note Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightExerciseAxis" xlink:label="loc_tpiv_ClassOfWarrantOrRightExerciseAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_ClassOfWarrantOrRightExerciseAxis" xml:lang="en-US">Class of Warrant or Right, Exercise [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseAxis" xlink:to="lab_tpiv_ClassOfWarrantOrRightExerciseAxis" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SeriesEWarrantMember" xlink:label="loc_tpiv_SeriesEWarrantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_SeriesEWarrantMember" xml:lang="en-US">Series E Warrant [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_SeriesEWarrantMember" xlink:to="lab_tpiv_SeriesEWarrantMember" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SubsequentWarrantIssuanceMember" xlink:label="loc_tpiv_SubsequentWarrantIssuanceMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_SubsequentWarrantIssuanceMember" xml:lang="en-US">Subsequent Warrant Issuance [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_SubsequentWarrantIssuanceMember" xlink:to="lab_tpiv_SubsequentWarrantIssuanceMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Significant other observable inputs (Level 2)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Significant other observable inputs (Level 3)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Change in fair value of warrant liability</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PromissoryNotesDueInTwoThousandTwelveMember" xlink:label="loc_tpiv_PromissoryNotesDueInTwoThousandTwelveMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_PromissoryNotesDueInTwoThousandTwelveMember" xml:lang="en-US">Promissory Notes Due In Two Thousand Twelve [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tpiv_PromissoryNotesDueInTwoThousandTwelveMember" xml:lang="en-US">Promissory Notes Due in 2012 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_PromissoryNotesDueInTwoThousandTwelveMember" xml:lang="en-US">Promissory Notes Due In Two Thousand Twelve [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_PromissoryNotesDueInTwoThousandTwelveMember" xlink:to="lab_tpiv_PromissoryNotesDueInTwoThousandTwelveMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement" xlink:label="loc_tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement" xml:lang="en-US">Noncash Or Part Noncash Transaction,Fair Value of Repriced Warrants as Inducement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement" xml:lang="en-US">Fair value of repriced warrants as inducement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement" xml:lang="en-US">Fair value of repriced warrants as inducement which classified as non financing and investing activities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement" xlink:to="lab_tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember" xlink:to="lab_us-gaap_RangeMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember" xlink:to="lab_us-gaap_MaximumMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember" xlink:to="lab_us-gaap_MinimumMember" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PresidentAndChiefOperatingOfficerMember" xlink:label="loc_tpiv_PresidentAndChiefOperatingOfficerMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_PresidentAndChiefOperatingOfficerMember" xml:lang="en-US">President and Chief Operating Officer [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_PresidentAndChiefOperatingOfficerMember" xlink:to="lab_tpiv_PresidentAndChiefOperatingOfficerMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Gross</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized stock-based compensation cost:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Expected weighted average period compensation costs to be recognized (years):</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="loc_us-gaap_DerivativesAndFairValueTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesAndFairValueTextBlock" xml:lang="en-US">Derivatives and Fair Value [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativesAndFairValueTextBlock" xml:lang="en-US">WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesAndFairValueTextBlock" xlink:to="lab_us-gaap_DerivativesAndFairValueTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Denominator:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Net (loss) income per share data:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Non-cash investing and financing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CrucellHollandBvMember" xlink:label="loc_tpiv_CrucellHollandBvMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_CrucellHollandBvMember" xml:lang="en-US">Crucell Holland BV [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_CrucellHollandBvMember" xlink:to="lab_tpiv_CrucellHollandBvMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xml:lang="en-US">Debt Instrument, Increase (Decrease), Net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ChiefFinancialOfficerTreasurerAndSecretaryMember" xlink:label="loc_tpiv_ChiefFinancialOfficerTreasurerAndSecretaryMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_ChiefFinancialOfficerTreasurerAndSecretaryMember" xml:lang="en-US">Chief Financial Officer, Treasurer and Secretary [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_ChiefFinancialOfficerTreasurerAndSecretaryMember" xlink:to="lab_tpiv_ChiefFinancialOfficerTreasurerAndSecretaryMember" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ChiefExecutiveOfficerAndPresidentMember" xlink:label="loc_tpiv_ChiefExecutiveOfficerAndPresidentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_ChiefExecutiveOfficerAndPresidentMember" xml:lang="en-US">Chief Executive Officer and President [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_ChiefExecutiveOfficerAndPresidentMember" xlink:to="lab_tpiv_ChiefExecutiveOfficerAndPresidentMember" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_BonusOnBaseSalariespercentage" xlink:label="loc_tpiv_BonusOnBaseSalariespercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_BonusOnBaseSalariespercentage" xml:lang="en-US">Bonus on Base Salaries,Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tpiv_BonusOnBaseSalariespercentage" xml:lang="en-US">Bonus on Base Salaries, Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_BonusOnBaseSalariespercentage" xml:lang="en-US">Represents the percentage rate of bonus on base salaries of officers.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_BonusOnBaseSalariespercentage" xlink:to="lab_tpiv_BonusOnBaseSalariespercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Units issued, value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficersCompensation" xml:lang="en-US">Officers&#39; Compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation" xlink:to="lab_us-gaap_OfficersCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_BonusPayableDescription" xlink:label="loc_tpiv_BonusPayableDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_BonusPayableDescription" xml:lang="en-US">Bonus Payable, Description</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_BonusPayableDescription" xml:lang="en-US">Description of the bonus which be payable to officers of the entity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_BonusPayableDescription" xlink:to="lab_tpiv_BonusPayableDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Sales price per unit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightWarrantPrice" xlink:label="loc_tpiv_ClassOfWarrantOrRightWarrantPrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_ClassOfWarrantOrRightWarrantPrice" xml:lang="en-US">Class of Warrant or Right, Warrant Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_ClassOfWarrantOrRightWarrantPrice" xml:lang="en-US">It represents the price per warrant.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_ClassOfWarrantOrRightWarrantPrice" xlink:to="lab_tpiv_ClassOfWarrantOrRightWarrantPrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Issuance of shares, net of finders&#39; fee</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities" xlink:label="loc_tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities" xml:lang="en-US">Liquidated Damages on Aggregate Purachase Price for Registrable Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities" xml:lang="en-US">Liquidated Damages on Aggregate Purchase Price for Registrable Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities" xml:lang="en-US">The percentage rate of liquidated damages on aggregate purchase price of registrable securities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities" xlink:to="lab_tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xml:lang="en-US">Loss Contingency, Damages Sought, Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of Stockholders&#39; Equity Note, Warrants or Rights [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Summary Of Number Of Price-Reduced and Price-Retained Warrants</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ValuationMethodologyTableTextBlock" xlink:label="loc_tpiv_ValuationMethodologyTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_ValuationMethodologyTableTextBlock" xml:lang="en-US">Valuation Methodology [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tpiv_ValuationMethodologyTableTextBlock" xml:lang="en-US">Valuation Methodology</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_ValuationMethodologyTableTextBlock" xml:lang="en-US">Tabular disclosure of valuation methodology.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_ValuationMethodologyTableTextBlock" xlink:to="lab_tpiv_ValuationMethodologyTableTextBlock" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightExerciseDomain" xlink:label="loc_tpiv_ClassOfWarrantOrRightExerciseDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_ClassOfWarrantOrRightExerciseDomain" xml:lang="en-US">Class of Warrant or Right, Exercise [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseDomain" xlink:to="lab_tpiv_ClassOfWarrantOrRightExerciseDomain" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRighttrancheOneMember" xlink:label="loc_tpiv_ClassOfWarrantOrRighttrancheOneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_ClassOfWarrantOrRighttrancheOneMember" xml:lang="en-US">Class of Warrant or Right,Tranche One [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tpiv_ClassOfWarrantOrRighttrancheOneMember" xml:lang="en-US">Number of Warrant Shares Repriced [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_ClassOfWarrantOrRighttrancheOneMember" xlink:to="lab_tpiv_ClassOfWarrantOrRighttrancheOneMember" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SeriesCWarrantMember" xlink:label="loc_tpiv_SeriesCWarrantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_SeriesCWarrantMember" xml:lang="en-US">Series C Warrant [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_SeriesCWarrantMember" xlink:to="lab_tpiv_SeriesCWarrantMember" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SeriesDWarrantMember" xlink:label="loc_tpiv_SeriesDWarrantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_SeriesDWarrantMember" xml:lang="en-US">Series D Warrant [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_SeriesDWarrantMember" xlink:to="lab_tpiv_SeriesDWarrantMember" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SeriesFWarrantMember" xlink:label="loc_tpiv_SeriesFWarrantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_SeriesFWarrantMember" xml:lang="en-US">Series F Warrant [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_SeriesFWarrantMember" xlink:to="lab_tpiv_SeriesFWarrantMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioPreviouslyReportedMember" xml:lang="en-US">Scenario, Previously Reported [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScenarioPreviouslyReportedMember" xml:lang="en-US">As Stated [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScenarioPreviouslyReportedMember" xml:lang="en-US">Weighted Average Inputs Before Modification [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioPreviouslyReportedMember" xlink:to="lab_us-gaap_ScenarioPreviouslyReportedMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestatementAdjustmentMember" xml:lang="en-US">Restatement Adjustment [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestatementAdjustmentMember" xml:lang="en-US">Weighted Average Inputs After Modification [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestatementAdjustmentMember" xlink:to="lab_us-gaap_RestatementAdjustmentMember" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:label="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance [Line Items]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance [Line Items]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="lab_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRighttrancheTwoMember" xlink:label="loc_tpiv_ClassOfWarrantOrRighttrancheTwoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_ClassOfWarrantOrRighttrancheTwoMember" xml:lang="en-US">Class of Warrant or Right,Tranche Two [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tpiv_ClassOfWarrantOrRighttrancheTwoMember" xml:lang="en-US">Price-retained Warrants [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_ClassOfWarrantOrRighttrancheTwoMember" xlink:to="lab_tpiv_ClassOfWarrantOrRighttrancheTwoMember" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_NumberOfUnitsSold" xlink:label="loc_tpiv_NumberOfUnitsSold" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_NumberOfUnitsSold" xml:lang="en-US">Number Of Units Sold</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tpiv_NumberOfUnitsSold" xml:lang="en-US">Amount of number of units Sold.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_NumberOfUnitsSold" xlink:to="lab_tpiv_NumberOfUnitsSold" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PrereducedPriceMember" xlink:label="loc_tpiv_PrereducedPriceMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_PrereducedPriceMember" xml:lang="en-US">Pre-reduced Price [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_PrereducedPriceMember" xlink:to="lab_tpiv_PrereducedPriceMember" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PostreducedPriceMember" xlink:label="loc_tpiv_PostreducedPriceMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tpiv_PostreducedPriceMember" xml:lang="en-US">Post-reduced Price [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tpiv_PostreducedPriceMember" xlink:to="lab_tpiv_PostreducedPriceMember" />
  </labelLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>tpiv-20170630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 04-Aug-2017 [07:27:56] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#DocumentAndEntityInformation" roleURI="http://www.tapimmune.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#SignificantAccountingPolicies" roleURI="http://www.tapimmune.com/role/SignificantAccountingPolicies" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#NetLossIncomePerShare" roleURI="http://www.tapimmune.com/role/NetLossIncomePerShare" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#ResearchAgreementObligations" roleURI="http://www.tapimmune.com/role/ResearchAgreementObligations" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#WarrantLiabilityAndFairValueMeasurements" roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurements" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#PromissoryNote" roleURI="http://www.tapimmune.com/role/PromissoryNote" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#StockholdersEquity" roleURI="http://www.tapimmune.com/role/StockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#StockbasedCompensation" roleURI="http://www.tapimmune.com/role/StockbasedCompensation" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#SubsequentEvent" roleURI="http://www.tapimmune.com/role/SubsequentEvent" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.tapimmune.com/role/SignificantAccountingPoliciesPolicies" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#NetLossIncomePerShareTables" roleURI="http://www.tapimmune.com/role/NetLossIncomePerShareTables" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#WarrantLiabilityAndFairValueMeasurementsTables" roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsTables" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#StockholdersEquityTables" roleURI="http://www.tapimmune.com/role/StockholdersEquityTables" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#LiquidityAndFinancialConditionAdditionalInformationDetail" roleURI="http://www.tapimmune.com/role/LiquidityAndFinancialConditionAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#NetLossIncomePerShareComputationOfIncomeLossPerShareDetail" roleURI="http://www.tapimmune.com/role/NetLossIncomePerShareComputationOfIncomeLossPerShareDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#NetLossIncomePerSharePotentiallyDilutiveSecuritiesDetail" roleURI="http://www.tapimmune.com/role/NetLossIncomePerSharePotentiallyDilutiveSecuritiesDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#NetLossIncomePerShareAdditionalInformationDetail" roleURI="http://www.tapimmune.com/role/NetLossIncomePerShareAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#ResearchAgreementObligationsAdditionalInformationDetail" roleURI="http://www.tapimmune.com/role/ResearchAgreementObligationsAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#WarrantLiabilityAndFairValueMeasurementsConversionOptionValuationMethodologyDetail" roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionValuationMethodologyDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#WarrantLiabilityAndFairValueMeasurementsConversionOptionFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#WarrantLiabilityAndFairValueMeasurementsConversionOptionScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueDetail" roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#PromissoryNoteAdditionalInformationDetail" roleURI="http://www.tapimmune.com/role/PromissoryNoteAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#StockholdersEquitySummaryOfNumberOfPricereducedAndPriceretainedWarrantsDetail" roleURI="http://www.tapimmune.com/role/StockholdersEquitySummaryOfNumberOfPricereducedAndPriceretainedWarrantsDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#StockholdersEquityConversionOptionValuationMethodologyDetail" roleURI="http://www.tapimmune.com/role/StockholdersEquityConversionOptionValuationMethodologyDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.tapimmune.com/role/StockholdersEquityAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#StockbasedCompensationAdditionalInformationDetail" roleURI="http://www.tapimmune.com/role/StockbasedCompensationAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#SubsequentEventAdditionalInformationDetail" roleURI="http://www.tapimmune.com/role/SubsequentEventAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#CondensedConsolidatedStatementOfStockholdersEquity" roleURI="http://www.tapimmune.com/role/CondensedConsolidatedStatementOfStockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#NatureOfOperations" roleURI="http://www.tapimmune.com/role/NatureOfOperations" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#BasisOfPresentation" roleURI="http://www.tapimmune.com/role/BasisOfPresentation" />

  <roleRef xlink:type="simple" xlink:href="tpiv-20170630.xsd#LiquidityAndFinancialCondition" roleURI="http://www.tapimmune.com/role/LiquidityAndFinancialCondition" />

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_DocumentAndEntityInformationAbstract" xlink:label="loc_tpiv_DocumentAndEntityInformationAbstract_2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_DocumentAndEntityInformationAbstract_2" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1142" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1142" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1143" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1142" xlink:to="loc_us-gaap_ClassOfStockDomain_1143" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_4" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_DocumentInformationLineItems_4" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentType_5" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentFlag_6" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_7" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_8" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_10" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityRegistrantName_10" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_11" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_12" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_12" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_13" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFilerCategory_13" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1101" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_TradingSymbol_1101" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1102" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1102" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_290" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_674" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_290" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_674" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/NetLossIncomePerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_731" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_732" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_731" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_732" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/ResearchAgreementObligations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_764" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_768" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_764" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_768" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurements">
    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_DerivativesAndFairValueAbstract" xlink:label="loc_tpiv_DerivativesAndFairValueAbstract_1085" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="loc_us-gaap_DerivativesAndFairValueTextBlock_1086" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_DerivativesAndFairValueAbstract_1085" xlink:to="loc_us-gaap_DerivativesAndFairValueTextBlock_1086" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/PromissoryNote">
    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PromissoryNotesAbstract" xlink:label="loc_tpiv_PromissoryNotesAbstract_312" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PromissoryNoteTextBlock" xlink:label="loc_tpiv_PromissoryNoteTextBlock_313" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_PromissoryNotesAbstract_312" xlink:to="loc_tpiv_PromissoryNoteTextBlock_313" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_797" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_798" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_797" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_798" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/StockbasedCompensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_434" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_435" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_434" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_435" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/SubsequentEvent">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_324" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_325" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_324" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_325" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/SignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_293" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_295" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_293" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_295" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/NetLossIncomePerShareTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_734" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_736" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_734" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_736" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_NetLossPerShareTableTextBlockTableTextBlock" xlink:label="loc_tpiv_NetLossPerShareTableTextBlockTableTextBlock_735" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_734" xlink:to="loc_tpiv_NetLossPerShareTableTextBlockTableTextBlock_735" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_16" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_15" xlink:to="loc_us-gaap_StatementTable_16" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_17" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_16" xlink:to="loc_us-gaap_StatementClassOfStockAxis_17" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_18" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_17" xlink:to="loc_us-gaap_ClassOfStockDomain_18" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_19" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_18" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_19" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_20" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_18" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_20" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_21" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_16" xlink:to="loc_us-gaap_StatementLineItems_21" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_22" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_AssetsAbstract_22" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_23" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_AssetsCurrentAbstract_23" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_24" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_Cash_24" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_25" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_25" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1050" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_AssetsCurrent_1050" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_26" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_Assets_26" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_28" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_28" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_29" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_29" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_30" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_30" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_31" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_31" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_32" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_NotesPayableCurrent_32" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_34" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_LiabilitiesCurrent_34" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_1051" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_Liabilities_1051" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_355" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_CommitmentsAndContingencies_355" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_35" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27" xlink:to="loc_us-gaap_StockholdersEquityAbstract_35" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_36" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_PreferredStockValue_36" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_37" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_CommonStockValue_37" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_38" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_AdditionalPaidInCapital_38" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_39" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_39" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_40" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_StockholdersEquity_40" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_41" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_41" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_DerivativesAndFairValueAbstract" xlink:label="loc_tpiv_DerivativesAndFairValueAbstract_307" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ValuationMethodology" xlink:label="loc_tpiv_ValuationMethodology_308" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_DerivativesAndFairValueAbstract_307" xlink:to="loc_tpiv_ValuationMethodology_308" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" xlink:label="loc_tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis_309" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_DerivativesAndFairValueAbstract_307" xlink:to="loc_tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis_309" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_MeasuredAtFairValue" xlink:label="loc_tpiv_MeasuredAtFairValue_310" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_DerivativesAndFairValueAbstract_307" xlink:to="loc_tpiv_MeasuredAtFairValue_310" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1147" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1148" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1147" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1148" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ValuationMethodologyTableTextBlock" xlink:label="loc_tpiv_ValuationMethodologyTableTextBlock_1149" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1147" xlink:to="loc_tpiv_ValuationMethodologyTableTextBlock_1149" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/LiquidityAndFinancialConditionAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_121" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_441" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_121" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_441" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_449" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_441" xlink:to="loc_us-gaap_StatementClassOfStockAxis_449" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_450" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_449" xlink:to="loc_us-gaap_ClassOfStockDomain_450" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_455" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_441" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_455" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_122" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_455" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_122" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/NetLossIncomePerShareComputationOfIncomeLossPerShareDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_499" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_500" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_499" xlink:to="loc_us-gaap_StatementTable_500" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_501" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_500" xlink:to="loc_us-gaap_StatementClassOfStockAxis_501" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_502" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_501" xlink:to="loc_us-gaap_ClassOfStockDomain_502" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_503" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_500" xlink:to="loc_us-gaap_StatementLineItems_503" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1106" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1106" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_504" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1106" xlink:to="loc_us-gaap_NetIncomeLoss_504" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaap_DilutiveSecurities_586" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1106" xlink:to="loc_us-gaap_DilutiveSecurities_586" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_587" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_1106" xlink:to="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_587" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1107" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1107" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_505" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1107" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_505" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_506" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1107" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_506" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_507" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1107" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_507" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_508" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1107" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_508" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_509" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_509" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_510" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_509" xlink:to="loc_us-gaap_EarningsPerShareBasic_510" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_511" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_509" xlink:to="loc_us-gaap_EarningsPerShareDiluted_511" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/NetLossIncomePerSharePotentiallyDilutiveSecuritiesDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_514" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_515" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_514" xlink:to="loc_us-gaap_StatementTable_515" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_516" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_515" xlink:to="loc_us-gaap_StatementClassOfStockAxis_516" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_517" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_516" xlink:to="loc_us-gaap_ClassOfStockDomain_517" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_518" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_515" xlink:to="loc_us-gaap_StatementLineItems_518" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityShares" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityShares_525" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_518" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityShares_525" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CommonStockWarrantsEquityTreatment" xlink:label="loc_tpiv_CommonStockWarrantsEquityTreatment_527" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_518" xlink:to="loc_tpiv_CommonStockWarrantsEquityTreatment_527" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CommonStockWarrantsLiabilityTreatment" xlink:label="loc_tpiv_CommonStockWarrantsLiabilityTreatment_528" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_518" xlink:to="loc_tpiv_CommonStockWarrantsLiabilityTreatment_528" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_530" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_518" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_530" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/NetLossIncomePerShareAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_NotestofinancialstatementsAbstract" xlink:label="loc_tpiv_NotestofinancialstatementsAbstract_532" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_533" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_NotestofinancialstatementsAbstract_532" xlink:to="loc_us-gaap_StatementTable_533" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_534" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_533" xlink:to="loc_us-gaap_StatementClassOfStockAxis_534" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_535" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_534" xlink:to="loc_us-gaap_ClassOfStockDomain_535" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_536" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_533" xlink:to="loc_us-gaap_StatementLineItems_536" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_537" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_536" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_537" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/ResearchAgreementObligationsAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_777" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_778" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_777" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_778" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_779" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_778" xlink:to="loc_us-gaap_StatementClassOfStockAxis_779" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_780" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_779" xlink:to="loc_us-gaap_ClassOfStockDomain_780" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_781" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_778" xlink:to="loc_dei_LegalEntityAxis_781" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1114" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_781" xlink:to="loc_dei_EntityDomain_1114" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CrucellHollandBvMember" xlink:label="loc_tpiv_CrucellHollandBvMember_1115" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1114" xlink:to="loc_tpiv_CrucellHollandBvMember_1115" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1113" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_778" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1113" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_782" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1113" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_782" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1116" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1113" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1116" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_1117" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1113" xlink:to="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_1117" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionValuationMethodologyDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_149" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_150" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_149" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_150" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_151" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_150" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_151" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_152" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_151" xlink:to="loc_us-gaap_EquityComponentDomain_152" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SharePurchaseWarrantsMember" xlink:label="loc_tpiv_SharePurchaseWarrantsMember_153" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_152" xlink:to="loc_tpiv_SharePurchaseWarrantsMember_153" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_154" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_150" xlink:to="loc_us-gaap_RangeAxis_154" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1065" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_154" xlink:to="loc_us-gaap_RangeMember_1065" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1066" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1065" xlink:to="loc_us-gaap_MaximumMember_1066" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1067" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1065" xlink:to="loc_us-gaap_MinimumMember_1067" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_150" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_155" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" xlink:to="loc_us-gaap_SharePrice_155" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_570" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_570" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_157" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_157" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_158" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_158" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_159" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_159" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_160" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1064" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_160" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNetAbstract" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_162" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_163" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_162" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_163" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_164" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_163" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_164" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_165" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_164" xlink:to="loc_us-gaap_HedgingRelationshipDomain_165" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="loc_us-gaap_FairValueHedgingMember_166" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_165" xlink:to="loc_us-gaap_FairValueHedgingMember_166" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_167" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_163" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_167" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_168" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_167" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_168" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_951" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_168" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_951" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_952" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_168" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_952" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_169" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_168" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_169" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_170" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_163" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_170" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_171" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_170" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_171" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_174" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_538" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_174" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_538" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_539" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_538" xlink:to="loc_us-gaap_StatementClassOfStockAxis_539" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_540" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_539" xlink:to="loc_us-gaap_ClassOfStockDomain_540" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_541" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_538" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_541" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_542" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_541" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_542" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_545" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_541" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_545" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_546" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_541" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_546" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_44" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_43" xlink:to="loc_us-gaap_StatementTable_44" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_45" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_44" xlink:to="loc_us-gaap_StatementClassOfStockAxis_45" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_46" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_45" xlink:to="loc_us-gaap_ClassOfStockDomain_46" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_47" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_46" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_47" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_48" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_46" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_48" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_49" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_44" xlink:to="loc_us-gaap_StatementLineItems_49" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_50" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_50" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_51" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_51" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_52" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_PreferredStockSharesIssued_52" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_53" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_53" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_54" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_54" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_55" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_55" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_56" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_CommonStockSharesIssued_56" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_57" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_57" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/PromissoryNoteAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaap_NotesPayableAbstract_179" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_180" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_179" xlink:to="loc_us-gaap_DebtInstrumentTable_180" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_181" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_180" xlink:to="loc_us-gaap_DebtInstrumentAxis_181" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_182" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_181" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_182" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PromissoryNotesDueInTwoThousandTwelveMember" xlink:label="loc_tpiv_PromissoryNotesDueInTwoThousandTwelveMember_979" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_182" xlink:to="loc_tpiv_PromissoryNotesDueInTwoThousandTwelveMember_979" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_184" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_180" xlink:to="loc_us-gaap_DebtInstrumentLineItems_184" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_185" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_184" xlink:to="loc_us-gaap_NotesPayableCurrent_185" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_186" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_184" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_186" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/StockholdersEquitySummaryOfNumberOfPricereducedAndPriceretainedWarrantsDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1151" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1152" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1151" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1152" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1153" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1152" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1153" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1155" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1153" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1155" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SeriesCWarrantMember" xlink:label="loc_tpiv_SeriesCWarrantMember_1162" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1155" xlink:to="loc_tpiv_SeriesCWarrantMember_1162" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SeriesDWarrantMember" xlink:label="loc_tpiv_SeriesDWarrantMember_1163" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1155" xlink:to="loc_tpiv_SeriesDWarrantMember_1163" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SeriesFWarrantMember" xlink:label="loc_tpiv_SeriesFWarrantMember_1165" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1155" xlink:to="loc_tpiv_SeriesFWarrantMember_1165" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightExerciseAxis" xlink:label="loc_tpiv_ClassOfWarrantOrRightExerciseAxis_1154" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1152" xlink:to="loc_tpiv_ClassOfWarrantOrRightExerciseAxis_1154" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightExerciseDomain" xlink:label="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1159" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseAxis_1154" xlink:to="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1159" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRighttrancheOneMember" xlink:label="loc_tpiv_ClassOfWarrantOrRighttrancheOneMember_1160" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1159" xlink:to="loc_tpiv_ClassOfWarrantOrRighttrancheOneMember_1160" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PrereducedPriceMember" xlink:label="loc_tpiv_PrereducedPriceMember_1194" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1159" xlink:to="loc_tpiv_PrereducedPriceMember_1194" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PostreducedPriceMember" xlink:label="loc_tpiv_PostreducedPriceMember_1195" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1159" xlink:to="loc_tpiv_PostreducedPriceMember_1195" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_1158" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1152" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_1158" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1166" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1158" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1166" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1167" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1158" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1167" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/StockholdersEquityConversionOptionValuationMethodologyDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1169" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1170" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1169" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1170" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1171" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1170" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1171" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1178" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1171" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1178" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SharePurchaseWarrantsMember" xlink:label="loc_tpiv_SharePurchaseWarrantsMember_1179" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1178" xlink:to="loc_tpiv_SharePurchaseWarrantsMember_1179" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_1177" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1170" xlink:to="loc_us-gaap_StatementScenarioAxis_1177" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_1181" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_1177" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_1181" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_1182" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_1181" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_1182" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_1183" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_1181" xlink:to="loc_us-gaap_RestatementAdjustmentMember_1183" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1180" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1170" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1180" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_1172" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1180" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_1172" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_1173" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1180" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_1173" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_1174" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1180" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_1174" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1175" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1180" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1175" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_1176" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1180" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_1176" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/StockholdersEquityAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_197" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:label="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_197" xlink:to="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_199" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_TitleOfIndividualAxis_199" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_200" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_199" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_200" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_201" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_200" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_201" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_PresidentAndChiefOperatingOfficerMember" xlink:label="loc_tpiv_PresidentAndChiefOperatingOfficerMember_1068" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_200" xlink:to="loc_tpiv_PresidentAndChiefOperatingOfficerMember_1068" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_202" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_TypeOfArrangementAxis_202" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_202" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ConsultingAgreementsMember" xlink:label="loc_tpiv_ConsultingAgreementsMember_204" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_tpiv_ConsultingAgreementsMember_204" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_205" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_205" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_391" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_205" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_391" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_392" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_391" xlink:to="loc_us-gaap_PrivatePlacementMember_392" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_430" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_430" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_429" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_429" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_621" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_429" xlink:to="loc_us-gaap_EquityComponentDomain_621" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1136" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_621" xlink:to="loc_us-gaap_CommonStockMember_1136" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1193" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_621" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1193" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_620" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_620" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_629" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_620" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_629" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_628" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_StatementClassOfStockAxis_628" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_810" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_628" xlink:to="loc_us-gaap_ClassOfStockDomain_810" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_809" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_809" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_835" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_809" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_835" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SeriesEWarrantMember" xlink:label="loc_tpiv_SeriesEWarrantMember_847" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_835" xlink:to="loc_tpiv_SeriesEWarrantMember_847" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_SubsequentWarrantIssuanceMember" xlink:label="loc_tpiv_SubsequentWarrantIssuanceMember_850" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_835" xlink:to="loc_tpiv_SubsequentWarrantIssuanceMember_850" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightExerciseAxis" xlink:label="loc_tpiv_ClassOfWarrantOrRightExerciseAxis_834" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_tpiv_ClassOfWarrantOrRightExerciseAxis_834" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightExerciseDomain" xlink:label="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1185" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseAxis_834" xlink:to="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1185" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRighttrancheOneMember" xlink:label="loc_tpiv_ClassOfWarrantOrRighttrancheOneMember_1186" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1185" xlink:to="loc_tpiv_ClassOfWarrantOrRighttrancheOneMember_1186" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRighttrancheTwoMember" xlink:label="loc_tpiv_ClassOfWarrantOrRighttrancheTwoMember_1187" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_ClassOfWarrantOrRightExerciseDomain_1185" xlink:to="loc_tpiv_ClassOfWarrantOrRighttrancheTwoMember_1187" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:label="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable_198" xlink:to="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_207" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_207" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_210" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_210" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_394" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_394" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightExpirationPeriod" xlink:label="loc_tpiv_ClassOfWarrantOrRightExpirationPeriod_411" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_tpiv_ClassOfWarrantOrRightExpirationPeriod_411" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_415" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_LegalFees_415" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_416" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_416" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_EquityUnitIssuedPricePerUnit" xlink:label="loc_tpiv_EquityUnitIssuedPricePerUnit_425" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_tpiv_EquityUnitIssuedPricePerUnit_425" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_990" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_990" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_1069" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_1069" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_1070" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_1070" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1071" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_SharePrice_1071" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1130" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1130" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1137" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1137" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ClassOfWarrantOrRightWarrantPrice" xlink:label="loc_tpiv_ClassOfWarrantOrRightWarrantPrice_1140" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_tpiv_ClassOfWarrantOrRightWarrantPrice_1140" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1141" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1141" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities" xlink:label="loc_tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities_1144" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities_1144" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_1145" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_1145" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1189" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1189" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_NumberOfUnitsSold" xlink:label="loc_tpiv_NumberOfUnitsSold_1190" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_1184" xlink:to="loc_tpiv_NumberOfUnitsSold_1190" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/StockbasedCompensationAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_870" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_871" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_870" xlink:to="loc_us-gaap_StatementTable_871" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_872" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_871" xlink:to="loc_us-gaap_StatementClassOfStockAxis_872" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_873" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_872" xlink:to="loc_us-gaap_ClassOfStockDomain_873" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_874" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_871" xlink:to="loc_us-gaap_AwardTypeAxis_874" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_884" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_874" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_884" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_883" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_871" xlink:to="loc_us-gaap_PlanNameAxis_883" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1010" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_883" xlink:to="loc_us-gaap_PlanNameDomain_1010" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1009" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_871" xlink:to="loc_us-gaap_StatementLineItems_1009" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_876" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1009" xlink:to="loc_us-gaap_ShareBasedCompensation_876" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1081" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1009" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1081" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1082" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1009" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1082" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/SubsequentEventAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_215" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_216" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_215" xlink:to="loc_us-gaap_SubsequentEventTable_216" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_217" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_216" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_217" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_218" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_217" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_218" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_219" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_218" xlink:to="loc_us-gaap_SubsequentEventMember_219" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_220" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_216" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_220" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_221" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_220" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_221" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_223" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_216" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_223" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_224" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_223" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_224" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_226" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_216" xlink:to="loc_us-gaap_StatementScenarioAxis_226" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_227" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_226" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_227" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_231" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_216" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_231" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_232" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_231" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_232" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_236" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_216" xlink:to="loc_us-gaap_TitleOfIndividualAxis_236" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1126" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_236" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1126" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ChiefFinancialOfficerTreasurerAndSecretaryMember" xlink:label="loc_tpiv_ChiefFinancialOfficerTreasurerAndSecretaryMember_1127" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1126" xlink:to="loc_tpiv_ChiefFinancialOfficerTreasurerAndSecretaryMember_1127" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ChiefExecutiveOfficerAndPresidentMember" xlink:label="loc_tpiv_ChiefExecutiveOfficerAndPresidentMember_1128" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1126" xlink:to="loc_tpiv_ChiefExecutiveOfficerAndPresidentMember_1128" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1125" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_216" xlink:to="loc_us-gaap_RangeAxis_1125" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1133" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_1125" xlink:to="loc_us-gaap_RangeMember_1133" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1134" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1133" xlink:to="loc_us-gaap_MaximumMember_1134" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1132" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_216" xlink:to="loc_us-gaap_SubsequentEventLineItems_1132" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_BonusOnBaseSalariespercentage" xlink:label="loc_tpiv_BonusOnBaseSalariespercentage_1129" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1132" xlink:to="loc_tpiv_BonusOnBaseSalariespercentage_1129" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_1131" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1132" xlink:to="loc_us-gaap_OfficersCompensation_1131" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_BonusPayableDescription" xlink:label="loc_tpiv_BonusPayableDescription_1135" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1132" xlink:to="loc_tpiv_BonusPayableDescription_1135" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_59" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_648" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59" xlink:to="loc_us-gaap_StatementTable_648" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_649" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_648" xlink:to="loc_us-gaap_StatementClassOfStockAxis_649" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_650" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_649" xlink:to="loc_us-gaap_ClassOfStockDomain_650" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_651" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_648" xlink:to="loc_us-gaap_StatementLineItems_651" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_60" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_651" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_60" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_60" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_62" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_60" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_62" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1053" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_60" xlink:to="loc_us-gaap_OperatingExpenses_1053" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_63" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_60" xlink:to="loc_us-gaap_OperatingIncomeLoss_63" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_651" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_65" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_65" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_364" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_364" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_67" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" xlink:to="loc_us-gaap_RevenueFromGrants_67" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_1103" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_1103" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_69" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" xlink:to="loc_us-gaap_OtherIncome_69" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_70" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_64" xlink:to="loc_us-gaap_NetIncomeLoss_70" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_71" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_651" xlink:to="loc_us-gaap_EarningsPerShareBasic_71" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_72" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_651" xlink:to="loc_us-gaap_EarningsPerShareDiluted_72" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_73" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_651" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_73" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_651" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/CondensedConsolidatedStatementOfStockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_76" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_77" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_76" xlink:to="loc_us-gaap_StatementTable_77" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_78" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_77" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_78" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_79" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_78" xlink:to="loc_us-gaap_EquityComponentDomain_79" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_80" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79" xlink:to="loc_us-gaap_CommonStockMember_80" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_81" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_81" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_82" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79" xlink:to="loc_us-gaap_RetainedEarningsMember_82" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_83" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_77" xlink:to="loc_us-gaap_StatementLineItems_83" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_84" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_StockholdersEquity_84" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_85" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_SharesIssued_85" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement" xlink:label="loc_tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement_388" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement_388" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement" xlink:label="loc_tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement_387" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement_387" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_389" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_389" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ExerciseOfWarrantsAmount" xlink:label="loc_tpiv_ExerciseOfWarrantsAmount_399" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_tpiv_ExerciseOfWarrantsAmount_399" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ExerciseOfWarrantsShare" xlink:label="loc_tpiv_ExerciseOfWarrantsShare_400" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_tpiv_ExerciseOfWarrantsShare_400" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants" xlink:label="loc_tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants_1121" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants_1121" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_402" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_402" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_88" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_88" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_89" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_89" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_90" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_NetIncomeLoss_90" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_91" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_StockholdersEquity_91" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_92" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_83" xlink:to="loc_us-gaap_SharesIssued_92" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_94" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_653" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_94" xlink:to="loc_us-gaap_StatementTable_653" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_654" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_653" xlink:to="loc_us-gaap_StatementClassOfStockAxis_654" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_655" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_654" xlink:to="loc_us-gaap_ClassOfStockDomain_655" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_656" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_653" xlink:to="loc_us-gaap_StatementLineItems_656" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_95" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_656" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_95" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_96" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_95" xlink:to="loc_us-gaap_NetIncomeLoss_96" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_95" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_98" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_98" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_1108" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_1108" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_100" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" xlink:to="loc_us-gaap_ShareBasedCompensation_100" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_403" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_403" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_101" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_95" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_101" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_102" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_101" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_102" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_103" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_101" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_103" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_104" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_95" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_104" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_105" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_656" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_105" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_107" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_105" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_107" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement" xlink:label="loc_tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement_1110" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_105" xlink:to="loc_tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement_1110" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_108" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_105" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_108" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_110" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_105" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_110" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_111" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_656" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_111" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_112" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_656" xlink:to="loc_us-gaap_Cash_112" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_113" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_656" xlink:to="loc_us-gaap_Cash_113" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_114" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_656" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_114" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_418" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_114" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_418" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation" xlink:label="loc_tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation_115" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_418" xlink:to="loc_tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation_115" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement" xlink:label="loc_tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement_1112" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_418" xlink:to="loc_tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement_1112" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_419" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_418" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_419" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/NatureOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_281" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_282" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_281" xlink:to="loc_us-gaap_NatureOfOperations_282" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/BasisOfPresentation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_284" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaap_BasisOfAccounting_285" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_284" xlink:to="loc_us-gaap_BasisOfAccounting_285" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/LiquidityAndFinancialCondition">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_287" />

    <loc xlink:type="locator" xlink:href="tpiv-20170630.xsd#tpiv_LiquidityAndFinancialConditionTextBlock" xlink:label="loc_tpiv_LiquidityAndFinancialConditionTextBlock_288" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_287" xlink:to="loc_tpiv_LiquidityAndFinancialConditionTextBlock_288" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812962608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Aug. 02, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TAPIMMUNE INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001094038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TPIV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,158,993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813382784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 9,962,615<span></span>
</td>
<td class="nump">$ 7,851,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and deposits</a></td>
<td class="nump">179,181<span></span>
</td>
<td class="nump">70,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">10,141,796<span></span>
</td>
<td class="nump">7,921,392<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">10,141,796<span></span>
</td>
<td class="nump">7,921,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,561,075<span></span>
</td>
<td class="nump">1,224,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Research agreement obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">492,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liability</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">14,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory note</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,576,075<span></span>
</td>
<td class="nump">1,736,805<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,576,075<span></span>
</td>
<td class="nump">1,736,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 41,666,667 shares authorized, 10,158,993 and 8,421,185 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively</a></td>
<td class="nump">10,159<span></span>
</td>
<td class="nump">8,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">159,306,674<span></span>
</td>
<td class="nump">151,991,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(150,751,112)<span></span>
</td>
<td class="num">(145,815,808)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">8,565,721<span></span>
</td>
<td class="nump">6,184,587<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">10,141,796<span></span>
</td>
<td class="nump">7,921,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813268832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized/designated</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock shares par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">41,666,667<span></span>
</td>
<td class="nump">41,666,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">10,158,993<span></span>
</td>
<td class="nump">8,421,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">10,158,993<span></span>
</td>
<td class="nump">8,421,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized/designated</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized/designated</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813339216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,202,725<span></span>
</td>
<td class="nump">$ 1,248,165<span></span>
</td>
<td class="nump">$ 2,191,817<span></span>
</td>
<td class="nump">$ 2,233,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,190,517<span></span>
</td>
<td class="nump">1,177,408<span></span>
</td>
<td class="nump">2,618,310<span></span>
</td>
<td class="nump">1,945,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,393,242<span></span>
</td>
<td class="nump">2,425,573<span></span>
</td>
<td class="nump">4,810,127<span></span>
</td>
<td class="nump">4,179,312<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,393,242)<span></span>
</td>
<td class="num">(2,425,573)<span></span>
</td>
<td class="num">(4,810,127)<span></span>
</td>
<td class="num">(4,179,312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">8,237,000<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">5,241,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment gain</a></td>
<td class="nump">492,365<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">492,365<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">231,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">231,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Shares issued in debt settlement agreements</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(70,315)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(70,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (1,893,377)<span></span>
</td>
<td class="nump">$ 5,974,140<span></span>
</td>
<td class="num">$ (4,313,262)<span></span>
</td>
<td class="nump">$ 1,224,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic</a></td>
<td class="nump">8,576,634<span></span>
</td>
<td class="nump">5,935,000<span></span>
</td>
<td class="nump">8,503,521<span></span>
</td>
<td class="nump">5,908,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted</a></td>
<td class="nump">8,576,634<span></span>
</td>
<td class="nump">6,524,750<span></span>
</td>
<td class="nump">8,503,521<span></span>
</td>
<td class="nump">6,652,417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804605344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 6 months ended Jun. 30, 2017 - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid In Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance, Amount at Dec. 31, 2016</a></td>
<td class="nump">$ 6,184,587<span></span>
</td>
<td class="nump">$ 8,421<span></span>
</td>
<td class="nump">$ 151,991,974<span></span>
</td>
<td class="num">$ (145,815,808)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance, Share at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,421,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement', window );">Common stock and warrants issued in private placement, Amount</a></td>
<td class="nump">6,190,003<span></span>
</td>
<td class="nump">$ 1,504<span></span>
</td>
<td class="nump">6,188,499<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement', window );">Common stock and warrants issued in private placement, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,503,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Fees and legal costs relating to private placement</a></td>
<td class="num">(781,660)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(781,660)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ExerciseOfWarrantsAmount', window );">Exercise of warrants, Amount</a></td>
<td class="nump">666,666<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">666,498<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ExerciseOfWarrantsShare', window );">Exercise of warrants, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants', window );">Legal costs relating to exercise of warrants</a></td>
<td class="num">(28,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(28,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of repriced warrants as inducement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">622,042<span></span>
</td>
<td class="num">(622,042)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation, Amount</a></td>
<td class="nump">647,387<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">647,321<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock-based compensation, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,313,262)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,313,262)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, Amount at Jun. 30, 2017</a></td>
<td class="nump">$ 8,565,721<span></span>
</td>
<td class="nump">$ 10,159<span></span>
</td>
<td class="nump">$ 159,306,674<span></span>
</td>
<td class="num">$ (150,751,112)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, Share at Jun. 30, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,158,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_AdjustmentsToAdditionalPaidInCapitalLegalCostsRelatingToExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ExerciseOfWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_ExerciseOfWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ExerciseOfWarrantsShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_ExerciseOfWarrantsShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the number of new stock and warrants issued in private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_StockAndWarrantsIssuedDuringPeriodShareUnderPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent value of new stock and warrants issued in private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_StockAndWarrantsIssuedDuringPeriodValueUnderPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79512289&amp;loc=d3e4724-112606<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804676192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (4,313,262)<span></span>
</td>
<td class="nump">$ 1,224,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Changes in fair value of warrant liabilities</a></td>
<td class="num">(4,500)<span></span>
</td>
<td class="num">(5,241,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Shares issued in debt settlement agreements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">647,387<span></span>
</td>
<td class="nump">544,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment gain</a></td>
<td class="num">(492,365)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="num">(109,032)<span></span>
</td>
<td class="nump">47,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">336,135<span></span>
</td>
<td class="nump">570,033<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(3,935,637)<span></span>
</td>
<td class="num">(2,783,908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Repayment of promissory note</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement', window );">Proceeds from issuance of common stock and warrants in private placement, net of offering costs</a></td>
<td class="nump">5,408,343<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of stock warrants, net of offering costs</a></td>
<td class="nump">638,666<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">6,047,009<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Net increase (decrease) in cash</a></td>
<td class="nump">2,111,372<span></span>
</td>
<td class="num">(2,808,908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at beginning of period</a></td>
<td class="nump">7,851,243<span></span>
</td>
<td class="nump">6,576,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at end of period</a></td>
<td class="nump">9,962,615<span></span>
</td>
<td class="nump">3,767,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation', window );">Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilson&#8217;s compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">191,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement', window );">Fair value of repriced warrants as inducement</a></td>
<td class="nump">$ 622,042<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of repriced warrants as inducement which classified as non financing and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_NoncashOrPartNoncashTransactionfairValueOfRepricedWarrantsAsInducement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity due to issue of common stock and warrants in a private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of accrued liability upon issuance of common shares relating to compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806114096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"> <font style="TEXT-TRANSFORM: uppercase">Note 1: Nature of Operations</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">TapImmune Inc. (the &#8220;Company&#8221; or &#8220;we&#8221;), a Nevada corporation incorporated in 1992, is a biotechnology company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6635969776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"> <font style="TEXT-TRANSFORM: uppercase">NOTE 2: Basis of Presentation</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (&#8220;SEC&#8221;) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The results for the condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2017 or for any future interim period. The condensed consolidated balance sheet at June 30, 2017 has been derived from unaudited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2016, and notes thereto included in the Company&#8217;s annual report on Form 10-K filed on March 14, 2017.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6604019456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND FINANCIAL CONDITION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_LiquidityAndFinancialConditionTextBlock', window );">LIQUIDITY AND FINANCIAL CONDITION</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"> <font style="TEXT-TRANSFORM: uppercase">NOTE 3: LIQUIDITY AND FINANCIAL CONDITION</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company&#8217;s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity and debt financings and warrant exercises.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company&#8217;s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of June 30, 2017, the Company had cash of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,963,000</font>. The Company had net losses and negative cash flows from operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_LiquidityAndFinancialConditionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity and financial condition text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_LiquidityAndFinancialConditionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799008896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"> <font style="TEXT-TRANSFORM: uppercase">Note 4: SIGNIFICANT ACCOUNTING POLICIES</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">There have been no material changes in the Company&#8217;s significant accounting policies to those previously disclosed in the Company&#8217;s annual report on Form 10-K, which was filed with the SEC on March 14, 2017.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>New Accounting Pronouncement</i>s</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i><u>Accounting for Certain Financial Instruments with Down Round Features</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">On July 13, 2017, the FASB has issued a two-part Accounting Standards Update (&#8220;ASU&#8221;), No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features and (ii) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company will be evaluating the impact of adopting this standard on the consolidated financial statements and disclosures.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><u>Compensation-Stock Compensation</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In May 2017, the FASB issued ASU 2017-09, Compensation&#151;Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the consolidated financial statements and disclosures, but does not expect it to have a significant impact.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806115472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET (LOSS) INCOME PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME (LOSS) PER SHARE</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"> <font style="TEXT-TRANSFORM: uppercase">Note 5: NET (LOSS) InCOME PER SHARE</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Basic (loss) income per common share is computed by dividing net (loss) income by the weighted average number of common shares outstanding during the reporting period. Diluted income per common share is computed similar to basic income per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Income (loss) per-share amounts for all prior periods have been retroactively adjusted to reflect the Company&#8217;s 1-for-12 reverse stock split, which was effective September 16, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table sets forth the computation of net loss per share:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Three&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Six&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>Numerator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Net (loss) income</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,893,377)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5,974,140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(4,313,262)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,224,401</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Less: non-cash income from change in fair value of common stock warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,697,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,492,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Net (loss) income - diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(1,893,377)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,277,140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(4,313,262)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(1,267,599)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>Denominator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Weighted average common shares outstanding - basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>8,576,634</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5,935,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>8,503,521</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5,908,917</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Dilutive effect of warrants, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>565,417</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>743,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Dilutive effect of stock options, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>24,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Weighted average common shares outstanding - diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>8,576,634</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6,524,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>8,503,521</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6,652,417</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>Net (loss) income per share data:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(0.22)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(0.51)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>(0.22)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>0.35</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>(0.51)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>(0.19)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Three&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Six&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Common stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>455,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>251,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>455,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>297,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Common stock warrants - equity treatment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,540,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>213,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,540,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>213,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Common stock warrants - liability treatment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,283,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,068,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Potentially dilutive securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6,998,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,747,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6,998,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,578,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798964976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AGREEMENT OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AGREEMENT OBLIGATIONS</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="TEXT-TRANSFORM: uppercase"><b>Note 6: Research Agreement OBLIGATIONS</b></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Crucell Holland B. V. (&#8220;Crucell&#8221;) &#150; Research License and Option Agreement</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In 2003 and further amended in 2008, the Company acquired a research license and option agreement from Crucell Holland B.V. for use of an adenovirus technology. The Company has not made use of the technology in its current work and has not asked for nor received any work product from Crucell. Crucell was acquired by Johnson and Johnson in 2010.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of December 31, 2016, the Company had accrued $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">492,365</font> under the amended agreement.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Upon further legal review and analysis of the agreement undertaken during the quarter, the Company concluded that the statute of limitations has run out on the obligation, and a legal opinion received by the Company confirms the amounts are not currently owed. As such, as of June 30, 2017, the Company was no longer obligated to make the payments under the agreement and therefore, the Company recorded a debt extinguishment gain of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">492,365</font> and reduced the liability amount owed to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806741568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_DerivativesAndFairValueAbstract', window );"><strong>Derivatives and Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesAndFairValueTextBlock', window );">WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"> <font style="TEXT-TRANSFORM: uppercase">Note 7: WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company&#8217;s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the six months ended June 30, 2017 and 2016 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="30%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"> <div>Six&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="30%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="30%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Stock price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>3.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6.12</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.20 - $300.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: calibri; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Contractual term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.28 - 4.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Volatility (annual)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>68% - 151</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Risk-free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Dividend yield (per share)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management&#8217;s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Financial Liabilities Measured at Fair Value on a Recurring Basis</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"> <div> Fair&#160;value&#160;measured&#160;at&#160;June&#160;30,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Quoted&#160;prices&#160;in&#160;active</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Significant&#160;other</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Significant</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>markets</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>observable&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>unobservable&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Fair&#160;value&#160;at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>(Level&#160;1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>(Level&#160;2)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>(Level&#160;3)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>June&#160;30,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"> <div> Fair&#160;value&#160;measured&#160;at&#160;December&#160;31,&#160;2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Quoted&#160;prices&#160;in&#160;active</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Significant&#160;other</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Significant</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>markets</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>observable&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>unobservable&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Fair&#160;value&#160;at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>(Level&#160;1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>(Level&#160;2)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>(Level&#160;3)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,&#160;2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>14,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>14,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div>Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;</div> </td> </tr> </table> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div>&#160;</div> </td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div>Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and</div> </td> </tr> </table> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div>Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">There were no transfers between Level 1, 2 or 3 during the&#160;six months ended June 30, 2017.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table presents changes in Level 3 liabilities measured at fair value for the&#160;six months ended June 30, 2017:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Warrant</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Liability</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Balance - December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>14,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Change in fair value of warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(4,500)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Balance &#150; June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_DerivativesAndFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_DerivativesAndFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesAndFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivatives and fair value of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesAndFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6697365888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_PromissoryNotesAbstract', window );"><strong>Promissory Notes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_PromissoryNoteTextBlock', window );">PROMISSORY NOTES</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="TEXT-TRANSFORM: uppercase"><b>Note 8: Promissory note</b></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">At June 30, 2017 and December 31, 2016, the Company had an outstanding promissory note in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000</font>. The promissory note outstanding and due at June 30, 2017 bears <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% annual interest.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_PromissoryNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Promissory Note [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_PromissoryNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_PromissoryNotesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_PromissoryNotesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6620461872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"> <font style="TEXT-TRANSFORM: uppercase">Note 9: STOCKHOLDERS&#8217; EQUITY</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Reverse Stock Split</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On September 16, 2016, the Company effected a one for twelve reverse stock-split of our issued and outstanding common stock and has retroactively adjusted our common shares outstanding, options and warrants amounts outstanding. The Company has presented its share data for and as of all periods presented on this basis. The par value was not adjusted as a result of the one for twelve reverse stock split. All prior period share transactions included in the Company&#8217;s stock transactions and balances have been retroactively restated.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>2017 Common Stock Transactions</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><u>June 2017 Private Placement Transaction</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 26, 2017, the Company completed private placement of units with certain accredited investors. In the private placement transaction, the Company sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,503,567</font> shares of common stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.97</font> per share and five-year warrants to purchase an equal number of shares of common stock, at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.97</font> per share, for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.125</font> per warrant, with one common share and one warrant being sold together as a unit for a total of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.095</font> per unit. The Company issued and sold an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,503,567</font> million units for aggregate gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.2</font> million. The Company incurred $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.8</font> million in agency fees and legal costs. In connection with the offering, the Company reduced the exercise price for the warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 653,187</font> shares of common stock issued to investors in the private placement that closed in August 2016 from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.00</font> per share to $3.97 per share.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In addition, the Company issued five-year warrants to the placement agent in the offering providing for the purchase of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 150,357</font> shares of Company common stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.97</font> per share.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Pursuant to a Registration Rights Agreement to be entered into at the closing of the private placement offering, promptly, but no later than 90 calendar days after the closing of the offering, the Company is required to file a registration statement with the Securities and Exchange Commission registering for resale (a) the common stock issued in the offering; (b) the shares of common stock issuable upon the exercise of the private placement warrants; and (c) the shares of common stock issuable upon the exercise of the warrants issued to Katalyst Securities LLC, which acted as placement agent for the offering. The Company is required to use its commercially reasonable efforts to ensure that the Registration Statement is declared effective within 90 calendar days after filing with the Securities and Exchange Commission, on or before December 23, 2017.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In accordance with the registration rights agreements, should the Company fail to meet the above criteria, the Company is subject to pay the investors liquidated damages. The liquidated damages shall be a cash sum payment calculated at a rate of ten percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>%) per annum of the aggregate purchase price for the registrable securities or aggregate amount upon exercise of the placement agent warrants.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In accordance with U.S. GAAP, a contingent obligation to make future payments must be recorded if the transfer of consideration under a registration payment arrangement is probable and can be reasonably estimated. The Company has determined that should it be required to pay liquidated damages to the investors of the private placements, the aggregate contingent liability it would be required to record would be approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">57,000</font> per month for each month it fails or is estimated to fail to meet the above criteria.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">At the June 26, 2017 private placement closing, and on June 30, 2017, the Company concluded that it is not probable that it will be required to remit any payments to the investors for failing to obtain an effective registration statement or failing to maintain its effectiveness.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><u>June 2017 Exercise and Repricing of Warrants Held by Existing Institutional Investors</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 23, 2017, certain existing institutional shareholders of the Company who hold various outstanding warrants (i.e. C, D, E and F) to purchase Company common stock, entered into warrant repricing and exercise agreements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Series E repriced and exercised warrants</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 168,000</font> of Series E warrants were repriced from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15.00</font> per share to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.97</font> per share and exercised immediately for gross proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.7</font> million. Series E warrants to purchase approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 187,000</font> shares of Company common stock being reduced from $15.00 per share to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.50</font> per share.</div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Series C, D &amp; F repriced warrants</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Additionally, the exercise prices for certain investors of Series C, Series D and Series F warrants were reduced as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="17%"> <div>Series</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number of Warrant Shares Repriced</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Pre-reduced Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Post-reduced Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="17%"> <div>Series C</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>313,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>4.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>Series D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>312,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>9.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>Series F</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>292,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The fair value relating to the modification of exercise prices on all of the repriced warrants was treated as deemed dividend on the statement of stockholders&#8217; equity of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">622,000</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company&#8217;s common stock purchase warrants that are included in the modification is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="6"> <div>Weighted&#160;Average&#160;Inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Before&#160;Modification</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>After&#160;Modification</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>8.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>4.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Contractual term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Volatility (annual)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Risk-free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>1.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>1.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Dividend yield (per share)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><u>2017 Management Compensation</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On March 9, 2017, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12,761</font> shares of stock in relation to the discretionary 2016 bonus awarded to Dr. Glynn Wilson. The fair value of the common stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">55,000</font> was recognized as stock-based compensation in general and administrative expenses. The issuance was based on the closing price or our common stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.31</font> per share, on the day immediately preceding the date the 2016 bonus award was approved by the Board of Directors.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On March 9, 2017, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,220</font> shares of stock in relation to the discretionary 2016 bonus awarded to our former Chief Operating Officer. The fair value of the common stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">22,500</font> was recognized as stock-based compensation in general and administrative expenses. The issuance was based on the closing price or our common stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.31</font> per share, on the day immediately preceding the date the 2016 bonus award was approved by the Board of Directors.</div> <i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><u>Consulting Arrangements</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the six months ended June 30, 2017, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 48,334</font> shares of common stock as part of consulting agreements. The fair value of the common stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">205,000</font> was recognized as stock-based compensation in general and administrative expenses.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806087344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="TEXT-TRANSFORM: uppercase; FONT-WEIGHT: bold">Note 10: STOCK-BASED COMPENSATION</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">271,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">331,000</font> of stock-based compensation expense for the three months ended June 30, 2017 and 2016, respectively. The Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">647,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">545,000</font> of stock-based compensation expense for the six months ended June 30, 2017 and 2016, respectively. Stock-based compensation expense is included in general and administrative expense on the condensed consolidated statements of operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">At June 30, 2017, the total stock-based compensation cost related to unvested awards not yet recognized was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">680,000</font>. The expected weighted average period compensation costs to be recognized was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.68</font> years.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Future option grants will impact the compensation expense recognized.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6640621344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="TEXT-TRANSFORM: uppercase; FONT-WEIGHT: bold">Note 11: SUBSEQUENT EVENT</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On July 6, 2017, the Board of Directors of&#160;the Company&#160;approved the 2017 bonus program for Dr. Glynn Wilson, our Chief Executive Officer and President, and Mr. Michael J. Loiacono, our Chief Financial Officer, Treasurer and Secretary, as recommended by the Compensation Committee of the Board of Directors. Under such bonus program, Dr. Wilson and Mr. Loiacono are eligible for bonuses of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">140,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font>, respectively, equaling up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font>%, of their respective base salaries.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The bonus amount of up to $140,000 to Dr. Wilson is to be allocated upon the achievement of the following objectives:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div>(i)</div> </td> <td style="TEXT-ALIGN: justify"> <div>up to 40% of the bonus amount for meeting scientific, technical and clinical objectives;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div>(ii)</div> </td> <td style="TEXT-ALIGN: justify"> <div>up to 20% of the bonus amount for financial performance and corporate objectives related to our raising capital; and</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div>(iii)</div> </td> <td style="TEXT-ALIGN: justify"> <div>up to 40% of the bonus amount designated to be discretionary as determined by the Board.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In order for Dr. Wilson to achieve his eligible bonus of $140,000, he would need 100% attainment in each of the above objectives<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The bonus amount of up to $60,000 to Mr. Loiacono is to be allocated upon the achievement of the following objectives:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div>(i)</div> </td> <td style="TEXT-ALIGN: justify"> <div>up to 33.3% of the bonus amount for meeting corporate and operational objectives;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div>(ii)</div> </td> <td style="TEXT-ALIGN: justify"> <div>up to 33.3% of the bonus amount for financial performance objectives including related to our raising capital; and</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div>(iii)</div> </td> <td style="TEXT-ALIGN: justify"> <div>up to 33.3% of the bonus amount designated to be discretionary as determined by the Board.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In order for Mr. Loiacono to achieve his eligible bonus of $60,000, he would need 100% attainment in each of the above objectives.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The bonuses will be paid in a combination of cash and common stock at the discretion of the Compensation Committee.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6620871024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>New Accounting Pronouncement</i>s</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i><u>Accounting for Certain Financial Instruments with Down Round Features</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">On July 13, 2017, the FASB has issued a two-part Accounting Standards Update (&#8220;ASU&#8221;), No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features and (ii) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company will be evaluating the impact of adopting this standard on the consolidated financial statements and disclosures.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><u>Compensation-Stock Compensation</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In May 2017, the FASB issued ASU 2017-09, Compensation&#151;Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the consolidated financial statements and disclosures, but does not expect it to have a significant impact.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754839648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET (LOSS) INCOME PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following table sets forth the computation of net loss per share:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Three&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Six&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>Numerator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Net (loss) income</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,893,377)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5,974,140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(4,313,262)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,224,401</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Less: non-cash income from change in fair value of common stock warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,697,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,492,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Net (loss) income - diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(1,893,377)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,277,140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(4,313,262)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(1,267,599)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>Denominator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Weighted average common shares outstanding - basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>8,576,634</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5,935,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>8,503,521</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5,908,917</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Dilutive effect of warrants, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>565,417</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>743,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Dilutive effect of stock options, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>24,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Weighted average common shares outstanding - diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>8,576,634</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6,524,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>8,503,521</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6,652,417</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>Net (loss) income per share data:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(0.22)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(0.51)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>(0.22)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>0.35</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>(0.51)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>(0.19)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NetLossPerShareTableTextBlockTableTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Three&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Six&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Common stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>455,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>251,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>455,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>297,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Common stock warrants - equity treatment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,540,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>213,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,540,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>213,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Common stock warrants - liability treatment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,283,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,068,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Potentially dilutive securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6,998,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,747,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6,998,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,578,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NetLossPerShareTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Loss Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_NetLossPerShareTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780165040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_DerivativesAndFairValueAbstract', window );"><strong>Derivatives and Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ValuationMethodology', window );">Valuation Methodology</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company&#8217;s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the six months ended June 30, 2017 and 2016 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="30%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"> <div>Six&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="30%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="30%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Stock price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>3.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6.12</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.20 - $300.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: calibri; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Contractual term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.28 - 4.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Volatility (annual)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>68% - 151</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Risk-free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div>Dividend yield (per share)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis', window );">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"> <div> Fair&#160;value&#160;measured&#160;at&#160;June&#160;30,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Quoted&#160;prices&#160;in&#160;active</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Significant&#160;other</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Significant</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>markets</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>observable&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>unobservable&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Fair&#160;value&#160;at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>(Level&#160;1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>(Level&#160;2)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>(Level&#160;3)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>June&#160;30,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"> <div> Fair&#160;value&#160;measured&#160;at&#160;December&#160;31,&#160;2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Quoted&#160;prices&#160;in&#160;active</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Significant&#160;other</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Significant</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>markets</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>observable&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>unobservable&#160;inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Fair&#160;value&#160;at</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>(Level&#160;1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>(Level&#160;2)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>(Level&#160;3)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,&#160;2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>14,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>14,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_MeasuredAtFairValue', window );">Schedule of Changes in Level 3 Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following table presents changes in Level 3 liabilities measured at fair value for the&#160;six months ended June 30, 2017:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Warrant</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Liability</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Balance - December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>14,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Change in fair value of warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(4,500)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Balance &#150; June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_DerivativesAndFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_DerivativesAndFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial assets and liabilities measured at fair value on recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_MeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_MeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ValuationMethodology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_ValuationMethodology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787613056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary Of Number Of Price-Reduced and Price-Retained Warrants</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Additionally, the exercise prices for certain investors of Series C, Series D and Series F warrants were reduced as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="17%"> <div>Series</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number of Warrant Shares Repriced</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Pre-reduced Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Post-reduced Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="17%"> <div>Series C</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>313,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>6.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>4.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>Series D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>312,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>9.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>Series F</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>292,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>7.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ValuationMethodologyTableTextBlock', window );">Valuation Methodology</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company&#8217;s common stock purchase warrants that are included in the modification is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="6"> <div>Weighted&#160;Average&#160;Inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Before&#160;Modification</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>After&#160;Modification</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>8.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>4.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Contractual term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Volatility (annual)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Risk-free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>1.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>1.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Dividend yield (per share)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ValuationMethodologyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_ValuationMethodologyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806087344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,963,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815600160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET (LOSS) INCOME PER SHARE - Computation of income (loss) per share (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (1,893,377)<span></span>
</td>
<td class="nump">$ 5,974,140<span></span>
</td>
<td class="num">$ (4,313,262)<span></span>
</td>
<td class="nump">$ 1,224,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Less: non-cash income from change in fair value of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,697,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,492,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToParentDiluted', window );">Net (loss) income - diluted</a></td>
<td class="num">$ (1,893,377)<span></span>
</td>
<td class="nump">$ 2,277,140<span></span>
</td>
<td class="num">$ (4,313,262)<span></span>
</td>
<td class="num">$ (1,267,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">8,576,634<span></span>
</td>
<td class="nump">5,935,000<span></span>
</td>
<td class="nump">8,503,521<span></span>
</td>
<td class="nump">5,908,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Dilutive effect of warrants, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">565,417<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">743,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of stock options, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,333<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted</a></td>
<td class="nump">8,576,634<span></span>
</td>
<td class="nump">6,524,750<span></span>
</td>
<td class="nump">8,503,521<span></span>
</td>
<td class="nump">6,652,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net (loss) income per share data:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1757-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToParentDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToParentDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToParentDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813464224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET (LOSS) INCOME PER SHARE - Potentially Dilutive Securities (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityShares', window );">Common stock options</a></td>
<td class="nump">455,000<span></span>
</td>
<td class="nump">251,000<span></span>
</td>
<td class="nump">455,000<span></span>
</td>
<td class="nump">297,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockWarrantsEquityTreatment', window );">Common stock warrants - equity treatment</a></td>
<td class="nump">6,540,000<span></span>
</td>
<td class="nump">213,000<span></span>
</td>
<td class="nump">6,540,000<span></span>
</td>
<td class="nump">213,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockWarrantsLiabilityTreatment', window );">Common stock warrants - liability treatment</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">2,283,000<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">2,068,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">6,998,500<span></span>
</td>
<td class="nump">2,747,000<span></span>
</td>
<td class="nump">6,998,500<span></span>
</td>
<td class="nump">2,578,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_CommonStockWarrantsEquityTreatment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants - equity treatment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_CommonStockWarrantsEquityTreatment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_CommonStockWarrantsLiabilityTreatment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants - liability treatment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_CommonStockWarrantsLiabilityTreatment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares that could be issued to net share settle a contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that may be required to be issued, disclose the fact that a potentially infinite number of shares could be issued to settle the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)(2),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6620069984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET (LOSS) INCOME PER SHARE - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 16, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">1-for-12 reverse stock split<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815651648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AGREEMENT OBLIGATIONS - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="nump">$ 492,365<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 492,365<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=tpiv_CrucellHollandBvMember', window );">Crucell Holland BV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 492,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Debt Instrument, Increase (Decrease), Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tpiv_CrucellHollandBvMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tpiv_CrucellHollandBvMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813528416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="nump">$ 6.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Contractual term (years)</a></td>
<td class="text">1 year 11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (annual)</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield (per share)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=tpiv_SharePurchaseWarrantsMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Contractual term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=tpiv_SharePurchaseWarrantsMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Contractual term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 11 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed upon price for the exchange of the underlying asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=tpiv_SharePurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=tpiv_SharePurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804972784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability - warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability - warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant other observable inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability - warrants</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">14,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability - warrants</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782771744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">$ 14,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value of warrant liability</a></td>
<td class="num">(4,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799265344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROMISSORY NOTE - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Outstanding promissory notes</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tpiv_PromissoryNotesDueInTwoThousandTwelveMember', window );">Promissory Notes Due in 2012 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tpiv_PromissoryNotesDueInTwoThousandTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tpiv_PromissoryNotesDueInTwoThousandTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813365264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Summary of number of price-reduced and price-retained warrants (Detail)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesCWarrantMember', window );">Series C Warrant [Member] | Number of Warrant Shares Repriced [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Warrant Shares | shares</a></td>
<td class="nump">313,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesCWarrantMember', window );">Series C Warrant [Member] | Pre-reduced Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price</a></td>
<td class="nump">$ 6.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesCWarrantMember', window );">Series C Warrant [Member] | Post-reduced Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price</a></td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesDWarrantMember', window );">Series D Warrant [Member] | Number of Warrant Shares Repriced [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Warrant Shares | shares</a></td>
<td class="nump">312,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesDWarrantMember', window );">Series D Warrant [Member] | Pre-reduced Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price</a></td>
<td class="nump">$ 9.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesDWarrantMember', window );">Series D Warrant [Member] | Post-reduced Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price</a></td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesFWarrantMember', window );">Series F Warrant [Member] | Number of Warrant Shares Repriced [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Warrant Shares | shares</a></td>
<td class="nump">292,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesFWarrantMember', window );">Series F Warrant [Member] | Pre-reduced Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price</a></td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesFWarrantMember', window );">Series F Warrant [Member] | Post-reduced Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price</a></td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesCWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesCWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ClassOfWarrantOrRightExerciseAxis=tpiv_ClassOfWarrantOrRighttrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_ClassOfWarrantOrRightExerciseAxis=tpiv_ClassOfWarrantOrRighttrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ClassOfWarrantOrRightExerciseAxis=tpiv_PrereducedPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_ClassOfWarrantOrRightExerciseAxis=tpiv_PrereducedPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ClassOfWarrantOrRightExerciseAxis=tpiv_PostreducedPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_ClassOfWarrantOrRightExerciseAxis=tpiv_PostreducedPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesDWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesDWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesFWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesFWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813327648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SharePurchaseWarrantsMember', window );">Weighted Average Inputs Before Modification [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 8.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Contractual term (years)</a></td>
<td class="text">3 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (annual)</a></td>
<td class="nump">200.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield (per share)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SharePurchaseWarrantsMember', window );">Weighted Average Inputs After Modification [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 4.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Contractual term (years)</a></td>
<td class="text">3 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (annual)</a></td>
<td class="nump">200.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield (per share)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed upon price for the exchange of the underlying asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SharePurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tpiv_SharePurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818248224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 09, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 26, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>$ / Warrant </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 23, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 638,666<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss Contingency, Damages Sought, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesEWarrantMember', window );">Series E Warrant [Member] | Class of Warrant or Right,Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesEWarrantMember', window );">Series E Warrant [Member] | Class of Warrant or Right,Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SubsequentWarrantIssuanceMember', window );">Subsequent Warrant Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ClassOfWarrantOrRightExpirationPeriod', window );">Class Of Warrant Or Right Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities', window );">Liquidated Damages on Aggregate Purchase Price for Registrable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock Issued During Period, Shares, Share-based Compensation, Gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ClassOfWarrantOrRightExpirationPeriod', window );">Class Of Warrant Or Right Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">653,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_EquityUnitIssuedPricePerUnit', window );">Equity Unit Issued Price Per Unit | $ / Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_ClassOfWarrantOrRightWarrantPrice', window );">Class of Warrant or Right, Warrant Price | $ / Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_NumberOfUnitsSold', window );">Number Of Units Sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,503,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Series E Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Series E Warrant [Member] | Class of Warrant or Right,Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,503,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tpiv_ConsultingAgreementsMember', window );">Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer, President and Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock Issued During Period, Shares, Share-based Compensation, Gross | shares</a></td>
<td class="nump">12,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock Issued During Period, Value, Share-based Compensation, Gross</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="nump">$ 4.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=tpiv_PresidentAndChiefOperatingOfficerMember', window );">President and Chief Operating Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock Issued During Period, Shares, Share-based Compensation, Gross | shares</a></td>
<td class="nump">5,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock Issued During Period, Value, Share-based Compensation, Gross</a></td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="nump">$ 4.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ClassOfWarrantOrRightExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_ClassOfWarrantOrRightExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ClassOfWarrantOrRightWarrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the price per warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_ClassOfWarrantOrRightWarrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_EquityUnitIssuedPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity units issued price per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_EquityUnitIssuedPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate of liquidated damages on aggregate purchase price of registrable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_LiquidatedDamagesOnAggregatePurachasePriceForRegistrableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_NumberOfUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of number of units Sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_NumberOfUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79512289&amp;loc=d3e4724-112606<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesEWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tpiv_SeriesEWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ClassOfWarrantOrRightExerciseAxis=tpiv_ClassOfWarrantOrRighttrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_ClassOfWarrantOrRightExerciseAxis=tpiv_ClassOfWarrantOrRighttrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_ClassOfWarrantOrRightExerciseAxis=tpiv_ClassOfWarrantOrRighttrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_ClassOfWarrantOrRightExerciseAxis=tpiv_ClassOfWarrantOrRighttrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tpiv_SubsequentWarrantIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tpiv_SubsequentWarrantIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tpiv_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tpiv_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=tpiv_PresidentAndChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=tpiv_PresidentAndChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784812704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="nump">$ 271,000<span></span>
</td>
<td class="nump">$ 331,000<span></span>
</td>
<td class="nump">$ 647,387<span></span>
</td>
<td class="nump">$ 544,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
<td class="nump">$ 680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6636068496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENT - Additional Information (Detail) - Subsequent Event [Member]<br></strong></div></th>
<th class="th">
<div>Jul. 06, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Chief Financial Officer, Treasurer and Secretary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_BonusPayableDescription', window );">Bonus Payable, Description</a></td>
<td class="text">The bonus amount of up to $60,000 to Mr. Loiacono is to be allocated upon the achievement of the following objectives: (i) up to 33.3% of the bonus amount for meeting corporate and operational objectives; (ii) up to 33.3% of the bonus amount for financial performance objectives including related to our raising capital; and (iii) up to 33.3% of the bonus amount designated to be discretionary as determined by the Board. In order for Mr. Loiacono to achieve his eligible bonus of $60,000, he would need 100% attainment in each of the above objectives.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Chief Financial Officer, Treasurer and Secretary [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_BonusOnBaseSalariespercentage', window );">Bonus on Base Salaries, Percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Officers' Compensation</a></td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Chief Executive Officer and President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_BonusPayableDescription', window );">Bonus Payable, Description</a></td>
<td class="text">The bonus amount of up to $140,000 to Dr. Wilson is to be allocated upon the achievement of the following objectives: (i) up to 40% of the bonus amount for meeting scientific, technical and clinical objectives; (ii) up to 20% of the bonus amount for financial performance and corporate objectives related to our raising capital; and (iii) up to 40% of the bonus amount designated to be discretionary as determined by the Board. In order for Dr. Wilson to achieve his eligible bonus of $140,000, he would need 100% attainment in each of the above objectives.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Chief Executive Officer and President [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tpiv_BonusOnBaseSalariespercentage', window );">Bonus on Base Salaries, Percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Officers' Compensation</a></td>
<td class="nump">$ 140,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_BonusOnBaseSalariespercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage rate of bonus on base salaries of officers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_BonusOnBaseSalariespercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tpiv_BonusPayableDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the bonus which be payable to officers of the entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tpiv_BonusPayableDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tpiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=tpiv_ChiefFinancialOfficerTreasurerAndSecretaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=tpiv_ChiefFinancialOfficerTreasurerAndSecretaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=tpiv_ChiefExecutiveOfficerAndPresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=tpiv_ChiefExecutiveOfficerAndPresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_RNPM9ILS?_V/@BV'?PZR[Z+U!+ P04    " #FBP=+F5R<(Q &  "<)P
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ME@^SI.(MX!V K@4[P3P8N)!AP%_%('$MV#GFP\ %%7^Q [>686(]1R/FX^6
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M'15S"V;$8Q?!%>L VJ, FY2*W YBEYK$$41,H)*B=[<\D0R=+#[ =ZF-]D7
MQJA<8P3L>)(+GKA+NB2 $ )'!R?*0544"H&.&01T8NTKX0!P32CME("M4KE6
M"817VOJE.EONGBLX.XVV'R#?TVJ?E;7W8!I[L.V.GSMC&FVSAC<VW\%^\XR#
M7.^:]C:Q]U5_\.\'C3D.'S7!^&4U_P=02P,$%     @ YHL'2Y,^B(N- P
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M/K#9D5#[8-ZB;<<U&QUONND%L?D9%Q]02P,$%     @ YHL'2V^\O=ZT 0
MT@,  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q]4]MNG# 0_17+'Q"#
ME[3I"I"RJ:I6:J55JJ;/7AC BHVI;9;T[SLVA*(6Y<7VC,\Y<_$XGXQ]=AV
M)R]:]:Z@G??#D3%7=:"%NS$#]'C3&*N%1].VS T61!U)6C&>).^8%K*G91Y]
M9UOF9O1*]G"VQ(U:"_O[!,I,!4WIJ^-1MIT/#E;F@VCA._@?P]FBQ5:56FKH
MG30]L= 4]#X]GK* CX G"9/;G$FHY&+,<S"^U 5-0D*@H/)!0>!VA0=0*@AA
M&K\63;J&#,3M^57]4ZP=:[D(!P]&_92U[PIZ1TD-C1B5?S339UCJN:5D*?XK
M7$$A/&2",2JC7%Q)-3IO]**"J6CQ,N^RC_LTWQRRA;9/X N!KX2[&(?-@6+F
M'X4796[-1.S<^T&$)TZ/''M3!6=L1;S#Y!UZKV6:?LC9-0@MF-.,X5O,BF"H
MOH;@>R%._#\ZWZ<?=C,\1/IA&YTG^P+9KD 6!;(W2]S!\'^+9)N>:K!MG"9'
M*C/V<9(WWG5@[WE\D[_P>=J_"=O*WI&+\?BRL?^-,1XPE>0&1ZC##[8:"AH?
MCN_Q;.<QFPUOAN4'L?4;EW\ 4$L#!!0    ( .:+!TL0ZVB,M0$  -(#   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;&U386_<( S]*X@?4.Y(VE6G
M)%*OT]1*FW3JM.TSES@)*H04R*7[]S,D3=,N7P ;O^=G8[+1V&?7 GCRJE7G
M<MIZWQ\8<V4+6K@KTT.'-[6Q6G@T;<-<;T%4$:05X[O=#=-"=K3(HN]DB\P,
M7LD.3I:X06MA_QY!F3&G>_KF>))-ZX.#%5DO&O@)_E=_LFBQA:62&CHG34<L
MU#F]VQ^.:8B/ ;\EC&YU)J&2LS'/P7BL<KH+@D!!Z0.#P.T"]Z!4($(9+S,G
M75(&X/K\QOXMUHZUG(6#>Z/^R,JW.;VEI():#,H_F?$!YGJN*9F+_PX74!@>
ME&".TB@75U(.SAL]LZ 4+5ZG779Q'Z>;-)EAVP ^ _@"N(UYV)0H*O\JO"@R
M:T9BI][W(CSQ_L"Q-V5PQE;$.Q3OT'LI]IQG[!*(YICC%,/7,4L$0_8E!=]*
M<>3_P?DV/-E4F$1X\D%ALDV0;A*DD2#]0)!^*G$KYOI3$K;JJ0;;Q&ERI#1#
M%R=YY5T&]H['-WD/GZ;]A["-[!PY&X\O&_M?&^,!I>RN<(1:_&"+H:#VX?@%
MSW8:L\GPII]_$%N^<?$/4$L#!!0    ( .:+!TN49%PSM0$  -(#   9
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;&U386_;(!#]*X@?4!*2M5ED6VI:
M59NT2E&GM9^)?;91P><!CMM_/\".ZW;^ MQQ[]V[XTAZ-*^V!G#D3:O&IK1V
MKMTS9O,:M+!7V$+C;THT6CAOFHK9UH H(D@KQE>K:Z:%;&B61-_19 EV3LD&
MCH;83FMAW@^@L$_IFEX<3[*J77"P+&E%!;_!_6F/QEML8BFDAL9*;(B!,J6W
MZ_UA&^)CP+.$WL[.)%1R0GP-QL\BI:L@"!3D+C (OYWA#I0*1%[&WY&33BD#
M<'Z^L#_$VGTM)V'A#M6++%R=TATE!92B4^X)^Q\PUO.-DK'X7W &Y<.#$I\C
M1V7C2O+..M0CBY>BQ=NPRR;N_7"SN<"6 7P$\ FPBP V)(K*[X4366*P)V;H
M?2O"$Z_WW/<F#\[8BGCGQ5OO/6=K?IVP<R :8PY##)_'3!',LT\I^%** _\/
MSI?AFT6%FPC??%)XLTRP72381H+M)X+=EQ*78KY_2<)F/=5@JCA-EN38-7&2
M9]YI8&]Y?)./\&':'X6I9&/)"9U_V=C_$M&!E[*Z\B-4^P\V&0I*%XXW_FR&
M,1L,A^WX@]CTC;-_4$L#!!0    ( .:+!TLUIG2SLP$  -(#   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;'U386_<( S]*X@?4'+DUE6G)%*O4]5*
MFW3JM/4SES@)*L0ID$OW[P<DS;(MVQ? QN_YV9AL1/-B6P!'WK3J;$Y;Y_H#
M8[9L00M[A3UT_J9&HX7SIFF8[0V(*H*T8CQ)KID6LJ-%%GTG4V0X."4[.!EB
M!ZV%^7$$A6-.=_3=\22;U@4'*[)>-/ 5W+?^9+S%%I9*:NBLQ(X8J'-ZNSL<
M]R$^!GR7,-K5F81*SH@OP7BL<IH$0:"@=(%!^.T"=Z!4(/(R7F=.NJ0,P/7Y
MG?T^UNYK.0L+=ZB>9>7:G-Y04D$M!N6><'R N9X/E,S%?X8+*!\>E/@<)2H;
M5U(.UJ&>6;P4+=ZF779Q'Z>;]'J&;0/X#. +X";F85.BJ/R3<*+(#([$3+WO
M17CBW8'[WI3!&5L1[[QXZ[V78I<F&;L$HCGF.,7P=<P2P3S[DH)OI3CRO^!\
M&YYN*DPC//U-X3_R[S<)]I%@_]\2MV+^5,E6/=5@FCA-EI0X='&25]YE8&]Y
M?)-?X=.T?Q&FD9TE9W3^96/_:T0'7DIRY4>H]1]L,134+AP_^K.9QFPR'/;S
M#V++-RY^ E!+ P04    " #FBP=+^<VX'+0!  #2 P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q]4V%OW" ,_2N('U#N2-I5IR12K].T2:MTZK3U
M,Y<X"2J$#,BE_?<S),W2+MH7P,;O^=F8;#3VV;4 GKQHU;F<MM[W!\9<V8(6
M[LKTT.%-;:P6'DW;,-=;$%4$:<7X;G?#M) =+;+H.]DB,X-7LH.3)6[06MC7
M(R@SYG1/WQR/LFE]<+ BZT4#/\#_[$\6+;:P5%)#YZ3IB(4ZIW?[PS$-\3'@
MEX31K<XD5'(VYCD8WZJ<[H(@4%#ZP"!PN\ ]*!6(4,;OF9,N*0-P?7YC_Q)K
MQUK.PL&]44^R\FU.;RFIH!:#\H]F_ IS/=>4S,5_APLH# ]*,$=IE(LK*0?G
MC9Y94(H6+],NN[B/TTUZ,\.V 7P&\ 5P&_.P*5%4_EEX4636C,1.O>]%>.+]
M@6-ORN",K8AW*-ZA]U+LDR1CET TQQRG&+Z.62(8LB\I^%:*(_\'SK?AR:;"
M),*3=PK3;8)TDR"-!.E_2]R*N?Z0A*UZJL$V<9H<*<W0Q4E>>9>!O>/Q3?Z&
M3]/^(&PC.T?.QN/+QO[7QGA *;LK'*$6/]AB**A].'["LYW&;#*\Z><?Q)9O
M7/P!4$L#!!0    ( .:+!TM=,!!LM@$  -(#   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;&U386_;(!#]*X@?4!*2M5ED6VHZ39NT25&G=9^)?;91
M@?, Q]V_'V#7<SM_ >ZX]^[=<60#VF?7 GCRHI5Q.6V][XZ,N;(%+=P-=F#"
M38U6"Q],VS#761!5 FG%^&9SR[20AA99\IUMD6'OE31PML3U6@O[YP0*AYQN
MZ:OC43:MCPY69)UHX ?XG]W9!HO-+)748)Q$0RS4.;W?'D_[&)\"GB0,;G$F
ML9(+XG,TOE8YW41!H*#TD4&$[0H/H%0D"C)^3YQT3AF!R_,K^^=4>ZCE(AP\
MH/HE*]_F]$!)!;7HE7_$X0M,]7R@9"K^&UQ!A?"H).0H4;FTDK)W'O7$$J1H
M\3+NTJ1]&&_X88*M _@$X#/@D/*P,5%2_DEX4606!V+'WG<B/O'VR$-ORNA,
MK4AW0;P+WFNQW=UF[!J)IIC3&,.7,7,$"^QS"KZ6XL3_@_-U^&Y5X2[!=V\4
MWJT3[%<)]HE@_X;@\*[$M9B/[Y*P14\UV"9-DR,E]B9-\L([#^P]3V_R+WR<
M]N_"-M(X<D$?7C;UOT;T$*1L;L((M>&#S8:"VL?C73C;<<Q&PV,W_2 V?^/B
M+U!+ P04    " #FBP=+?T[1<;,!  #2 P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q]4V%OW" ,_2N('U!R7-96IR12K].T29MTZK3U,Y<X"2J$
M%,BE^_<S),W2+ML7P,;O^=F8;#3VR;4 GKQHU;F<MM[W!\9<V8(6[LKTT.%-
M;:P6'DW;,-=;$%4$:<5XDEPS+61'BRSZ3K;(S."5[.!DB1NT%O;7$909<[JC
MKXX'V;0^.%B1]:*![^!_]">+%EM8*JFA<])TQ$*=T[O=X9B&^!CP4\+H5F<2
M*CD;\Q2,+U5.DR (%)0^, C<+G /2@4BE/$\<](E90"NSZ_LGV+M6,M9.+@W
MZE%6OLWI+245U&)0_L&,GV&NYP,E<_%?X0(*PX,2S%$:Y>)*RL%YHV<6E*+%
MR[3++N[C=+._F6'; #X#^ *XC7G8E"@J_RB\*#)K1F*GWO<B//'NP+$W97#&
M5L0[%._0>REV:9*Q2R":8XY3#%_'+!$,V9<4?"O%D?\%Y]OP_:;"?83OWRC\
M1_YTDR"-!.E_2]R*>:^2K7JJP39QFAPIS=#%25YYEX&]X_%-_H1/T_Y-V$9V
MCIR-QY>-_:^-\8!2DBL<H18_V&(HJ'TXWN#93F,V&=[T\P]BRS<N?@-02P,$
M%     @ YHL'2QASKT2T 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL?5/;;M0P$/T5RQ]0[WI36JV22-TB!!)(JR+HLS>9)%9]";:S*7_/
MV$E#@(@7VS.><^;,>)R/UKWX#B"05ZV,+V@70G]DS%<=:.%O; \&;QKKM AH
MNI;YWH&H$T@KQG>[=TP+:6B9)]_9E;D=@I(&SH[X06OA?IY V;&@>_KF>))M
M%Z*#E7DO6O@*X5M_=FBQA:66&HR7UA '34$?]L=3%N-3P'<)HU^=2:SD8NU+
M-#[5!=U%0:"@"I%!X':%1U J$J&,'S,G75)&X/K\QOXAU8ZU7(2'1ZN>91VZ
M@MY34D,C!A6>[/@1YGIN*9F+_PQ74!@>E6".RBJ?5E(-/E@]LZ 4+5ZG79JT
MC]/-73;#M@%\!O %<)_RL"E14OY>!%'FSH[$3;WO17SB_9%C;ZKH3*U(=RC>
MH_=:[K-#SJZ1:(XY33%\';-$,&1?4O"M%"?^#YQOPP^;"@\)?OA#8;9-D&T2
M9(D@^V^)6S&W?R5AJYYJ<&V:)D\J.Y@TR2OO,K //+W)[_!IVK\(UTKCR<4&
M?-G4_\;: "AE=X,CU.$'6PP%38C'.SR[:<PF(]A^_D%L^<;E+U!+ P04
M" #FBP=+6(GZ1[0!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q]4V%OVR 0_2N('U 2XK599%MJ.DVKU$I1IVV?B7VV4<%X@./VW^_ KN>U
MUKX =]Q[]^XXTL'89]< >/*B5>LRVGC?'1AS10-:N"O308LWE;%:>#1MS5QG
M0901I!7CF\TUTT*V-$^C[V3SU/1>R19.EKA>:V%?CZ#,D-$M?7,\R;KQP<'R
MM!,U? ?_HSM9M-C,4DH-K9.F)1:JC-YN#\<DQ,> GQ(&MSB34,G9F.=@W)<9
MW01!H*#P@4'@=H$[4"H0H8S?$R>=4P;@\OS&_C76CK6<A8,[HW[)TC<9W5-2
M0B5ZY9_,\ VF>CY1,A7_ !=0&!Z48(["*!=74O3.&SVQH!0M7L9=MG$?QAO^
M>8*M _@$X#-@'_.P,5%4_D5XD:?6#,2.O>]$>.+M@6-OBN",K8AW*-ZA]Y)O
MD^N470+1%',<8_@R9HY@R#ZGX&LICOP#G*_#=ZL*=Q&^^T?AS3I!LDJ01(+D
MOR6NQ>S?)6&+GFJP=9PF1PK3MW&2%]YY8&]Y?)._X>.T/PI;R]:1L_'XLK'_
ME3$>4,KF"D>HP0\V&PHJ'XXW>+;CF(V&-]WT@]C\C?,_4$L#!!0    ( .:+
M!TM//0;6M0$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;&U3
MVVZ<,!#]%<L?$+.&M.D*D+*)HE9JI56JML]>&,"*S5#;+.G?US:$HI07VS,^
MY\S%XWQ"\V([ $=>M>IM03OGAB-CMNI "WN# _3^ID&CA?.F:9D=#(@ZDK1B
M/$D^,"UD3\L\^LZFS'%T2O9P-L2.6@OSYP0*IX(>Z)OC6;:="PY6YH-HX3NX
M'\/9>(NM*K74T%N)/3'0%/3^<#QE 1\!/R5,=G,FH9(+XDLPOM0%34)"H*!R
M04'X[0H/H%00\FG\7C3I&C(0M^<W]:=8NZ_E(BP\H/HE:]<5](Z2&AHQ*O>,
MTV=8ZKFE9"G^*UQ!>7C(Q,>H4-FXDFJT#O6BXE/1XG7>91_W:;[)TH6V3^ +
M@:^$NQB'S8%BYH_"B3(W.!$S]WX0X8D/1^Y[4P5G;$6\\\E;[[V6A^Q3SJY!
M:,&<9@S?8E8$\^IK"+X7XL3_H_-]>KJ;81KIZ38Z3_<%LEV!+ ID6X';Y%V)
M>YCW1;)-3S68-DZ3)16.?9SDC7<=V'L>W^0??)[V;\*TLK?D@LZ_;.Q_@^C
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MJ5@,#I5QV[W=JVE@)L/(?GX+R/(@Y7\ 4$L#!!0    ( .:+!TN9R$,6QP$
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MUCV?T.1**0LNE<V-RZ5Q4SP; BKKM[=NK\>W/!I6==.8DOE?D7\ 4$L#!!0
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M]S9=>3*\&>?7S)9?JGD#4$L#!!0    ( .:+!TM$@S5 . ,   0-   9
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M;+K#K91*:.^U'M_;ZRM)/\C%5IE7KM^KMB]O!TH>NCM'T%]\9O\!4$L#!!0
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M9S--RF0X[.=/P):?6/P#4$L#!!0    ( .:+!TO";"V^10(  )<'   9
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M"=S+.8=S""8?A7Q5+8!&[YSUJL"MUL..$%6UP*FZ$P/T9J41DE-M2GDB:I!
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MO4?.J;2_7GZ2BC.GHJTP\MF.967'QNE?:..$R!&BCA F#PFQ(\17 GY(P(Z
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M+&*B!2P>V#+@]/KR<G9W.;V"79]<$57<S:Y^FEZ=SJ;STF"4Z"?)UO7D'W\
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MH1OG#HTC%51(H/3IZNJ!\=3/+ARXD3GX3H<1+J2M[2JXWU4W?2?0CPP@H70
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MZ5"O75?/9>FINK#VFW1S8*S[V)UU7_\$4$L#!!0    ( .:+!TME0E[)B $
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #FBP=+H<"J-NX    K @  $0
M            @ &9 0  9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #F
MBP=+F5R<(Q &  "<)P  $P              @ &V @  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( .:+!TO+T]!;9 (  !4(   8
M  "  ?<(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #F
MBP=+!,X'76$#  #R#@  &               @ &1"P  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ YHL'2\2N>!RJ @  2 L  !@
M         ( !* \  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( .:+!TN(6]=TU0,  "$1   8              "  0@2  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #FBP=+KD4BJDL#  !E#0
M&               @ $3%@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ YHL'2Y,^B(N- P  > X  !@              ( !E!D  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .:+!TNLR>ZLL $
M -(#   8              "  5<=  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " #FBP=+\[.SR+ !  #2 P  &               @ $]
M'P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ YHL'2V^\
MO=ZT 0  T@,  !@              ( !(R$  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( .:+!TL0ZVB,M0$  -(#   9
M  "  0TC  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
MYHL'2Y1D7#.U 0  T@,  !D              ( !^20  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " #FBP=+-:9TL[,!  #2 P  &0
M            @ 'E)@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( .:+!TOYS;@<M $  -(#   9              "  <\H  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ YHL'2UTP$&RV 0
MT@,  !D              ( !NBH  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " #FBP=+?T[1<;,!  #2 P  &0              @ &G
M+   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( .:+!TL8
M<Z]$M $  -(#   9              "  9$N  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ YHL'2UB)^D>T 0  T@,  !D
M     ( !?#   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .:+!TL\.43*H $  %X#   9              "
M 58Z  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ YHL'
M2T2#-4 X P  ! T  !D              ( !+3P  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " #FBP=+]HL=[6 "  #R!P  &0
M        @ &</P  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( .:+!TNQTTHGK $  )4#   9              "  3-"  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ YHL'2\)L+;Y% @  EP<
M !D              ( !%D0  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " #FBP=+.C&*=Z,"   B"@  &0              @ &21@
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( .:+!TN&C'.M
M'@(  #\'   9              "  6Q)  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ YHL'2T#1C+/> 0  I 0  !D
M ( !P4L  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #F
MBP=+=+22BLP!  "Y!   &0              @ '630  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .:+!TN/W&<JE0(    +   9
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M970S-2YX;6Q02P$"% ,4    " #FBP=+"O$>[VPE  "AFP  %
M    @ '#7@  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " #FBP=+
MS*%;)DX"   %#   #0              @ %AA   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( .:+!TLKNM%L.P,  %H7   /              "  =J&  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #FBP=+94)>R8@!  #^%0  &@
M            @ %"B@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " #FBP=+"3F(>YD!  "!%@  $P              @ $"C   6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     +  L .8+  #,C0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>78</ContextCount>
  <ElementCount>133</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>33</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>105 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/CondensedConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>107 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/NatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>108 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/BasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>109 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/LiquidityAndFinancialCondition</Role>
      <ShortName>LIQUIDITY AND FINANCIAL CONDITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>110 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>111 - Disclosure - NET (LOSS) INCOME PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/NetLossIncomePerShare</Role>
      <ShortName>NET (LOSS) INCOME PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>112 - Disclosure - RESEARCH AGREEMENT OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/ResearchAgreementObligations</Role>
      <ShortName>RESEARCH AGREEMENT OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>113 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurements</Role>
      <ShortName>WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>114 - Disclosure - PROMISSORY NOTE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/PromissoryNote</Role>
      <ShortName>PROMISSORY NOTE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>115 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>116 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StockbasedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>117 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/SubsequentEvent</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>118 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>119 - Disclosure - NET (LOSS) INCOME PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/NetLossIncomePerShareTables</Role>
      <ShortName>NET (LOSS) INCOME PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/NetLossIncomePerShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>120 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsTables</Role>
      <ShortName>WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>121 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/StockholdersEquity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>122 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/LiquidityAndFinancialConditionAdditionalInformationDetail</Role>
      <ShortName>LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>123 - Disclosure - NET (LOSS) INCOME PER SHARE - Computation of income (loss) per share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/NetLossIncomePerShareComputationOfIncomeLossPerShareDetail</Role>
      <ShortName>NET (LOSS) INCOME PER SHARE - Computation of income (loss) per share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/NetLossIncomePerShareTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>124 - Disclosure - NET (LOSS) INCOME PER SHARE - Potentially Dilutive Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/NetLossIncomePerSharePotentiallyDilutiveSecuritiesDetail</Role>
      <ShortName>NET (LOSS) INCOME PER SHARE - Potentially Dilutive Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/NetLossIncomePerShareTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>125 - Disclosure - NET (LOSS) INCOME PER SHARE - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/NetLossIncomePerShareAdditionalInformationDetail</Role>
      <ShortName>NET (LOSS) INCOME PER SHARE - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/NetLossIncomePerShareTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>126 - Disclosure - RESEARCH AGREEMENT OBLIGATIONS - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/ResearchAgreementObligationsAdditionalInformationDetail</Role>
      <ShortName>RESEARCH AGREEMENT OBLIGATIONS - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>127 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Valuation Methodology (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionValuationMethodologyDetail</Role>
      <ShortName>WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Valuation Methodology (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>128 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>129 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueDetail</Role>
      <ShortName>WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>130 - Disclosure - PROMISSORY NOTE - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/PromissoryNoteAdditionalInformationDetail</Role>
      <ShortName>PROMISSORY NOTE - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>131 - Disclosure - STOCKHOLDERS??? EQUITY - Summary of number of price-reduced and price-retained warrants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StockholdersEquitySummaryOfNumberOfPricereducedAndPriceretainedWarrantsDetail</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Summary of number of price-reduced and price-retained warrants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>132 - Disclosure - STOCKHOLDERS??? EQUITY - Conversion Option - Valuation Methodology (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StockholdersEquityConversionOptionValuationMethodologyDetail</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Conversion Option - Valuation Methodology (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>133 - Disclosure - STOCKHOLDERS??? EQUITY - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>134 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StockbasedCompensationAdditionalInformationDetail</Role>
      <ShortName>STOCK-BASED COMPENSATION - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tpiv-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>135 - Disclosure - SUBSEQUENT EVENT - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/SubsequentEventAdditionalInformationDetail</Role>
      <ShortName>SUBSEQUENT EVENT - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tpiv-20170630.xml</File>
    <File>tpiv-20170630.xsd</File>
    <File>tpiv-20170630_cal.xml</File>
    <File>tpiv-20170630_def.xml</File>
    <File>tpiv-20170630_lab.xml</File>
    <File>tpiv-20170630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>55
<FILENAME>0001144204-17-040922-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-17-040922-xbrl.zip
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M*_-FK*611T-<^4.&#7U:$A5=(KI1!"-S4 R+9YP+KU0ELS"A=W/]Z^W9#1W
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M"SNQ8165?E2DS1M2BO5>P$3(7-]S434E]&?%5DT)'8\HFY)WK&BH!W+>M-3
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MHZJ"6?+,3864O6^DTA!ZH+YFVM2XU%P; NJ-?4=KESAB07N>!['M0.Q6MLX
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M9[W:C%4DY&>96C\LY03O?64$S+P]%-OT-VT,++\QIH"_0L/E9KLF+<KZ( @
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M;;Q ,Z<DNT<AR6V,O)53DE@6F']).A!X[<V\VSE%V:@$*+<6Y3;VW1&B+,K
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MY"B$CC!S4 (\BM$C[".)7QDXD9^58;16 BDM:BM_/2N7G[<Y@4O,67N!V9Q
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MR;0 ^.6$]/O]Y;&"-'-GP72:1X@0=D:>..-W<H;'V'"4MW'DHRA%/OXAC</
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MXQ0=S9%E#'0N#R5C0)&I/U'&0 > Q8+QM3"60 &8H\\8Z "P7=1@C T&6,9
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M8X27SDDP$[A!ZG6(!0K/9V)HVM G:Q.Y 8L1H(Q5Z'9FML$(87A>FA!$IUR
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M+XM?7WOW,/H"X)8?[Y9"@;YO]540O49<FN+S%J9A$BSBTQCN4IOG?)U[:3Z
M]R:]2>XW2>Y%)_'=I#3)\0T\;9QK.J/CBXPF/&U\&Y1C<YRSW/8>5&8T(_SS
M->*AQ1W\E,,X@$')'Z:6V%72.;''Q$3B;A._U6&$C7.2MN7-]^$368C>?//N
M#9$(_^8?EXE_V,$XG\?(..1A?ES&VR3=$>,^O\_PLI27'1'V2??_Z$%;2E_*
MWV(UA5ER2'W82W8ZJFV>O/L^/*$U#U'BI1W&9Q_77_Q'2080':"$H$$)?BUI
M_^LO]/L=H>9I>PJ\U"\Y1/]42%6T>.TG:$'>YV<M ;=ILNL]Y@4K2>^!:4Z6
M#JH*F8@\&?1?/21/KP,8(KG>?HW_@1'W]=F;M\6J_B7Z5<5)@X&-=U_K9P-F
M\N;&D*7@6@BF%H)(:XOPT1GZ$C'ZX]X7)%LONR>L'[*S!\_;8Z1\^QI&>5;^
MAABI!F2*7_\#K?\YQ Q=1%Z6K;;K//%_FW\*,PYN-&B,@4>'_RZ"2!.0; %I
MA*P/:B: SF"^\\8J:IIY$[C7QD\)_I[@F=I,;E"W"M-(FU@QAP5W0A.(_^Z&
MS6N.(\_.L8,XU<S.T><"_,FKR'L03&VGC=&Y[?+7G=SJ[P WL#N[W+%L3J]D
M(*?6W.K,?8D,B4*%.VVMZ'*77Z%2TX9HGQQ@[Y<C^LT=;9ZB2X9Z:D1<A9GO
M1;] +[U"O^'M7*2MK:""Y5F("]H4X+: -'8#&8)1YV%#.N1FT$'AJ8^/5GN+
M"&GSK<)(84*<0PEG],4X$0[]5$BA)_<[^!#B WN<WW@[T<+";VH4'P)NN] H
MW"UU.X ;V@6%;*";>%"/\K10N$!83+UH&0?PT]_@48H%IJT%,+#\"M!0- 2D
M)4!-7<"#8+190$B'>BI$7!S2M+6$R7>>XN9&<2'AFG$LT*:M;88;>U#5T#<1
MHC?NTYJ-JS""Z07ZZ$.2RHU&IZ4%D]'E56 P2#-0MG/!6G 'F;45DA&>"@2;
MU,.!#>OC[CYA!K^0H=/&Z,1W^>M.>?%W0!O8G6ON6#9G63*0$^\-DMTNB8G7
M<OWHH3E:'7(<](&YD6\4I(0V=@UR241;"$)%O= S0 E!@](%&Z$S1YSMA?8$
M6;B>66VOPMB+_1"=CY(L5%PD]R.W=VDCEZJ+P(H,7X-4A*"D=.(Z^92)$UZ1
M:,^:!4"*+I=%#>V!3'2A7,-)>HL\F-%^5X$#N;6"<>YMMPX0S.&V>=MXF>R\
M,)9@E]?8.'ZY'*MNA6E#JT@>GV^3F!;CI(MK%4@,VF28AC";WZ(N(3H%!X2E
M#W!W#U.9@991F;?64AD88TA:@SFHVI= HB1V3;D)48S:>36^&*.O"R[36G)^
MDI8(J"QIB4@& ;3.'=:2B44QKR52?/&U1 -<%O;WUV$,E^B?6H& C<;V]OE-
MCB6[9]P,D'9N;/C'8MO*SI]!B7#W+X"(.63/LPSFF8;3I-O0.*(93IE0,=)
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MZ<#''/[O8.Z%,0P67HJ#TK.Y[Q]VAP@7P+F$V] /96<1'6+C6J$E$7MC18E
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MBSVDH^]I>%VX%-;Q7O.NQ W-A.^$YV4J"6RBOX,BE0)P(615!Y0!;!(:%_1
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MZ-CBAUI5!V5$YI/PR"1@<L_4>Z6RM5,+C'HZF'0RFG,Q8,EIE*S%("X?E$J
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MVR)KAD>/Z6;9XHM'G/@FP[F5KN$38O*=AE6Q:4!ZSDM+Y6WKMT0#6BJKA/\
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MOW99W_PBR7+9V6Q8M^:#VX:- A/^5G>'"Q#7'0+<(U:&HL\9:.:BIUGG<<>
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M#)_" ,;!'3H[ZQA<91?V;*A:.K%9! UB7&.<DH.2'N .;.Z"!@A9R7 ,812
M%SAA&:D2^M)NI(]!D:R8*4UE$UJ>7IIF, -X$C\@R.XNX7V^01^;?PJER<"Y
MS<WG!>=SS3QM1<W.<#N &\X ;@I^Q8T=.##(1IY)'ZX<=GN(46;S$Q%81XTP
M?Q\?-\ZD[I//@ H[=I/U-=/9EIE<E_$V27=DPZ7Q4$"[!_,^=6W9I$E^JVS(
MH$$\_5V5UL9E)!&#5HHTFL48"QS67=E7LYY096X03L&IT:<[F*O;-,&;D.#\
M^#&#P3+FI%"^2.(\C _H=ZL]I%5+9%N$H1W;>-8S;"1XCWR($I==XG(&+W"O
M". ON<G,9Z#N&]2=6\X ,/ZP$%7?-X?E4 X++XVY?2,PCIIP7@V-IB,&U^[P
M(0ZWH>_%^=SW<90*KFF:1*&/&-7)#JK;@?F56U<R9E6K"4%-"4I2$\D\=:OW
MGBSBQP\?YG>_@-456"_?WRROEA?SFPV87URL/MYLEC?OP>WJ>GFQ7*SM:VL_
MA#(K]@GPM%Z"FSX@XI<3?I\FF6RI/KU+5\IQZTC?IR@W[4]6E9OT:G4+/O)(
M<(MQ2Y*T&0_@&8!YS8K</0%O+_FDSB(KH;&>?E*VSO#R3SJ2"GN@&'-T$$2K
M"KZ/W22M6N%%@)G=G4$?Z6X6&["\N5A]6( 7UZOU^B6X7=R!]8_SNX5]:Z'4
M%E6.4/MK?)5]N<L:2:0YCX,BG0 )L-+:<I_:H\7LW'UEE^7KYCV\H$E)<3:N
M*LG&AFJG&^9FO)%HWV;C\:AR<%#Y89SLT*$3_USX)W#*,O\025ZN-.U9[J ]
MLP@D^S9PH 41IX,?8#Z&O%Z!.4ZL4AGHUE>41K!_%X;?L_22CN=/P^2M#9,A
M.Z;UL&5DZ6P^CS4CB[DG.OW5JOU6YU2=,K>5NH,91$."2PI<PB<8)7N2-$U]
MOZ@B-+XQ4DK"KOJ4H%CB*Q*G\OGKS4]W/>HS.>:QUF0I#N@K3Z0BR39_1EI2
M5P/2V;@/Z-,:0D^17P3>61.Y,UKWI.@0E#VV2@!;7_0F&8W%>C&_N_@1S-_?
M+18?%C<;L#J_7KXG=;,<<+@/1KY(P0?"WL:176";ZC2=^"X/FZE-@A9.' AP
ME:2K_!$=F/0K:@W_B,6#_0@C)#NB"=>]QA?H13O^!DFV2;\"T/\!^AUWGN*-
M#RSQX6Y<5/55O@SZKQZ2I]<!#+'>?8W_@=7MZX:ZH5_]XQH^>-$BSL/\* A3
MY;8R!G@^CVR]%=0"T";6@U$EPUJB13FF!E/=^'YZ@$'Y# .'1QS2E"X1N!P\
M_4%B1W4[,)^L1E<R)AL-)00-2ONFJ]\\,?E33I@DF\D@<.(*G;A5!:$#*2 Z
MDNAF?P"8SJG#I=XDJ7,^B&?(-N#Z'29[].$(#/6.1W)$.GDZ'"0N+J#\X^KZ
M<G&W_M.7WWWU]ELD\-\_+C>_N*IR/4Y^)V)T2')1WN/[Q2>8^F$F>@BE2V@X
MJ:B&)-J)%?"#24II?7O:;YK:.1O[S=$ &*UABO.[%5_Z '?W,!4AA]_6+%@$
M_#+&AC0#BPH?O]*FMN$@&^X6 M1C/632#_<9_/V WY'3_G%4&7Y9KYA_%9EA
M*"BE8)_QE!05+DH:9P"B-S5MK/29%X,'WF<O#32>Y7;:F3^^=OAD3JGX[^KG
MMX/YU JO&8E9HP=J'@Z8<[,8!.80>XN&\L;;J0#;;F8<KQTNF?RUZ"> _^X,
M 'C#VIU_\9@:/*QR8ZB;I<K.CVPE,PS<&KUQ4$JB?%H^S>?,'X&G&34F-)F>
MC:E]DS]G-V.)W9/;Z(EY0EUA#M>3*XJ%_$<T8],UOK#Z2KCMUJ*RE^6(*X,L
MWQLEF %" KY2;+K-Z'$_:9IO)A-\AP@:">M"FK#N12&>2QF Q' 3)OU18<VN
MTKP[26G>.:4T[TY0FG?.*HU8FAY*\\Y1I7G77VFX6',_#ZH@:R!];$BJ_:)5
M]A+2_^JHW[3?_VSRI/8=UY'SILK2ILZ*)\2@9 .\*!EQ)3&?X<&^>,1[2_RB
M:(N'_8GD94RV99&HND*40];*A)Z/E9MT@)(/\'O?HL$+LRQ)R>U<=HG-]>8Y
MV3PFA\R+@\TSC)X4/O!>79CUA_>3CG$;5=2 UF=!],@> -0#*+L M(^I=R Z
M[W,F$!8I.X+,Y(<2K2<[KLREL7N/$U2S=0=RLEZ:3%KVW,C,DB8Q^J=/_1<D
M3\N1_K].2$S_KBPD)NLM+?OR[+F5EZC5R8SF*3J"7XO_.A,D,[7D]K<<IR*9
MS20V!,;F[X64+GWKSGBE.[EQ.^2,+UG/"^R&_W:>93"7WF87#<Q?8Y><,5?"
MY ]62W6*6-M@:N!)&#1Z4=V:6^:&FC.Q!NM");M=F-.*@OA)&3&9,,;)W21@
ME%*9KP@EE8%7G+EH73R@;+2W6@6JGQBK#Q^6&_SX<0WF-Y?@8D7R#BYNW$@Z
MJ($KINR3+J@&%7Z-<;;557KKI7GQPR;UX@RG5TWB;>EVP*^_]FGHPZ"L;3W/
MEG%PH+L(T2%^K-Y-%Y =:4S8>JRD+[!* >X:E#\W.I\URI.0QXKT V48'=+0
M#-3?L*&=TP[15<L+F);B/S?$#Z<67R_7AQ,C )X?0_\1^#B,.=R&J!WZ<YS$
MS3S),4[8] 2SO)TU^97M["*C6IY.D>#QS8ZY'4B1PCE^6,9^LH/7\NRLW-;&
M=QQ\GKO0KEH!V@R\P VGNOG0VC'K,4[2\F#\@D21==WDED("E.Y60HD2.X7)
M(-G9--YP%K<;P:J^N*#O.=/6/0:F)[.P@?YC'/Y^@-FU1NG6Z3]MM1#:1*,I
M*:#6N(QJE8O$:T[S,S-0?0/4'W&FW.P??!"M7)).K-VR"FK3J[;!I%'X>EP9
M@=5J93ZQ4XM')CD1N>!W(9!X.)]&DR:Q,\^D01)-NSE\?O ^A;O#3HG03COC
M&.WRV9W]XN].Q/R-PZM)K')1T$6K! (&\1K&>GAMMS./UPZ?# ;HW]W ZRB\
M&L4K#P4,7L40&!0:!3-<SY4DK'L,X;8ZFJVVV]"'J2HL2I/<=$B4KE1L"$U!
M2>\>,"VH_00%M0/0.67R.H$S)\R<]<)!9$\]:MT@=8^NE W2D+U/U: BI/BD
MHD'&<[2<C@3-:CK]8&"PF,YN'R5'"-<P?4):R><0'1VQ0QW2=V\9N5UO_OTB
MR?*;)/\%YC@:]R$._P4#B:9,^$WSQ7PF'#_FR6;Q+5!\3*);U1?I T]22K/^
M.\ ?Q"&<X AS4'_3<LD=@T/Y$?M"BC^#3%#Q"_V0Y3_8MU"3ZRA3 LB,@OX!
MK!PU[E=)6OP*MWMKP_0)&/GCV$/12!LWDM6C)IP?N<',']1X:H_[ISWT\5@^
M0YQ4#%_-(]:]!PCV=+@8RYKA9-/W$#0L\8LC]-+LY1_9YDHMAC%#K&$NS%GG
M2\3,$V(528$.B]75ALZ#!36I<0NH(4U7=QHDQ"W0N"US)T?G"7+]/+^[PV61
MKY?S\^7U<O,+B52\FB_OP$_SZX\+\&$Q7W^\(R4<'(A9U,5A5TO[@="<7OU<
M6.(Y-<0W!^QP66UI8=?5(<]R!#9\.:C.T]R_*^-Z=X*T#%[+I:OH ]!.<& :
M[08T^IG5A1(529Y-:>@((]"H?>C (GPJ@+L*.@R]]BH;=\H):NBI=@_6JQZ+
M95,7#^96*W5$"4^7$Q?$>Q'A"$$0TGA!M',&&:EA&'BYYX!"]@2HJK2P%CH-
M/J2EH;/+,GH8+^9E7#&)BM%0P!Y]F'\ZVT,^42S_L@ZMQAO5*NR:T#NCA ,E
M/2.BABU1&Q'F54RY?87L#5GFJ>QI>+5>LE*G"M.U1HSL.-V[4OZR[ZAH%\GL
M52SLVJ4(S3'QHUEX<P!XIJH21LM4"=^9LTV,U@?K<,=L (NR8-9C%44CV:P*
M)A[&(44YTH,/H^C')$(#$YP_R8-F1*T-E]\0\<R\9*4-0=$2G/_D2OR+?-C;
ME34TQMRD1_4^7\9HX28/^[IYKY 1HOY?=.*0^E;U.['@9>TA(>OEN,]!33WC
MY:>; 41K?_GJ/Y.L=_*T:1QBKG"\5[&-]*(BWFN3TF<)*5HMU_CKN9<>%8:L
M=S^&35Q_.=F$@#@"L.JCC "<@:H;LA>K.G+&-)XXQ6VC.6A^AP)T\0GZ!^RU
M+SZ,<WF708L:N-0AMP!'+:GX**Q(JSA4#+TZ8M4EZ.E/'HNXOC,W &CG27S(
M5C&^LUU[D8=K+^TAFO,X]QYX26YUB,R"2B5!%TJD/4AB[**%H"29W58T%I,[
MCB0+F%P8K90,?:7!C__1@14G54!'4%"W!:F7D^P+]Z6\.%H&9$6G^"\)U13K
M612T]*FE\3V4R8WH\QOX3/YR:JQY@]ZIR/*F7"?$D>/4A93>:G&6$P7\&(=(
M[4)".*/I3NR?+7JAL$^<NP""!G.*%.:J&08E42=^<_-91?A<,VE%BF:TMF^S
ML7U(R0:>2=*A''6#!KDJ=;AX0O^G<W,@)C%O=L7<2TI5DK;.)*685@:C9E6!
M)<:2:@%IZ"'DUCOBI/F7,//3<"\PB/+F%@X>7*[YV_2BZ0PT&EO?GFOQW_@K
MWFOCS3G=B=-L9_=HKTZ[P1=NY4Z\; G)?8,+VW(QPM@-N0I>AHLS9G0C<XN3
MHY7!*3+3+Z:Q4R91P#]C.&D0X[+8AI+F=525]:*'NE)X$1*")+(C$5('M+=V
MP.JK<,2M/J@&T1 O)Z_:>_$3^:+0OZDF-.S9U)"$\6EB&FPERY+<^+D.IIM5
MOR&D-M>(4^1:YB1+9M.34ZE"D373MI=&&WAMWVP_U!E,TY\F/H1!=H6D+$N@
MK[8X77$2DV.P9*G0H#6?S%]#'D[I%T)#TT)6U>V1>E$Z0 AM+B&G2-64@P3:
M9C,0PQS_N WCH#ID;Z$#[AIM&#(5#OIA<*H8I,O"(BYC' E%[*+LG*TF,1JC
MI.">V=,7S4&CO2/G5-VY:$8UZ4_$@/W*=?C[(0R\' :7WLY[@-DJGC\\I/ !
M_>KVD'K^HY=!LA*0AXL/(8Y,1:>(-4YK2 )R11N:,7HVN^,992R8O+Y5IZ#H
M%5_V5/V"JN/B:$!?.%=]@[ISBY=XMD;&ZL!H[28G&9D-_ZHPJ@<LJ ?,JP9L
M7PX8W9R2U.[U>&75%VUO5<>S.:V][-@&Q]QF%^?*KFMO' OVU\D!;<;)Y8YD
MLZM!:WRSJR,/-_]Y@VA6&05*5UQ*VM\2:D]6=TO8<Z8,NN/\1Q@<(K0_)3O3
MQR3"N_ %TJ:<5& L*Q<4Q\-,)TG @#[-N_,&R,\XRHJ^R/OE1F_T3$/[)(4\
M9W6]E=))DH%?-\14.Y-_8-21.>QV.)ARM2V?>*-_$7-\=@=Q08R@"'VCO\D]
MM->MB]+8U_O!6L(X(\=1D0&;_RH;^0>8/R9!$B4/1X) F89K4YK=O&O)TL5D
MG>V^0>6,%HXLE\UM\DE2H :'R$M!$&9^E.#X9&Q5GRK9=G5?MK>T^IK4VK+V
M5:.Q+R86G] I(\S$Q5#U21VXG&"DZ7$]4=(Z\.*M[W2I'?JRN1H;4NA,%:.%
M;16+2TKT(78 5AR)](&UH<0 44^=2%UG-3E5P#HI3REA<:]=50]TY:%"'TRJ
M-4<.R &ZLX8X*OJB^)I<5?AMS6J&@%]FDT^:@8L*)H[ 0C;<+12HQWKPI%_V
MF/1N6QN3SO KF/1+-R>=/]R<29>-]>!)O^HQZ=VV-B:=X5<PZ5=N3CI_N#F3
M+AMKDQXX&'MIF-RF\"E,#EET1.MJDN8P4%:149-:\*<II6'=9I0$!\B51*"D
M<J("S0E"S3.PSCT# FA[\WJ+P&1G7,;[0YZ!<[A-T''\0Q*$V] O;MJM&X"^
MZL1ZY/KHDM%\3!A')-%-\,]#1@JVJROVR:AL9$^2R,!)BE2V!G5S1_2HGR@B
M%9IOD=UQ58,T$,=)S*0'MR$>ASI^ZL+;A[D7T6,H3@J5/D&<7/OJD!]26(9<
M74N"G0;W:-@W,41VQF'1"" $17?UD9YV"%"/@'99!Q_:?KKTWVLH] *:/Y/1
M,.<#&FPEVHZAD4S$1)[6S7-RNJ>U0>R.I[4I47]/*Z)VW=,J$Y#>?Z?=^V\'
M]@;]D:CM7Q7 <(#&E/G&21* =1+Q:J.)&IK5!!ZG O?[:@MH4@/<S.:2H\/S
M?)<<8A+6'U>7!X>*>]L7MD)\M#"K ,>P&JTIC7HA"J^LR,IK;+S^*I=C3K75
MLZ)A$;GKB.F2#GFWCJIJO(=,?9+E/>9>T-KPY(MX9F8?-71T^J7#WIY_R9@C
MOJD<:)?W&_H9_83^@9,W$<'^/U!+ P04    " #FBP=+\PJ7$'TN   X 0,
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M)&"A<?E<4IG-6GGG"$60)P9/(D)9( P%3;#/*PUQ*=H5PY^=(QP/9;AD</;
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MXR(+YRC/TLR-_""::O)=J>G@B&3<FO0ZI/[X'%[&\WD<-5WH%6H[..(?:ZF
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M\'$BX]#U"H$P>&S=IC/\@NOX*V+=$%I3KH/M[B\:*TBA\X85A-\FB R77<R
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M&U!+ 0(4 Q0    ( .:+!TO<4.RW.VP  *]9!P 1              "  0
M  !T<&EV+3(P,3<P-C,P+GAM;%!+ 0(4 Q0    ( .:+!TN7B<G!?PT  $1_
M   1              "  6IL  !T<&EV+3(P,3<P-C,P+GAS9%!+ 0(4 Q0
M   ( .:+!TLXK^G31@<  +)9   5              "  1AZ  !T<&EV+3(P
M,3<P-C,P7V-A;"YX;6Q02P$"% ,4    " #FBP=+B?Z5EN I  "8F0( %0
M            @ &1@0  ='!I=BTR,#$W,#8S,%]D968N>&UL4$L! A0#%
M  @ YHL'2V11IRGU/P  _7$# !4              ( !I*L  '1P:78M,C Q
M-S V,S!?;&%B+GAM;%!+ 0(4 Q0    ( .:+!TOS"I<0?2X  #@! P 5
M          "  <SK  !T<&EV+3(P,3<P-C,P7W!R92YX;6Q02P4&      8
,!@"* 0  ?!H!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
